vaso10qmarch-2012.htm

0001201800-12-000013.txt : 20120515 0001201800-12-000013.hdr.sgml : 20120515 20120515163608 ACCESSION NUMBER: 0001201800-12-000013 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 9 CONFORMED PERIOD OF REPORT: 20120331 FILED AS OF DATE: 20120515 DATE AS OF CHANGE: 20120515 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VASOMEDICAL INC CENTRAL INDEX KEY: 0000839087 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 112871434 STATE OF INCORPORATION: DE FISCAL YEAR END: 0531 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-18105 FILM NUMBER: 12845373 BUSINESS ADDRESS: STREET 1: 180 LINDEN AVENUE CITY: WESTBURY STATE: NY ZIP: 11590 BUSINESS PHONE: 5169974600 MAIL ADDRESS: STREET 1: 150 MOTOR PARKWAY STREET 2: SUITE 408 CITY: HAUPPAUGE STATE: NY ZIP: 11788 FORMER COMPANY: FORMER CONFORMED NAME: FUTURE MEDICAL PRODUCTS INC /DE/ DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: FUTURE MEDICAL PRODUCTS INC /NY/ DATE OF NAME CHANGE: 19920506 10-Q 1 vaso10qmarch-2012.htm vaso10qmarch-2012.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q

[X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended March 31, 2012

[ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the transition period from _______________ to ______________

Commission File Number: 0-18105

VASOMEDICAL, INC.

(Exact name of registrant as specified in its charter)

Delaware	11-2871434
(State or other jurisdiction of. incorporation or organization)	(IRS Employer Identification Number)

180 Linden Ave., Westbury, New York 11590

(Address of principal executive offices)

Registrant’s Telephone Number

(516) 997-4600

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days Yes [X] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer.

Large Accelerated Filer [ ] Accelerated Filer [ ] Non-Accelerated Filer [ ] Smaller Reporting Company [X]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes [ ] No [X]

Number of Shares Outstanding of Common Stock, $.001 Par Value, at May 10, 2012 – 158,682,110

Page 1

Vasomedical, Inc. and Subsidiaries

INDEX

PART I – FINANCIAL INFORMATION	3

ITEM 1 - FINANCIAL STATEMENTS (unaudited)	3

CONSOLIDATED CONDENSED BALANCE SHEETS as of March 31, 2012 and December 31, 2011 (audited)	3

CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS for the Three Months Ended March 31, 2012 and March 31, 2011	4

CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS for the Three Months Ended March 31, 2012 and March 31, 2011	5

NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS	6

ITEM 2 - MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	17

ITEM 4 - CONTROLS AND PROCEDURES	22

PART II - OTHER INFORMATION	23

ITEM 6 – EXHIBITS:	23

Page 2

ITEM 1 - FINANCIAL STATEMENTS

Vasomedical, Inc. and Subsidiaries

CONSOLIDATED CONDENSED BALANCE SHEETS

(in thousands, except per share data)

	March 31, 2012			December 31, 2011
ASSETS	(unaudited)			(audited)
CURRENT ASSETS
Cash and cash equivalents	$	13,331		$	2,294
Short-term investments		110			110
Accounts and other receivables, net of an allowance for doubtful
accounts and commission adjustments of $2,089 at March 31,
2012 and $2,163 at December 31, 2011		6,228			20,695
Receivables due from related parties		41			196
Inventories, net		2,185			2,421
Financing receivables, net		20			19
Deferred commission expense		2,559			2,053
Deferred related party consulting expense - current portion		467			510
Other current assets		282			202
Total current assets		25,223			28,500

PROPERTY AND EQUIPMENT, net of accumulated depreciation of
$1,493 at March 31, 2012 and $1,774 at December 31, 2011		514			429
GOODWILL		3,939			3,939
FINANCING RECEIVABLES, net		11			16
DEFERRED RELATED PARTY CONSULTING EXPENSE		-			85
OTHER ASSETS		931			1,337
	$	30,618		$	34,306

LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES
Accounts payable	$	362		$	273
Accrued commissions		2,103			3,889
Accrued expenses and other liabilities		2,270			2,531
Sales tax payable		399			355
Income taxes payable		101			278
Deferred revenue - current portion		11,311			9,484
Deferred gain on sale-leaseback of building - current portion		18			31
Deferred tax liability, net		112			112
Notes payable due to related party		3			193
Total current liabilities		16,679			17,146

LONG-TERM LIABILITIES
Deferred revenue		3,470			5,743
Other long-term liabilities		73			141
Total long-term liabilities		3,543			5,884

COMMITMENTS AND CONTINGENCIES (NOTE N)

STOCKHOLDERS' EQUITY
Preferred stock, $.01 par value; 1,000,000 shares authorized; nil shares
issued and outstanding at March 31, 2012, and December 31, 2011		-			-
Common stock, $.001 par value; 250,000,000 shares authorized;
158,182,110 and 153,186,295 shares issued and outstanding
at March 31, 2012 and December 31, 2011		158			153
Additional paid-in capital		60,669			60,188
Accumulated deficit		(50,409	)		(49,065	)
Accumulated other comprehensive loss		(22	)		-
Total stockholders’ equity		10,396			11,276
	$	30,618		$	34,306

The accompanying notes are an integral part of these consolidated condensed financial statements.

Page 3

Vasomedical, Inc. and Subsidiaries

CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(Unaudited)

(in thousands, except per share data)

	Three months ended March 31,
	2012			2011
Revenues
Equipment sales	$	1,453		$	528
Equipment rentals and services		533			577
Commissions		4,057			3,740
Total revenues		6,043			4,845

Cost of revenues
Cost of sales, equipment		606			394
Cost of equipment rentals and services		293			265
Cost of commissions		963			930
Total cost of revenues		1,862			1,589
Gross profit		4,181			3,256

Operating expenses
Selling, general and administrative		5,330			3,629
Research and development		152			108
Total operating expenses		5,482			3,737
Operating loss		(1,301	)		(481	)

Other income (expenses)
Interest and financing costs		(3	)		(1	)
Interest and other income, net		(28	)		2
Amortization of deferred gain on
sale-leaseback of building		13			13
Total other income (expenses), net		(18	)		14

Loss before income taxes		(1,319	)		(467	)
Income tax benefit (expense), expense net		(25	)		2
Net loss		(1,344	)		(465	)

Preferred stock dividends		-			(128	)
Net loss applicable to common stockholders		(1,344	)		(593	)

Other comprehensive loss
Foreign currency translation loss		(22	)		-
Comprehensive loss	$	(1,366	)	$	(593	)

Loss per common share
- basic and diluted	$	(0.01	)	$	(0.01	)

Weighted average common shares outstanding
- basic and diluted		154,377			111,937

The accompanying notes are an integral part of these consolidated condensed financial statements.

Page 4

Vasomedical, Inc. and Subsidiaries

CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS

(Unaudited)

(in thousands)

	Three months ended
	March 31, 2012			March 31, 2011
Cash flows from operating activities
Net loss	$	(1,344	)	$	(465	)
Adjustments to reconcile net loss to net cash
provided by operating activities
Depreciation and amortization of property and equipment		49			39
Amortization of deferred gain on sale-leaseback of building		(13	)		(13	)
Provision for doubtful accounts and commission adjustments		(74	)		(202	)
Amortization of deferred distributor costs		-			31
Share-based compensation		129			126
Amortization of deferred consulting expense		152			47
Changes in operating assets and liabilities:
Accounts and other receivables		14,543			10,837
Receivables due from related parties		158			-
Inventories, net		226			(84	)
Finance receivables		5			4
Deferred commission expense		(507	)		162
Other current assets		(91	)		22
Other assets		414			69
Accounts payable		89			180
Accrued commissions		(1,786	)		(608	)
Accrued expenses and other liabilities		(278	)		(788	)
Sales tax payable		43			3
Income taxes payable		(177	)		(2	)
Deferred revenue		(447	)		(1,845	)
Deferred tax liability		(1	)		-
Trade payable due to related party		-			(243	)
Other long-term liabilities		(68	)		(481	)
Net cash provided by operating activities		11,022			6,789

Cash flows from investing activities
Purchases of property and equipment		(113	)		-
Purchases of short-term investments		-			(40	)
Net cash used in investing activities		(113	)		(40	)

Cash flows from financing activities
Proceeds from exercise of warrant		343			-
Repayment of note payable		-			(294	)
Repayment of notes payable due to related party		(190	)		-
Proceeds from issuance of preferred stock		-			150
Net cash provided by (used in) financing activities		153			(144	)
Effect of exchange rate differences on cash		(25	)		-

NET INCREASE IN CASH AND CASH EQUIVALENTS		11,037			6,605
Cash and cash equivalents - beginning of period		2,294			3,101
Cash and cash equivalents - end of period	$	13,331		$	9,706

SUPPLEMENTAL DISCLOSURE OF CASH INFORMATION
Interest paid	$	2		$	4
Income taxes paid	$	186		$	5

SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES
Inventories transferred to property and equipment,
attributable to operating leases, net	$	12		$	62
Accrued preferred stock dividends	$	-		$	128
Issuance of preferred stock in satisfaction of accrued dividend	$	-		$	101
Common shares issued for consulting agreements	$	-		$	1,020

The accompanying notes are an integral part of these consolidated condensed financial statements.

Page 5

Vasomedical, Inc. and Subsidiaries

Notes to Consolidated Condensed Financial Statements (unaudited)

NOTE A - ORGANIZATION AND PLAN OF OPERATIONS

Vasomedical, Inc. was incorporated in Delaware in July 1987. Unless the context requires otherwise, all references to “we”, “our”, “us”, “Company”, “registrant”, “Vasomedical” or “management” refer to Vasomedical, Inc. and its subsidiaries. Since 1995, we have been primarily engaged in designing, manufacturing, marketing and supporting EECP® enhanced external counterpulsation systems based on our unique proprietary technology currently indicated for use in cases of stable or unstable angina (i.e., chest pain), congestive heart failure (“CHF”), acute myocardial infarction (i.e., heart attack, (MI)) and cardiogenic shock. The Company, through its wholly-owned subsidiary Vaso Diagnostics, Inc. d/b/a VasoHealthcare, is the exclusive sales representative for GE Healthcare (“GEHC”), the healthcare business unit of General Electric Company (NYSE: GE), for the sale of select GE Healthcare Diagnostic Imaging products. Under the GEHC Agreement, VasoHealthcare has been appointed the exclusive representative for these products to specific market segments in the 48 contiguous states of the United States and the District of Columbia. The GEHC Agreement has an initial term of three years commencing July 1, 2010, subject to extension and also subject to earlier termination under certain circumstances.

In September 2011, the Company acquired Fast Growth Enterprises Limited (FGE), a British Virgin Islands company which, through its subsidiaries, owns and controls two Chinese operating companies - Life Enhancement Technologies Ltd. and Biox Instruments Co. Ltd., respectively – to expand its technical and manufacturing capabilities and to enhance its distribution network, technology, and product portfolio. Also in September 2011, the Company restructured to further align its business management structure and long-term growth strategy and now operates through three wholly-owned subsidiaries. Vaso Diagnostics d/b/a VasoHealthcare continues as the operating subsidiary for the sales representation of GE Healthcare diagnostic imaging products; Vasomedical Global Corp. operates the Company’s recently-acquired Chinese companies; and Vasomedical Solutions, Inc. manages and coordinates our EECP® therapy business as well as other medical equipment operations.

We report the operations of Vasomedical Global Corp. and Vasomedical Solutions, Inc. under our Equipment reportable segment. VasoHealthcare activities are included under our Sales Representation reportable segment (See Note C).

NOTE B - BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES

Basis of Presentation and Use of Estimates

The accompanying consolidated condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") and pursuant to the accounting and disclosure rules and regulations of the Securities and Exchange Commission (the "SEC"). Certain information and disclosures normally included in the consolidated condensed financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these consolidated condensed financial statements should be read in connection with the audited consolidated financial statements and related notes thereto included in the Company's Annual Report on Form 10-K for the transition period ended December 31, 2011, as filed with the SEC. These consolidated condensed financial statements include the accounts of the companies over which we exercise control. In the opinion of management, the accompanying consolidated condensed financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of interim results for the Company. The results of operations for any interim period are not necessarily indicative of results to be expected for any other interim period or the full year.

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the consolidated condensed financial statements, the disclosure of contingent assets and liabilities in the consolidated condensed financial statements and the accompanying notes, and the reported amounts of revenues, expenses and cash flows during the periods presented. Actual amounts and results could differ from those estimates. The estimates and assumptions the Company makes are based on historical factors, current circumstances and the experience and judgment of the Company's management. The Company evaluates its estimates and assumptions on an ongoing basis.

Page 6

Vasomedical, Inc. and Subsidiaries

Notes to Consolidated Condensed Financial Statements (unaudited)

Significant Accounting Policies

Note B of the Notes to Consolidated Financial Statements, included in the Transition Report on Form 10-K for the seven months ended December 31, 2011, includes a summary of the significant accounting policies used in the preparation of the consolidated condensed financial statements.

Reclassifications

Certain reclassifications have been made to prior period amounts to conform with the current period presentation.

NOTE C – SEGMENT REPORTING AND CONCENTRATIONS

The Company views its business in two segments – the Equipment segment and the Sales Representation segment. The Equipment segment is engaged in designing, manufacturing, marketing and supporting EECP® enhanced external counterpulsation systems both domestically and internationally, as well as the marketing of other medical devices. The Sales Representation segment operates through the VasoHealthcare subsidiary and is currently engaged solely in the execution of the Company’s responsibilities under our agreement with GEHC. The Company evaluates segment performance based on operating income. Administrative functions such as finance, human resources, and information technology are centralized and related expenses allocated to each segment. There are no intersegment revenues. Summary financial information for the segments is set forth below:

(in thousands)

	As of or for the three months ended March 31, 2012
	Equipment Segment			Sales Representation Segment			Corporate			Consolidated

Revenues from external customers	$	1,986		$	4,057		$	-		$	6,043
Operating loss	$	(157	)	$	(796	)	$	(348	)	$	(1,301	)
Total assets	$	9,227		$	8,381		$	13,010		$	30,618
Accounts and other receivables, net	$	1,224		$	5,004		$	-		$	6,228
Deferred commission expense	$	-		$	3,399		$	-		$	3,399

		As of or for the three months ended March 31, 2011
	Equipment Segment			Sales Representation Segment			Corporate			Consolidated

Revenues from external customers	$	1,105		$	3,740		$	-		$	4,845
Operating loss	$	(266	)	$	(32	)	$	(183	)	$	(481	)
Total assets	$	4,095		$	4,148		$	9,801		$	18,044
Accounts and other receivables, net	$	454		$	1,874		$	-		$	2,328
Deferred commission expense	$	-		$	2,270		$	-		$	2,270

Page 7

Vasomedical, Inc. and Subsidiaries

Notes to Consolidated Condensed Financial Statements (unaudited)

For the three months ended March 31, 2012 and 2011, GE Healthcare accounted for 67% and 77% of revenue, respectively. Also, GE Healthcare accounted for $4.9 million, or 76%, and $19.7 million, or 95%, of accounts and other receivables at March 31, 2012 and December 31, 2011, respectively.

NOTE D – SHARE-BASED COMPENSATION

The Company complies with ASC Topic 718 “Compensation – Stock Compensation” (“ASC 718”), which requires all share-based awards to employees, including grants of employee stock options, to be recognized in the consolidated condensed financial statements based on their estimated fair values.

During the three-month period ended March 31, 2012, the Company’s Board of Directors granted 500,000 restricted shares of common stock, valued at $120,000 to an officer, of which half vested immediately and the remainder vests over one year. During the three-month period ended March 31, 2011, 200,000 shares of common stock valued at $62,000 were issued to two directors for joining the Board of Directors.

During the three-month periods ended March 31, 2012 and 2011, the Company’s Board of Directors did not grant any stock options.

Share-based compensation expense recognized for the three months ended March 31, 2012 and 2011 was $129,000 and $126,000, respectively. These expenses are included in cost of revenues; selling, general, and administrative expenses; and research and development expenses in the consolidated condensed statements of operations. Expense for share-based arrangements was $152,000 and $47,000 for the three months ended March 31, 2012 and 2011, respectively. Unrecognized expense related to existing share-based arrangements is approximately $1.1 million at March 31, 2012 and will be recognized ratably through July 2013.

NOTE E – LOSS PER COMMON SHARE

Basic earnings per common share is computed as earnings applicable to common stockholders divided by the weighted-average number of common shares outstanding for the period. Diluted earnings per common share reflects the potential dilution that could occur if securities or other contracts to issue common shares were exercised or converted to common stock.

Basic and diluted loss per common share was $0.01 for the three months ended March 31, 2012 and 2011.

The following table represents common stock equivalents that were excluded from the computation of diluted earnings per share for the three months ended March 31, 2012 and 2011, because the effect of their inclusion would be anti-dilutive.

(in thousands)

	March 31, 2012		March 31, 2011
Stock options		1,810		1,864
Warrants		1,500		4,286
Contingently issuable shares		2,000		-
Convertible preferred stock		-		31,855
Common stock grants		2,948		4,050
		8,258		42,055

Page 8

Vasomedical, Inc. and Subsidiaries

Notes to Consolidated Condensed Financial Statements (unaudited)

NOTE F – FAIR VALUE MEASUREMENTS

The Company complies with the provisions of ASC 820 “Fair Value Measurements and Disclosures” (“ASC 820”). Under ASC 820, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the “exit price”) in an orderly transaction between market participants at the measurement date.

The following tables present information about the Company’s assets and liabilities measured at fair value as of March 31, 2012 and December 31, 2011:

(in thousands)

	Quoted Prices in Active Markets for Identical Assets		Significant Other Observable Inputs		Significant Unobservable Inputs		Balance as of March 31,
	(Level 1)		(Level 2)		(Level 3)		2012
							(unaudited)
Assets
Cash equivalents invested in money market funds (included in cash and cash equivalents)	$	12,078	$		$		$	12,078
Investment in certificates of deposit (included in short-term investments)		110						110
	$	12,188	$	-	$	-	$	12,188

	Quoted Prices in Active Markets for Identical Assets		Significant Other Observable Inputs		Significant Unobservable Inputs		Balance as of December 31,
	(Level 1)		(Level 2)		(Level 3)			2011
Assets
Cash equivalents invested in money market funds (included in cash and cash equivalents)	$	1,313	$		$		$	1,313
Investment in certificates of deposit (included in short-term investments)		110						110
	$	1,423	$	-	$	-	$	1,423

The fair values of the Company’s cash equivalents invested in money market funds are determined through market, observable and corroborated sources.

NOTE G – ACCOUNTS AND OTHER RECEIVABLES, NET

The following table presents information regarding the Company’s accounts and other receivables as of March 31, 2012 and December 31, 2011:

(in thousands)

	March 31, 2012			December 31, 2011
	(unaudited)
Trade receivables	$	8,189		$	22,737
Due from employees		128			121
Allowance for doubtful accounts and
commission adjustments		(2,089	)		(2,163	)
	$	6,228		$	20,695

Page 9

Vasomedical, Inc. and Subsidiaries

Notes to Consolidated Condensed Financial Statements (unaudited)

Trade receivables include amounts due for shipped products and services rendered. Amounts currently due under the GEHC Agreement are subject to adjustment in subsequent periods should the underlying sales order amount, upon which the receivable is based, change.

Allowance for doubtful accounts and commission adjustments include estimated losses resulting from the inability of our customers to make required payments, and adjustments arising from subsequent changes in sales order amounts that may reduce the amount the Company will ultimately receive under the GEHC Agreement. Due from employees primarily reflects commission advances made to sales personnel.

NOTE H – INVENTORIES, NET

Inventories, net of reserves, consist of the following:

(in thousands)

	March 31, 2012		December 31, 2011
	(unaudited)
Raw materials	$	896	$	842
Work in process		577		528
Finished goods		712		1,051
	$	2,185	$	2,421

At March 31, 2012 and December 31, 2011, the Company had reserves for excess and obsolete inventory of $563,000 and $606,000, respectively.

NOTE I– BUSINESS COMBINATION

On September 2, 2011, Vasomedical Global successfully completed the purchase of all the outstanding capital stock of privately-held Fast Growth Enterprises Limited (“FGE”), a British Virgin Islands company that owns subsidiaries which own and control Life Enhancement Technology Ltd (“LET”) and Biox Instruments Co. Ltd. (“Biox”), respectively, as per the stock purchase agreement signed on August 19, 2011. The consideration of this acquisition includes a cash payment of $1 million as well as the issuance of 5 million restricted shares of the Company’s common stock, up to 2.4 million shares of common stock contingently issuable upon the achievement of certain operating performance targets, and warrants covering 1.5 million shares of common stock.

LET, based in Foshan, Guangdong, China, has been Vasomedical’s supplier for its proprietary Enhanced External Counterpulsation (EECP®) systems, including certain Lumenair systems and all AngioNew® systems. Biox, a developer and manufacturer of ambulatory monitoring devices in China, is located in Wuxi, Jiangsu, China, and has been Vasomedical’s partner on the BIOX series ECG Holter recorder and analysis software as well as ambulatory blood pressure monitoring systems. Vasomedical has obtained FDA clearance to market these products in the United States. The acquisition of LET provides Vasomedical with consolidated technical and manufacturing capability in its EECP business which should significantly increase gross margins and enable the Company to meet anticipated increasing demand for its EECP systems. The acquisition of Biox greatly enhances Vasomedical's distribution network, technology and product portfolio, and with combined market and sales efforts of the two companies, should help improve performance and profitability of Vasomedical's equipment segment.

The operating results of FGE are included in the accompanying Consolidated Condensed Statements of Operations and Comprehensive Loss and Cash Flows for the three months ended March 31, 2012. The Consolidated Condensed Balance Sheet as of March 31, 2012 reflects the acquisition of FGE, effective September 2, 2011. The acquisition date fair value of the total consideration transferred was $3.979 million, which consisted of the following:

Page 10

Vasomedical, Inc. and Subsidiaries

Notes to Consolidated Condensed Financial Statements (unaudited)

(in thousands)

Cash	$	1,000
Vasomedical, Inc. common stock ($0.42 per share)		2,100
Vasomedical, Inc. warrants to purchase common stock		304
Contingent issuance of Vasomedical, Inc. common stock ($0.42 per share)		575
Total purchase price	$	3,979

In accordance with Accounting Standards Codification ("ASC") 805, Business Combinations ("ASC 805"), the total purchase consideration is allocated to the net tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values as of September 2, 2011 (the acquisition date). The purchase price was allocated based on the information currently available, and may be adjusted after obtaining more information regarding, among other things, asset valuations, liabilities assumed, and revisions of preliminary estimates. The following table summarizes the estimated fair values of the assets acquired and liabilities assumed at the acquisition date:

(in thousands)

Cash and cash equivalents	$	442
Accounts receivable and other current assets		283
Inventories		476
Property and equipment		32
Goodwill		3,939
Accounts payable and other current liabilites		(1,193	)
Net assets acquired	$	3,979

The goodwill is attributable to the synergies expected to arise after the Company’s acquisition of FGE as well as FGE’s projected growth and profitability. The goodwill is not expected to be deductible for tax purposes.

After elimination of intercompany transactions which reduce the income from FGE, the amounts of revenue and net income of FGE included in the Company’s Consolidated Condensed Statement of Operations for the three months ended March 31, 2012 was $578,000 and $35,000, respectively. The effect of FGE earnings on earnings per share was $0.00.

The following supplemental pro forma information presents the financial results as if the acquisition of FGE had occurred June 1, 2009 (amounts in thousands, except per share amounts):

(in thousands except per share data)

	Three months ended March 31,
	2012			2011
Revenue	$	6,043		$	5,219

Net loss		(1,170	)		(274	)

Basic and diluted loss per share	$	(0.01	)	$	(0.00	)

Page 11

Vasomedical, Inc. and Subsidiaries

Notes to Consolidated Condensed Financial Statements (unaudited)

NOTE J – GOODWILL AND OTHER INTANGIBLES

Goodwill aggregating $3,939,000 was recorded on the Company’s Consolidated Condensed Balance Sheets at March 31, 2012 and December 31, 2011, pursuant to the acquisition of FGE in September 2011. All of the goodwill was allocated to the Company’s Equipment segment.

The Company’s other intangible assets consist of capitalized patent costs, as follows:

(in thousands)

	March 31, 2012			December 31, 2011
	(unaudited)
Patent Costs
Costs	$	469		$	469
Accumulated amortization		(420	)		(413	)
	$	49		$	56

Patents are included in other assets in the accompanying Consolidated Condensed Balance Sheets. Amortization expense amounted to $7,000 and $10,000 for the three months ended March 31, 2012 and 2011, respectively.

NOTE K - DEFERRED REVENUE

The changes in the Company’s deferred revenues are as follows:

(in thousands)

	For the three months ended March 31,
	2012			2011
	(unaudited)			(unaudited)
Deferred revenue at the beginning of the period	$	15,227		$	12,637
Additions:
Deferred extended service contracts		327			397
Deferred in-service and training		5			8
Deferred service arrangements		25			15
Deferred commission revenues		1,350			1,027
Recognized as revenue:
Deferred extended service contracts		(275	)		(314	)
Deferred in-service and training		(3	)		(8	)
Deferred service arrangements		(22	)		(16	)
Deferred commission revenues		(1,853	)		(2,954	)
Deferred revenue at end of period		14,781			10,792
Less: current portion		11,311			7,585
Long-term deferred revenue at end of period	$	3,470		$	3,207

NOTE L – RELATED-PARTY TRANSACTIONS

On June 21, 2007, we entered into a Securities Purchase Agreement with Kerns Manufacturing Corp. (“Kerns”). Pursuant to this agreement, a five-year warrant to purchase 4,285,714 shares of our common stock at an initial exercise price of $0.08 per share was issued to Kerns. In March 2012, Kerns exercised its warrant and purchased 4,285,714 shares of common stock. Concurrently with our entry into the Securities Purchase Agreement, we also entered into a Distribution Agreement and a Supplier Agreement with Living Data Technology Corporation (“Living Data”), an affiliate of Kerns. Pursuant to the Distribution Agreement, as amended, we became the exclusive worldwide distributor of the AngioNew EECP® systems manufactured through Living Data. The Distribution Agreement had an initial term extending through May 31, 2012. Subsequent to August 31, 2011 the Company acquired Life Enhancement Technology (LET) (see Note I), the manufacturer of the AngioNew EECP® system. Consequently, the Distribution Agreement is no longer effective, and the Company wrote-off the remaining unamortized balance of Deferred Distributor Costs during the seven months ended December 31, 2011.

Page 12

Vasomedical, Inc. and Subsidiaries

Notes to Consolidated Condensed Financial Statements (unaudited)

On February 28, 2011, David Lieberman and Edgar Rios were appointed by the Board of Directors as directors of the Company. Mr. Lieberman, a practicing attorney in the State of New York, was appointed to serve as the Vice Chairman of the Board. He is currently a senior partner at the law firm of Beckman, Lieberman & Barandes, LLP, which firm performs certain legal services for the Company. Fees of approximately $67,000 were billed by the firm through the three months ended March 31, 2012, at which date no amounts were outstanding.

Mr. Rios currently is President of Edgary Consultants, LLC, and was appointed a director in conjunction with the Company’s consulting agreement with Edgary Consultants, LLC. The consulting agreement (the “Agreement”) between the Company and Edgary Consultants, LLC (“Consultant”) commenced on March 1, 2011 and runs for a two year term.. The Agreement provides for the engagement of Consultant to assist the Company in seeking broader reimbursement coverage of EECP® therapy. More specifically, Consultant will be assisting the Company in the following areas:

1.	Engaging the adoption of EECP® therapy as a first line option for FDA cleared indications as it relates to CCS Class III/IV angina with a major commercial healthcare third-party payer.

2.	Engaging a major commercial healthcare payer to formally collaborate and co-sponsor a study with Vasomedical for the efficacy, efficiency and/or cost effectiveness of the EECP® therapy for NYHA Class II/III heart failure.

3.	Engaging final approval from the Centers for Medicare and Medicaid Services (“CMS”) of EECP® therapy as a first line treatment for CCS Class III/IV angina.

4.	Engaging final approval from CMS to extend coverage and provide for the reimbursement of EECP® therapy for CCS Class II angina; and

5.	Engaging final approval from CMS to extend coverage and provide for the reimbursement of EECP® therapy for NYHA Class II/III heart failure.

In consideration for the services to be provided by Consultant under the Agreement, the Company has agreed to issue to Consultant or its designees, approximately 10% of the outstanding capital stock of the Company, of which the substantial portion (in excess of 82%) is performance based as referenced above. In conjunction with the Agreement, 3,000,000 shares of restricted common stock valued at $1,020,000 were issued in March 2011. In connection with the Agreement, Mr. Lieberman received 600,000 of these restricted shares. The Company has recorded the fair value of the shares issued to Consultant as a prepaid expense and is amortizing the cost ratably over the two year agreement. The unamortized value is reported as Deferred Related Party Consulting Expense in our accompanying consolidated condensed balance sheets as of March 31, 2012 and December 31, 2011.

During the three months ended March 31, 2012, a director performed consulting services for the Company aggregating approximately $10,000.

Through the Company’s acquisition of FGE in September 2011, it assumed the liability for $288,000 in unsecured notes payable to the President of LET and his spouse, of which $95,000 was repaid in December 2011, and $190,000, bearing interest at 6% per annum, was paid in March 2012. In addition, receivables due from FGE management aggregating $158,000 were collected during the three months ended March 31, 2012.

Page 13

Vasomedical, Inc. and Subsidiaries

Notes to Consolidated Condensed Financial Statements (unaudited)

NOTE M – STOCKHOLDERS’ EQUITY

Common Stock

On June 17, 2010 the Board of Directors approved the 2010 Stock Plan (the “2010 Plan”) for officers, directors, employees and consultants of the Company. The stock issuable under the 2010 Plan shall be shares of the Company’s authorized but unissued or reacquired common stock. The maximum number of shares of common stock which may be issued under the 2010 Plan is 5,000,000 shares.

The 2010 Plan is comprised of two separate equity programs, the Options Grant Program, under which eligible persons may be granted options to purchase shares of common stock, and the Stock Issuance Program, under which eligible persons may be issued shares of common stock directly, either through the immediate purchase of such shares or as a bonus for services rendered to the Company.

The 2010 Plan provides that the Board of Directors, or a committee of the Board of Directors, will administer it with full authority to determine the identity of the recipients of the options or shares and the number of options or shares. Options granted under the 2010 Plan may be either incentive stock options or non-qualified stock options. The option price shall be 100% of the fair market value of the common stock on the date of the grant ( or in the case of incentive stock options granted to any individual stockholder possessing more than 10% of the total combined voting power of all voting stock of the Company, 110% of such fair market value). The term of any option may be fixed by the Board of Directors, or its authorized committee, but in no event shall it exceed five years from the date of grant. Options are exercisable upon payment in full of the exercise price, either in cash or in common stock valued at fair market value on the date of exercise of the option.

As of March 31, 2012, 3,790,000 restricted shares of common stock were granted under the 2010 Plan to non-officer employees and consultants of the Company. As of March 31, 2012, 545,000 shares have been forfeited. In March 2012, 500,000 restricted shares of common stock were granted under the 2010 Plan to an officer, of which 250,000 vested immediately with the remainder vesting over a one year period.

No options were issued under the 2010 Plan during the three months ended March 31, 2012 and 2011.

In September 2011, the Company issued 5,000,000 shares of restricted common stock and a two year common stock purchase warrant for 1,500,000 shares at an exercise price of $0.50 per share as partial consideration for the acquisition of FGE. In addition, up to 2,400,000 shares of common stock are contingently issuable should FGE attain certain operating targets for the twelve months ending December 31, 2011. The Company is completing its evaluation of FGE’s calendar year 2011 results and believes it is likely that the targets have been met. The aggregate value of the aforementioned noncash consideration relative to the FGE acquisition was $2,979,000.

Preferred Stock

On June 24, 2010, the Company filed a Certificate of Designations of Preferences and Rights of Series E Convertible Preferred Stock (“Certificate of Designations”), as authorized by the Board of Directors, designating 350,000 shares of its 1,000,000 shares of preferred stock as Series E Convertible Preferred Stock (“Series E Preferred”). The conversion rights of the Series E Preferred are that each share will be convertible at any time on or after January 1, 2011, at the holder’s option into 100 shares of common stock (an exercise price of $.16 per share of common stock, the “Conversion Price”), subject to anti-dilution adjustment as set forth below. Each share of outstanding Series E Preferred Stock shall automatically be converted into shares of common stock on or after July 1, 2011, at the then effective applicable conversion ratio, if, at any time following the Issuance Date, the price of the common stock for any 30 consecutive trading days equals or exceeds three times the Conversion Price and the average daily trading volume for the Company’s common stock for the 30 consecutive trading days exceeds 250,000 shares.

Page 14

Vasomedical, Inc. and Subsidiaries

Notes to Consolidated Condensed Financial Statements (unaudited)

Pursuant to its conversion terms, the Series E Preferred was deemed automatically converted to common stock effective July 1, 2011. As of March 31, 2012, 30,603,700 shares of common stock had been issued for 306,037 shares of Series E Preferred, with 64,750 shares of common stock yet to be issued.

For the three months ended March 31, 2011, the Company sold 9,375 shares of Series E Preferred aggregating $150,000, and recorded dividends totaling $128,000. Included in such dividends is the recognition of the value of the embedded beneficial conversion feature of the Series E Preferred, which reflects the difference between the conversion price and the market price at time of investment. The amounts included in the dividends reported attributable to this beneficial conversion feature are $65,000 for the three months ended March 31, 2011. These are noncash dividends requiring no payment and ceased on conversion of the Series E Preferred to common stock.

NOTE N – COMMITMENTS AND CONTINGENCIES

Sales representation agreement

The GEHC Agreement is for an initial term of three years commencing July 1, 2010, subject to extension and also subject to earlier termination under certain circumstances. These circumstances include not materially achieving certain sales goals, not maintaining a minimum number of sales representatives, and various legal and GEHC policy requirements. Under the terms of the agreement, the Company is required to lease dedicated computer equipment from GEHC for connectivity to their network.

Facility Leases

On August 15, 2007, we sold our facility in Westbury, New York under a five-year leaseback agreement, which expires August 31, 2012. VasoHealthcare also leases facilities in Greensboro, North Carolina pursuant to a lease which expires in May 2013. In May 2012, the Company entered into a five year lease agreement, expiring in May 2017, for approximately 1,800 square feet of office space in New York, New York.

Vehicle Lease Agreement

In June 2011, the Company began taking deliveries under a closed-end master lease agreement for the provision of vehicles to the sales team of its Sales Representation segment. Vehicles obtained under the terms of the agreement are leased generally for a 36 month term, and payments are fixed for each year of the agreement, subject to readjustment at the beginning of the second and third year.

Future rental payments under these operating leases aggregate approximately as follows:

For the years ended December 31:

(in thousands)

	Vehicles		Facilities		Total
2012	$	217	$	178	$	395
2013		277		106		383
2014		154		44		198
2015		5		42		47
2016		-		42		42
Thereafter		-		18		18
Total	$	653	$	430	$	1,083

Page 15

Vasomedical, Inc. and Subsidiaries

Notes to Consolidated Condensed Financial Statements (unaudited)

Employment Agreement

On March 21, 2011, the Company entered into an Employment Agreement with its President and Chief Executive Officer, for a three-year term ending on March 14, 2014 (the “Employment Agreement”). The Employment Agreement currently provides for annual compensation of $275,000, eligibility for annual bonuses and long-term incentive awards, and certain severance benefits in the event of termination prior to the expiration date of the Employment Agreement.

NOTE O - RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

Other Comprehensive Income: Presentation of Comprehensive Income

In June 2011, new guidance was issued that amends the current comprehensive income guidance. The new guidance allows the option to present the total of comprehensive income, the components of net income, and the components of other comprehensive income either in a single or continuous statement of comprehensive income or in two separate but consecutive statements. The amendments in this update do not change the items that must be reported in other comprehensive income or when an item of other comprehensive income must be reclassified to net income. The new guidance is to be applied retrospectively and is effective for fiscal years, and interim periods, beginning after December 15, 2011, with early adoption permitted. The Company does not expect that it will have a material impact on its consolidated condensed financial statements.

In December 2011, the FASB issued authoritative guidance to defer the effective date for those aspects of the guidance relating to the presentation of reclassification adjustments out of accumulated other comprehensive income. The adoption of this new guidance will not have an impact on the Company’s consolidated financial position, results of operations or cash flows as it only requires a change in the format of the current presentation of other comprehensive income.

Page 16

Vasomedical, Inc. and Subsidiaries

ITEM 2 - MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Except for historical information contained in this report, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this report, words such as “anticipates”, “believes”, “could”, estimates”, “expects”, “may”, “plans”, “potential” and “intends” and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company’s management, as well as assumptions made by and information currently available to the Company’s management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the effect of the dramatic changes taking place in the healthcare environment; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in the conduct of clinical trials and other product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; uncertainties about the acceptance of a novel therapeutic modality by the medical community; continuation of the GEHC Agreement and the risk factors reported from time to time in the Company’s SEC reports, including its recent transition report on Form 10-K. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.

General Overview

In 2010, the Company, through its wholly-owned subsidiary Vaso Diagnostics d/b/a VasoHealthcare, organized a group of medical device sales professionals and entered into the sales representation business as the exclusive representative for the sale of select General Electric Company (GE) diagnostic imaging equipment to specific market segments in the 48 contiguous states of the United States and the District of Columbia.

In September 2011, the Company acquired Fast Growth Enterprises Limited (FGE), a British Virgin Islands company, which, through its subsidiaries, owns and controls two Chinese operating companies - Life Enhancement Technology Ltd. and Biox Instruments Co. Ltd., respectively - to expand its technical and manufacturing capabilities and to enhance its distribution network, technology, and product portfolio. Also in September 2011, the Company restructured to further align its business management structure and long-term growth strategy, and now operates through three wholly-owned subsidiaries. Vaso Diagnostics d/b/a VasoHealthcare continues as the operating subsidiary for the sales representation of GE diagnostic imaging products; Vasomedical Global Corp. operates the Company’s newly-acquired Chinese companies; and Vasomedical Solutions, Inc. was formed to manage and coordinate our EECP® therapy business as well as other medical equipment operations.

We now report the operations of Vasomedical Global Corp. and Vasomedical Solutions, Inc. under our Equipment reportable segment. VasoHealthcare activities are included under our Sales Representation reportable segment (see Note C).

The Company will seek to improve profitability through our recent accretive acquisition of the two Chinese medical device companies and by expanding our U.S. market product portfolio. In addition, the Company plans to actively pursue other accretive acquisitions in the international market and is in preliminary discussions to secure a credit facility for up to $25 million to be utilized for this purpose.

Critical Accounting Policies and Estimates

Our discussion and analysis of our financial condition and results of operations are based upon the accompanying unaudited consolidated condensed financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). The preparation of financial statements in conformity with U.S. GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Although these estimates are based on our knowledge of current events, our actual amounts and results could differ from those estimates. The estimates made are based on historical factors, current circumstances, and the experience and judgment of our management, who continually evaluate the judgments, estimates and assumptions and may employ outside experts to assist in the evaluations.

Page 17

Vasomedical, Inc. and Subsidiaries

Certain of our accounting policies are deemed “critical”, as they are both most important to the financial statement presentation and require management’s most difficult, subjective or complex judgments as a result of the need to make estimates about the effect of matters that are inherently uncertain. For a discussion of our critical accounting policies, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Transition Report on Form 10-K for the seven months ended December 31, 2011.

On June 15, 2011, the Board of Directors approved a change of the Company’s fiscal year end from May 31st to December 31st. As a result of this change, the Company filed a Transition Report on Form 10-K for the seven-month transition period ended December 31, 2011. Going forward, references to our 2012 and 2011 fiscal years herein mean the fiscal years ended December 31, 2012 and December 31, 2011, respectively.

New Accounting Pronouncements - Adoption of New Standards

Other Comprehensive Income: Presentation of Comprehensive Income

Consolidated Results of Operations

Three Months Ended March 31, 2012 and March 31, 2011

Total revenue for the three months ended March 31, 2012 and March 31, 2011, was $6,043,000 and $4,845,000, respectively, an increase of $1,198,000, or 25%. Net loss for the three months ended March 31, 2012 was $1,344,000 compared to a net loss of $465,000 for the three months ended March 31, 2011. We reported net loss applicable to common stockholders of $1,344,000 for the first quarter of fiscal year 2012 compared to a net loss applicable to common stockholders of $593,000 for the first quarter of fiscal year 2011. The increase in net loss applicable to common stockholders was primarily attributable to a $1,701,000 increase in selling, general and administrative (“SG&A”) costs (of which $1,049,000 was attributable to VasoHealthcare), partially offset by a $128,000 decrease in preferred stock dividends. Our total net loss was $0.01 per basic and diluted common share for the three months ended March 31, 2012 and 2011.

Page 18

Vasomedical, Inc. and Subsidiaries

Revenues

Revenue in our Equipment segment increased by $881,000, or 80%, to $1,986,000 for the three-month period ended March 31, 2012 from $1,105,000 for the same period of the prior year. Equipment segment revenue from equipment sales increased by $925,000, or 175%, to $1,453,000 for the three-month period ended March 31, 2012 as compared to $528,000 for the same period in the prior year. The increase in equipment sales is due primarily to an increase in the number of EECP® units shipped internationally as well as an increase in the sales price per EECP® unit, partially offset by a decrease in sales of other medical equipment, and by the inclusion of $578,000 in equipment sales generated by our Chinese subsidiaries acquired in September, 2011.

Current demand for EECP® systems will likely remain soft until there is greater clinical acceptance for the use of EECP® therapy in treating patients with angina or angina equivalent symptoms who meet the current reimbursement guidelines, or a favorable change in current reimbursement policies by CMS or third party payers to consider EECP therapy as a first-line treatment option for angina or cover some or all Class II & III heart failure patients. Patients with angina or angina equivalent symptoms eligible for reimbursement under current policies include many with serious comorbidities, such as heart failure, diabetes, peripheral vascular disease and/or others. As described in Note L, we are pursuing initiatives to expand reimbursement that we expect should ultimately increase overall market demand for our EECP® systems.

Equipment segment revenue from equipment rental and services decreased 8% to $533,000 in the first quarter of fiscal 2012 from $577,000 in the first quarter of fiscal year 2011. Revenue from equipment rental and services represented 27% and 52% of total Equipment segment revenue in the first quarters of fiscal 2012 and fiscal 2011, respectively. The decrease in revenue generated from equipment rentals and services is due primarily to decreased service revenue, partially offset by higher accessory part revenue.

Commission revenues in the Sales Representation segment were $4,057,000 in the first quarter of fiscal 2012, as compared to $3,740,000 in the first quarter of fiscal 2011, an increase of 8%. The increase in commission revenue in the first quarter of fiscal 2012 is due to increased volume of equipment delivered. The Company recognizes revenue when the underlying equipment has been accepted at the customer site in accordance with the specific terms of the sales agreement. Consequently, amounts billable under the agreement with GE Healthcare prior to customer acceptance of the equipment are recorded as deferred revenue in the Consolidated Condensed Balance Sheet. Due to the nature of our commission structure under the GEHC Agreement, wherein the Company earns progressively higher commission rates retroactively as calendar year targets are met, revenues earned in the first and fourth fiscal quarters typically reflect a higher blended commission rate than revenues earned in the second and third fiscal quarters. As of March 31, 2012, $13,581,000 in deferred commission revenue was recorded in the Company’s consolidated condensed balance sheet, of which $3,105,000 is long-term. At March 31, 2011, $9,763,000 in deferred commission revenue was recorded in the Company’s consolidated condensed balance sheet, of which $2,929,000 was long-term.

Gross Profit

The Company had a gross profit of $4,181,000 in the first quarter of fiscal 2012 compared to $3,256,000 in the first quarter of the prior fiscal year, an increase of 28%. Equipment segment gross profit increased to $1,087,000, or 55% of Equipment segment revenues, for the first quarter of fiscal 2012 compared to $446,000 or 40% of Equipment segment revenues, for the same quarter of fiscal 2011. Equipment segment gross profit was favorably impacted both in absolute dollars and gross profit percentage by the $578,000 in sales of other medical equipment sold through our Chinese subsidiaries in the first quarter of fiscal 2012. In addition, gross profit on EECP® equipment improved due to lower production costs arising from the acquisition of LET, our primary supplier of certain EECP® systems. Gross profit in the Equipment segment is dependent on a number of factors, particularly the mix of new and refurbished EECP® systems and the mix of models sold, their respective average selling prices, the mix of EECP® units sold, rented or placed during the period, the ongoing costs of servicing EECP® systems, and certain fixed period costs, including facilities, payroll and insurance.

Sales Representation segment gross profit was $3,094,000 for the three months ended March 31, 2012 as compared to $2,810,000 for the three months ended March 31, 2011. Cost of commissions of $963,000 and $930,000, for the three months ended March 31, 2012 and 2011, respectively, reflects commission expense associated with recognized commission revenues. Commission expense associated with deferred revenue is recorded as deferred commission expense until the related commission revenue is earned.

Page 19

Vasomedical, Inc. and Subsidiaries

Operating Loss

Operating loss increased by $820,000, or 170%, to $1,301,000 for the three months ended March 31, 2012 as compared to an operating loss of $481,000 for the three months ended March 31, 2011. The increase in operating loss was primarily attributable to higher operating losses in the Sales Representation segment of $764,000 and higher corporate expenses od $165,000, both arising from higher SG&A costs, partially offset by a $925,000 improvement in gross profit.

Selling, general and administrative (“SG&A”) expenses for the first quarter of fiscal 2012 and 2011 were $5,330,000, or 88% of revenues, and $3,629,000, or 75% of revenues, respectively, reflecting an increase of $1,701,000 or approximately 47%. The increase in SG&A expenditures in the first quarter of fiscal 2012 resulted primarily from increased sales and marketing costs in both segments, including SG&A costs of the recently acquired Chinese entities, and higher corporate compensation costs.

During the first quarter of fiscal 2012, the Company recorded a reduction in provision for doubtful accounts and commission adjustments of $74,000 as compared to the first quarter of fiscal year 2011 when the Company recorded a reduction in its provision for doubtful accounts and commission adjustments of $202,000. These reductions were primarily net reversals of previous provisions to reduce gross deferred revenues for estimated adjustments.

Research and development (“R&D”) expenses of $152,000, or 3% of revenues, for the first quarter of fiscal 2012 increased by $44,000, or 41%, from $108,000, or 2% of revenues, for the first quarter of fiscal 2011. The increase is primarily attributable to an increase in clinical research expenses.

Interest and Financing Costs

Interest and financing costs for the first quarters of fiscal 2012 and 2011 were $3,000 and $1,000, respectively. Interest and financing costs for the first quarter of fiscal 2012 consisted primarily of interest on the notes payable to a related party in one of the China subsidiaries. Interest and financing costs for the first quarter of fiscal 2011 consisted of interest on a short-term note to finance the Company’s insurance premiums.

Interest and Other Income (Expenses), Net

Interest and other income (expense) for the first quarters of fiscal 2012 and 2011, was ($18,000) and $14,000, respectively. The increase of $32,000 in expense in the first quarter of fiscal 2012 is due primarily to certain non-operating expenses incurred by our Chinese subsidiaries, partially offset by higher interest earned on the Company’s cash balances.

Amortization of Deferred Gain on Sale-leaseback of Building

The amortization of deferred gain on sale-leaseback of building for the first quarter of fiscal years 2012 and 2011 was $13,000. The gain resulted from the Company’s sale-leaseback of its facility.

Income Tax Expense, Net

During the first quarter of fiscal year 2012 we recorded a provision for income taxes of $25,000 as compared to a tax benefit of $2,000 for the first quarter of fiscal 2011. The increase arose primarily from foreign tax liabilities associated with the acquisition of FGE.

Liquidity and Capital Resources

Cash and Cash Flow

We have financed our operations primarily from working capital, and, in the first quarter of fiscal 2011, from the issuance of the Company’s Series E Preferred Stock. At March 31, 2012, we had cash and cash equivalents of $13.3 million, short-term investments of $110,000 and working capital of $8.6 million compared to cash and cash equivalents of $2.3 million, short-term investments of $110,000 and working capital of $11.4 million at December 31, 2011.

Page 20

Vasomedical, Inc. and Subsidiaries

Cash provided by operating activities was $11,022,000 during the first three months of fiscal year 2012, which consisted of a net loss after adjustments to reconcile net loss to net cash of $1,101,000, offset by cash provided by operating assets and liabilities of $12,123,000. The changes in the account balances primarily reflect a decrease in accounts and other receivables of $14,543,000, offset by increases in deferred revenue and accrued commissions of $447,000 and $1,786,000, respectively, and increases in deferred commission expense of $507,000. As noted above, under the GEHC Agreement the Company earns progressively higher commission rates as calendar year targets are met, which also has a significant impact on our cash flows. As we achieve these targets the higher commission rates are retroactive to the beginning of the calendar year, and therefore, the significantly higher commission billings and recognized revenue generated in the fourth quarter of fiscal year 2011 resulted in significant cash inflows in the first quarter of fiscal 2012.

Investing activities during the three-month period ended March 31, 2012 used cash of $113,000 for the purchase of property and equipment.

Financing activities during the three-month period ended March 31, 2012 provided cash of $153,000, consisting of $343,000 provided through the cash exercise of warrants, offset by $190,000 for the repayment of notes payable to a related party.

Liquidity

While we expect to generate positive operating cash flows for fiscal 2012, the progressive nature of earned commissions under the GEHC Agreement can cause related cash inflows to vary widely during the year.

Page 21

Vasomedical, Inc. and Subsidiaries

ITEM 4 - CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Disclosure controls and procedures reporting as promulgated under the Exchange Act is defined as controls and procedures that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act are recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms. Disclosure controls and procedures include without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Our CEO and our CFO have evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of March 31, 2012 and have concluded that the Company’s disclosure controls and procedures were not effective as of March 31, 2012 due to insufficient controls and management review over the recording of certain transactions, and to lack of accounting personnel with appropriate level of knowledge and experience in accounting principles generally accepted in the United States of America and related accounting systems and closing process at our China subsidiaries. The Company intends to engage additional accounting personnel, including an accounting controller, and strengthen its internal controls with regard to its closing process, related disclosures, and the approval of certain transactions.

Changes in Internal Control Over Financial Reporting

There was no change in the Company’s internal control over financial reporting during the Company’s last fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

Page 22

Vasomedical, Inc. and Subsidiaries

PART II - OTHER INFORMATION

ITEM 6 – EXHIBITS:

Exhibits

31	Certifications of the Chief Executive Officer and the Chief Financial Officer pursuant to Rules 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32	Certifications of the Chief Executive Officer and the Chief Financial Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

Page 23

Vasomedical, Inc. and Subsidiaries

In accordance with the requirements of the Exchange Act, the Registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

VASOMEDICAL, INC.

By: /s/ Jun Ma

Jun Ma

President and Chief Executive Officer

(Principal Executive Officer)

/s/ Michael J. Beecher .

Michael J. Beecher

Chief Financial Officer and Principal Accounting Officer

Date: May 15, 2012

Page 24

GRAPHIC 2 vaso10q2012.jpg begin 644 vaso10q2012.jpg M_]C_X``02D9)1@`!`0$`8`!@``#_X0!F17AI9@``34T`*@````@`!`$:``4` M```!````/@$;``4````!````1@$H``,````!``(```$Q``(````0````3@`` M``````!@`````0```&`````!4&%I;G0N3D54('8U+C`P`/_;`$,``0$!`0$! M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`?_;`$,!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`?_``!$(`"L! M$`,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_ MQ`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C M0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-CH.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJ MLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X M^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($ M!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B M7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>X MN;K"P\3%QL?(RKR\_3U]O?X^?K_V@`,`P$` M`A$#$0`_`/[^**_FM_X+3?\`!4[]J7_@G[\9_AKX3^$EEX'N/"7CKP3>^(U? MQ'HLVI7AN["_@TVXC25;B!(D68RN`!*7!`(3;D]I_P`$2_\`@J+^T!_P4!\8 M?&7P[\:K+P?;V_@3PUH^M:+-X8TR3397GO\`5([2:&YC>:?>B0OE)`Z[FS^[ M&*_1*GAAQ/3X,CQVUE\LAE0AB%*&-C+%J$\7]2L\-R74XU[QG'FTBN;8_/X> M)7#<^,)<#IX^.>1KSP[C+!M85SAA/KMXXCGLX2H:QERZO2U]OZ'JHZCJFFZ1 M:R7VK:A9:99PJSRW5_=06EO&B`LS/-(XO@!\0--URW\+>'K>^EM;6?4/"NJ6VE:I?7,5ML\_P"W MS/YT<,C,HCW*Z.#Q^/\`%>;8GAGAK%\3?V9B+QRJO# M0K5Y*2ASJC4=HPG*R^%73/ZO^CAX.4OI!^,&1^$E/B[+>$L?G&59SG<,7CL- M6Q^(K8#(:-*OCZ>7X"A.D\5C'3JITH5<1AJ/NSXL?$_QS\(/JUN7232=*N9-1O1)'D,F((S#G*D9$I''N*^+?%O\`P7B_8X\. MRR0:78^/O%$JLRQOIVE6T%M*1T*W-S`_B5\1K];?POX M:\4>*;^>98FCT;2=2U.?S9`"%E^QV\@0D$-F9T4`Y+`&OOCX:_\`!(_]M[XD MI9WMC\*-2TG2[E8Y#?\`B2]L]'2-'SC]S/<-<%Q_%&T2<=&R<5^%KQ0XZSB; MCDF34.6]DL+@,7CY+;XJLI*E?S<8Q[KM_K;6_9Z_1`\+<)"MXM>+.;*O&,95 M9<0<8\-<&4JDK)OV&6TJ%7,N23ORQAB,1/5+G;U?[A:Q_P`'"7P93=_8/PF\ M57)`R/[0U#3(AR>.8+L@G&O'^KN#^ M)XKY<\&?\&^G[0NK1V\WB3XB^`_"H?!N()8=1U.>(-C*J;6?RV9>%W*A5SQ9]6I74OJ.<>(. M=*JM[E6W5:,J+_P<):C(^(O@3HI7N7\1W(YSQTE/YX]/6NFT MO_@OXEPR_P!H_!.QA4XW?9==FD89]/,F"GCU(]`2>OI^D?\`!`/X%6RK_:?Q M1\9SO@;S:6.CH"V.2HEM#WY'L:[NR_X(/_LO6P7[1XV^)%R5ZE;C3;:<3_LLZ2G3PO"7%>(TLJF# MPO&Z;VUC+%YU2\]91_R.5T#_`(+M?"R[V_VW\+?$5L2,G^S]0T^49XR%\^Z7 MGTSCT([U[CX:_P""SW[+^NE$O=&\>:)*Q4-]ITVUN8%SU/GV]QM(!XX!/?IS M7/6W_!#W]E2W`'_"0_$:0C`W-JMIG`X_Y]C_`)]3DG6A_P""*O[+]NH$/B+X MC(0W_D(!_GVXKJI4O'VA_R_X7Q2O\.(]BM/\5&G2?X[GY;G6,_9NYAS M?V?EWB[E$G\,\#]=E&-^U/'XO&Q:7FKGTQX:_P""D7[(_B)(F?XG6&B/*0!' MK,,UNRLW16*)(`>N1VQ7T+X;_:+^!OB_RQX;^*/A'53*`4$&IHA(.,<3K%CK MT./T-?GC%_P1O_9[M_\`CU\9?$.+C@27EC<`'CD+-"R@X&.`./>M*V_X)+?" MK3\?V;\1?&L)4D@O#I).<="PM"Q'8@D\5[.&S7QIP[BL;PMPGCXJW-+"YQ5P ME1][>T=6"^<.NETC\=SWAGZ'&,YY<-^)?BID\VWR4\XX3PV94(;6YGAJ>%K. MW;VE]]=%?]4[76M'OD62RU73;M'^X]M>VTZMGT,4K`]:T@P)V9QTZUZ;I/[.?[1_AV96 MT?\`:4U">U7&++5;.>X@.WINVQEC[\\^W2OH\+Q)Q>K+,N`<;2?6>79WE&.C MTUY:U7!2[Z:O3K<_*,TX'\-DY/(/&#+<9%*\89SPKQ%E%26ND>;#T,TIIVZR M<5Z'W=17SUH6C_M%:*BQ:KXG\$>)HU(4R_V=?6MR5Y^8LS+EOKQSSP*]9T:] M\4L`FMZ7;HW`,EG,#&.<$A7._'!(!YP17U&$S5XCE57+Q^>YADD<$Y.AG&39G33TJ8#%SO)=U2Q=#"UEZ.G?NCK**!GN,?K1 M7JGAA1110`45\^?M5?&^S_9Q_9Z^*_QJO3;@>`?".IZS:+=_\>TFI)%Y6FQS M#(W1/>R0B11RR;@.37\D7[)?_!=__@H!^TO^TC\)_@M8:)\+Y+;QSXWTG2M4 M%IX:N8;BUT&:[1]5F2X%Y*4>TT_SF24Q,&D1-R1*2R?><+>'7$?%^5YOG65K M`T\NR12>.KXW%QPR7L\//%5/9)PE[3V=&'-/:W-!:N1\1Q-X@\/<*9IE.3YI M+&3S#.7%8*A@\++$M\^(IX:G[5J453]I5J';+4=8^'7B#5;J_P!4LX$75KQ;VW"1 M2VQNRZ6ZH"-J;E?YL#^B3]@SXE_&;XQ?LK_"KXG?'W3+'1OB=XRT>36=;TG3 M["?3+>PBGN)%L(38W&9;>8VJI++&Q;:9``S8W&.(/#WB#AG(= M>P>"HTL;"MC;8C#?6XNMAHQ4J7)2Y?::2YI=%=] M#CS#'8;+,#C,QQDW3PN!PU;%XB:7,XT:%.52HU'[4N6+Y8KXG9=3[6HK^/#_ M`()U?\%JOV[OVR/VMOA9\$=4TKX;?\(?KFM2R>-;[3/#=U:7ECX:M;>5[J[A MG%W<".43>0BAEVD2'YU(57_K`T?XM^$];\;:A\/[4ZDOB+39)UFCFTZYCM'B M@BFE:>.\9!"R,L+A/FR6VCJ0*^FXOX#S_@K,(99G$<)/%2P*S&<$9+B[_9K\:B/]W9:1XF\/O+CO/?/? M+'G'JN['X_3Q+_@UMU;ROV@OV@=()(-U\,-'N-N>HBUX\D9R?]4,9'T)QQ^E MO_!RY\.=0\6?LI_#'Q#I-FMS=Z#\3([2X6>EZ#X=^"%Y-!#-,BR:EJT>HRR:;I\0+[W:ZN%6' M"!F7S-V,#!_IGAK"8[/_`*-N-PN!P>(Q5:E];R^E"A2G4E4Q"SW#5:5**BG[ M\Y8B"4=_>3ZW/YJXES+*^'_I&X*MF&88/!1K+"9A5>(KPI1XB%:M)3:M M",,-4RN#'>Z-X M*W+);6!,;;E;7RLT4J$H?LZENH`;X/\`^"=_@[]G3XC_`/!.VW^+/[:-QKWA MCX1?LM^//$7_``CTEHTUK-\1)/$EW-JEUX=T5U*OJ4XOU@T][*$,Q,N"-B.X M_*9?AG^T=_P5,_;HNKV^MKBY\0?%GQK)>7$?#NDV=SI7PY7 M3X-5USQ3K5G`!J/B1=,)11=7=X9KC[1(W$7C]P7QU1X%P_"F4YQPWPYQ1+'+"X?!?VM@YX#V7UI3A[*53#X MF6)Q;H3ABO;8FA1HN,^5P_GB'_!<;XB:;XIB^&W_``3T_9)\!>`-.CEGT[0H MX/"+^+/&/B"S@/_!,PZW\0==@;36US68GE*QI<+)%Y#Z2EVFCRRS^4 M[".6&=ES&Q=!)7Y%_P#!6'XZ?MU?M*_$?PIH/[4WPTT;X7:CX4T[^T=`\"V- MO`MWI5MK8<+]MO!)-*ACQ]UPSX>Y&\WP7#L/!K(>'\HC@9 MU9T?L$?L^QZM'9/4NU6)E#*?$_V7_P#@G-\;OBK_ M`,$6_BI:_"VQN9?B;\3_`(K:?XI_X16.1H)?%'AGP'?_`+JQMOF7SKB]B"]?\`>*=2TUM!\06WB/PDUW M;7NEK.MTUE7OA35_AXVB:G M>::\O^ML)X!<2/!,JLJ3V_FB,D;MK8`_IU_9X_X*0?"+XJ_L7VO[8WQ*$OP? M\+Z7%>V/C/3_`!$&ADT[Q%I:HMWIVD"X\F35/MDKA=*5`'NB<#`5F'\UGPI_ MX+K?%K4O&FAG]J/]EGX)?$^VBEM]-U/QC=>'[2?QAI&EB=#<'3EO;":V<1J9 M)5MVD"EP%1CZ):P:% M::GXG\3QRRR-JNF:<+>SDN-)2U$<8DB8QRN)%^;FN?.O"/'\19OP[PYBO#+# M\%8BK.KB\PXCR#&O%X#$X+!4X_7<+0P2I?N\16G5PZPOUJ2JTI2E+][34T;9 M-XQY+P_E/$7$.%\4O]5"G&EB'B? MJT94JBC&*]E4<&_IS]H[_@Y<^)/B#Q?>^%?V0OA/91:9#?/:Z/XB\6V,VN:O MK$;"7"^'8K9S:!NJPDF4<[P%PS?,_@O_@Y)_;B\#^,(K7XN^#_`?B'2[2]7 M^UO#I\+'PMJPB+*9+=;E4:>V8ICRRZ)@,&Q@@U^J_P#P;Y?\$^OAOX)_9Z/[ M2OQ&\(:'XG^)?Q%U74;30)M>TVTU./PUX:TN:6T5;&WO(IX$GU-F6X>XV^:A M1A&5!!K\K_\`@XZ^'W@JY_:T\$0?"SPSX=TK5[;X>HGCP:':6FGBXUF?4`^G M->6]FD,8NTL<*S%=[(5+9+"NCAW*_#',^.L=X899X=T\>LLH8VEC,\Q%2MB, M:\7ET;8MS=U6ITXU7*@J].K2_?6<*,:=D\^(\Y\1,JX#P/B?FGB+_9T,SKX" MM@\GHPP^&P/U3,9)X-4Y-.C4G.C;$.C4I5?W'-SU934F?THM_P`%4_ACXM_X M)V>,?VYOA];*?^$8T62UO_"NI.K2Z)XZ;R8$T&[?Y5N%2XN8620!%FB)P.#G M$/V>/\`@Y1^*FM_$FTA^/.A^#]&^&MAIFJ:EK,OA_1S)K-]-9HKV6F:>@5) M#<7SL85,6YE*Y"GDU^;8N?B?\+/^"3,?PR-K/:Q_';XZW.HRV$K%%ET+PQIE MG<0:DB%AO@N;FU:.-P-KX7DD`5]*?\$"?^"=7A/]H7XV>+OB?\<_"]IXD\$? M"6PLY=/\.:BGF:7JOB?5'D-A)=QG*W*:8+=;DV[9C?S/FZ4UX7<#\(<+%674 MJ.*]E2G!RA5E3C)*:DNN^.G_```O!<5W*NFV?B+1X MO$VKW%I%*RP37=S*(5BEN(0DDL<6](W'?"_A:V:S\/>+HI+*.==6O;I1Y>@6UO'/!\GAOP3:6_C6'P[9VVF6-]K&H2V]U82 MFSM4A@BEALQ)$X5>2Q)QTK]/?^"`_P#P37^$L7P.US]I+X]?#[0_%WBOQ3J5 M[IWA2#Q/:1:GHVE>$K."(W%]%972R6YNKJY24O.4.R--N6VJ5.(^'/"[!>&. M1\9YAP)B.>75\!A,)6E1S7&U*\I^RPE?,Y/,'FF.P"S&EF%?$TH5LNP-.@J4:V+HY9#E="OA:] M6%"E14U35>].K*I!._YMZK_P$;K3 M;J/7;.]E22X;Q'I;FUO=*T2$NCZC<7=W&XL;>$EG!QNPN:_@8_;U^&>FZI^V MA\>8O@]X4L])\#3?$S6[3POI&F!?LR6\=X;58K**/$:QR7`80QQJ$`*X`SS] M%_\`!0#5_B7X=^&?[.7[&OAT7%I\/O@]\/M-\4:CIZ3O%#JGC7QU;V^LZE/? MPJZK-/I;--#;M,C%%N#@[AQ[O$O@MPYQ-1X*PV3<-2X9K9E*.:8Z>$H3CBZ> M14\!2KXNC5A*4Z=;%?6,5@L/2K33<*M:'?&_-N&ZO&F)SGBS#\2 M4,KOE>$CBL52>$EGE7'5*&%J4Y14)T'?VAOAGX51K:2&[U+PIK/@F?P9K4UC,V0 M(IWA-Q$CH&"3*C@'T^[7G7_!*_\`:=\9_L'>`=?U71OV+=0^*GC?QIJ:7VO[*.O_``XO?"_AYM'O;BWT+6)[S5U-Q+,KW<[VH>40&4K&TC%E154< M5M@O#C(%J3 MITW&JVW4I2C^[!_`_AZWO+7QKI M>I2QR:AHOB;3@J7&@6B;D;4+B[N&$6EE`#=Y)7(1FK^:?]HK_@YC_:!\0^-+ MVR_9F\"^%_!_@ZVNY+;3Y_%FE)XDUO5K:.1EAO9[>1(TLI+I0'^RQ.[1A@C# M=N%?D1\2O#O[0OPL_90\"_`?69-3\/:5XM\6ZYXS\2>!KX36#_`()T?#V]\#^+OVG?C5X)T?Q7XCGUQ_#G MP\L])\->!/#3)>(> M-^(#\3>,?$K/,@X(X=SO#9!F4,GH8[B'&X91^M^UCAZ5?$UW27[W#T(PK8 M>,,/3=&<\37<*E2%-1BOSF_:F_X+J?$7]K+]BGQ=^SM\4O!MEI7Q*\1ZY8KJ MOB?P]"=/T?4_#]H\=PUE+I8P+2']OA'2?^$XL=`@MK"Q'BJ66X:9_L%HL5O;3-;-!YL<:* MN[!VKD`>J_!+P=K7[,'_``1+^-OC"WA_LCXH?M1_$33O`^E`MY4UWX-TNY6. M[E0G:TD+PF20;205)/3`K[:668"/AGEM#A?A_$Y!0\3,RRO"X?+;5*CI3S^M M1IX_V4GJZ4,JPF)G3Y;1C2M.,8)\J^+CG=9^)>9U.)N)<%GE?PSRS-,7B\>Y MTJ=Z>0TJD\%+$0O:-5YIC,-"HY^\ZUX2E*6K]%^$7_!>']H3X]_'SP5\,M%^ M!?P9O+SXC^/],\/6#77A.SN-4>#5M1CA5KBXDA_>745L6GFE9V.49OFQ@_NG M_P`%"O\`@L5\#OV`-+L?``L;/XB?'C^R+*2?X=^'[F.VTCPY))`HD_MV_MA* MFFJLVY[>Q6/SI(`"OS';7\C/_!)WX:ZWX(^-GCC]I#Q%H4=S8?L[?"OQC\2= M%:4!K=_&5E:QQ^'(=QROF&0W3`<'N.E>$?!_X)_%C]O']M[PQH_CR^O+S5/C M1\4Y+KQ-JUU)K3J5)TL/A,MPT:]54G"I4>(A M"$HJ3D=^2^,_$.$X>P=*EQ#ALUXGXUSIX'(ZF*GA)QP>$P]6E@IU,)1A"$*] M?%YEB)8>G[55*=/V$YRC-I1?Z?:__P`'$7_!1/Q;_:OB3X?^"?!NE>#M/N'E MD>W\!S:]#80`EA#>ZJ85C&Q/ON[*<#+**^M?V%O^#D#QWXU^*OA3X;?M5>$/ M#9T;QAK%CH,7CGPG:_V0=!OM2N8+*QFO=+6,PS63W,ZKOA1\)].^$'ACX5^![+P5I_A_^P;JVG\/Z3<37]L]F;6\N=1OKFT> MXN+FY5I))+B:0LC/E-FT`?`GAK_@B)_P3<\.^(KKQQ_PK)=4NX=4F\01->^* M[W^R-*=)S>!HK:"Y2WAM[67,B'*)&JKP`BX_&Y<<>#&9X+-L!C/#BIE4%&5' M*,;E"A5S";DI0IUZ]6=;#^PK0E&G4Y)3Q<*G-*G-2LW+]FAP7XPY9C,JQN$\ M0Z6:2YU5S7!YMSTL#%1<)5*%&C&AB%7I3BZE-3C'"SIM*<7&Z4(O@+:?M'^.= M/MK3PU^%_V(/\`@GAHOPL^#_AC0]1\KQ7J-O$` MR2&ZD:XFF#*66<,9=B:GA'+%9ABY498C/?$',\)D^4UH5K2 M3P%"O7I5TFI0C0HPPLZTU+GE4J2<8+Y7B7CJGF?$^886CXO4*&"P<:T:&0^' M^`Q.<9M1G1?+-8ZOAZ-:CHX5'7K3Q,*5-QY5"FDYGR?\#/\`@Y0_:C\/_$O2 M=`_:*\!^#]?\-G6K71_$-MH^B'PMKFE)+>Q6=[=;%C8FXT]7>8VTFWS#$8R, ML,_7_P#PWFTPW,0.=K MRWVW:<@2@@C%?R^_#WX5_%;]IK]JGPK'XEL8+KQ!\5?BOHK^('L8$@B#:[X@ MM)=4EBM[?]W#%';23N%4;55/7K^BW_!=._U_QK^UUIGPM\*2IJ/@?X"?#GPC M\,?#ZB7>(KO3-.A.M`8.%_TF&,$+SN5L]./U"MX79'@O$O@>>3\.0RK'8/+< MUS[-<%@:=9X5QP:PN%P-6-.>D91S+%N-.HH0]K3HMR@Y1LOS*EXL9CC/#7C9 MYMQ53S3+\3F>59!E>.QM>@L2IXQ8C%XVE.K"S?/EN%4YTY3J>RG45I.,_>^U MO^#7OX%2:M\3?C5\?;VV$MCX5T.W\#:9)+&"(M5UC[)J<\L3$'Y_L8V<8*E< MYR,5_:2MC9)=/>I:6Z7CIY;W*PQB=DSG:TH7>1GL37XP?\$%_P!GM_@7^P;X M1U+4;`Z?XC^*FJWWC/6H73;-L$LUEIAE[[OLB\`G@$`<8K]JJ_D_QASN6=^( MG$==2DZ.#Q2RF@KO2EEL8X62WM9UZ=6>FCYK[ZG]6^$63PR?P^X7=Z7K.GVFJ M:==)_)X:JYTJF;5\RHUX9A#"PIJ MO2P\?92IRPU9MQJ4'/G4E\2LDXW/R#QH^C=6\5N+0E;KPSX1DC\VRLU251-:WVH&:22_0A&VJB%=I7'\\/_!6VR^- M6K?MG_%&_P#B#HVOK##J5O9^'7:TU!]+?P[#;QC2_P"S9Q$;5HGB4/,+=L^< M#Y@)"FO[W(HHX(XX88TAAB18XHHD6...-`%1(T0!415`"JH"J```!7G_`(U^ M$?PH^)+P2?$7X8?#SQ]):KLM7\:^"O#?BI[9#_#`VNZ;?M"O^S&5'M7E<&>/ M>.R+Q)X@\0L_RB.>5\_PE7!.A3Q'L*N5X9UJ-3#8?+JM2G5A&A1I4*>&E2<8 M^TIWESJ3ES^MQQ]'?`<0>%_#GAMPYG+R##\.XNACO;U,,\11S;%*A6I8O$9E M2IU*4Y5\16KU,5&JI2]E4:@HN"CR_P`OW["7_!2BP^#W[.W@?X$_"#]CSQCX ML^-<2S:5_P`)!I&GVHT/7M?NGN);;7-:N4M6U&&)=Z).))52..+(`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`L?)]Q_X*R_\`!/+Q MQ^SYX^\*^)?AQX9USQ#\)9O!WA[0;/6=/LKO49;/7-'AG74H=46SCG:T2X>= M);:615B*@J6!Q7]K>@^&_#OA73X])\+Z!HOAO2H3F+3-!TJQT?3XC@#,=EIT M%O;(<`#Y8QP`.U6-7T?2-?T^YTG7=*TW6]*O$\N[TS5[&UU+3[J/.?+N;*\B MFMITR`=LL;+D9Q7O?\32Y]0XIR/,(<5B^+>(, MSHYS7XHA@,/AJ&%QE"=>JL+A_MXH\W4 M5O*28%5"Q&$==N17G'P-_8T_:T_X*6_M":G\2_B+I^NZ/H^O^(8]4\<^/O$N MF7NF6-EI[2IFUT:VNU@FNVCMHUMK"*U22*$@.6)!4_V@1_LM_LR0W0OH?V=/ M@3%?!_-%Y'\(OA^ET),Y\P7"^'A-OSSOW[L\YKVC3=,TW1K*WTW1].L=*TZT M01VNGZ;:6]C96T8Z1V]K:QQ00H.RQQJOM5XSZ1>0934SW-O#_P`.L%P[Q7Q) M[1YCQ%C<8\=6A4K3]K5JX?#*"I*2,%G@OHS<1YQ3 MX>R?Q'\3&XN9"(MTZL/WW_P"")'P>;X._L7IXQ\2:9<:/KOCC7=<\ M1:HMU;2072Z+IY)TUI(Y%64XMFD*C;_"0`2:_5G5_@W\(?$&H76KZ_\`"KX; MZWJM\Y>]U/5_`WAC4M0O'889[J]O=+FN;AV`P6FEWKXFK."H4W"IB\PQ-3&3(KA=;\=ZGIU@Z:3J3L] MGIMV='L-F+9E_>+:*T85L%75N]?V7:+9VG[&O_!-NTLOL=P;CP'\$WB\BRMI M9KR36=0S6DL:%5*I)$RK@8`P*T\0O&O`<;Y;P+D-#ANM ME>0<(8G"UL3@?K\*T\QHX.AA<)1I0G'#TH4''"T<1!2<*EI8ERM:-GGX;>!. M8:'X4UK4OAGXO MTS2KCPUJ^FV-Y?V=FVGV$-K>Z5>O:PR+9RVLBL8?.")+&#M(VJ&_LVT/X1?" M?PQJ4&L^&_AA\//#VL6JNEMJNA^"O#>DZE;K(,.L%]8:9;W42N``ZQRJ&`Y! MKJ/$/AGPWXMTR;1?%?A_1/$VCW!!GTGQ#I-AK6F3E<[3-8:E;W-K(5R<%XFQ MDXZU]OC?I48RIQQDO$V"X9]AD^79)B\DQ61U/P6!^B+@:7`.>\*X_BEXC.LSS_!9]A<^I9;R0PU3 M`8.MA*>%Q&$GB9SQ%&NL7C)UG&O3DIU*4X>]2M/^1K]DK_@LK)^S_P#LX^%O M@MXB_9WO/%OBGP1I-QH_AOQ!9QV-K:7,1EGFMI-3:5H>A>'Y)T M-PT.L7!MI+V>*T^6%88+AYIV4N(@Q8?O^G[*O[+\4PN8_P!F_P"`L=P&W"=/ M@_\`#U)@P.0PE7PZ'#9YR&SGFO8]$T#0?#.GQ:3X;T32/#^E0$F#3-$TVSTK M3X20`3%96$-O;1DA0#LC&0`.PKY#/O%CPTQ,,\Q>2>$>">>Y]6KXBMF'$6;8 MK,\-@L5B)2J5<3@L#!TXTYNK.=54XU*5-U&G-2IKV1]KP[X/>*6%GD&#S[QD MQW]@G?M'Z!\5/["OM1\*>*/`/A_2UU31]-N6T>VU?P]"+?4;9(RQ9FKR#]@#]O#]MOX/^![C]G;X#_#B'QT?$>I74GAR7 M4=`U:]N/#6H7\#/!_CK2GT+ MQOX4\->,M$EUO+1W&>&:$D=C7/>"_@]\(_AO- M/OEGTA,G7A MQEG`W$O`&"XFJ9+0HT<#/&8R5/+*E3!2F\OQ.)PU.FL0JF'A-TZD*-:,:\%* M+E"-6:/%S/Z-V=?\10S7Q`X6\1<=PK3SS$5JV80P6"C5S6G3QL:2S'"87%5: MCPSI8B=)5*4Z]"<\/-PDHSE1A)_YVWQF\'?'GQK\>?%4GQ'@\0^*/B#K/B[R MM>UEK#4+F.[UNZDMHGCBE6W\LPV\LB6<04J@2#`/!:OU+_X*L66M^`O@Y^Q[ M^R3X?T#699_A;\*=,\5>)_L&FWK)YHNS=G23.;H2_O!<>9YHD^ MUF_%M",16XO-1TZYN! M!$`!'")/+0#"J*]S%_2?P6,S?@G'5.#9T\%P?3Q]6&7X?,*5"CB,RQ.6PRO" MXFC"&%5/"X?!8>>,]CAE"HHNO34)15*[\#`_10QV`R;CO+Z?&\:N/XUJY=1J M9GB,MK5Z^'RO"YI/-L9AJ\YXSVN+Q./Q-/!>VQ4IP:WNK M68O;JES:3QNRB:%Y$92DR[@NT_Z-&@>&_#OA/38M&\+:!HOAK2(&=X=*T#2K M'1M-A>0YD:*QTZ"VM8V<\NR1`L>6)-^(5T+WQ]\*/AKXXO0JH+O MQAX$\+^);H(@PBBXUK2KV7:HX5=^`.`!7!D?TFZN#SOCFOG?"\,XX>XTQOUF M>5O&\E?`T5@*65?4G6E1E2Q6&K8"C2IU8.%%J<93IM>TDCT,^^BI2QF0<`8? M(.+*F2<2\"X+ZM#-XX#GPV/KRS&IF[QJH0KQJX7$T77@6;78(;;Q!K'A2PUG4?$=T`4$UII M;VL,S6EM=L661EC,VTA`.04[KX.?LJ?\%`-#_9&^+_QR\7>/OBEI/E^";^U\ M)_"E]2O9]6U_1]0B=-4UB[L7:2ZMS9PD&QM5"W3,LCYYV1?U,^&_V?/@)X,O MXM4\'_!#X0^%-3@=7AU'PW\-?!FA7\+JBVMQ&ZD`JR2`@C(->N.B2 M(\RO+&C7A25"5=5:E6E1E*-!4FW)^Y@/H^ M<29KFN)S_P`1O%+/N)(H5*5/%U,-AJ].GBI8>I5>( MAAG2I4JM91EB)5E%17^;E^SCXIA^#/[0_P`/_B'\3OAIK'Q`T'PCXKM]5USP M??6=PEQK$<,CDP2)?PJGG^:PE(N!AFSO#$XK]Y?VRO\`@HI^T!^TQ^S?X[T' M]G']FOQS\*_A!;VMCIGC_P`9:W8+:7UQIUTUN;?3O#L>G0VL7V21S&ES+;1R MM'"IB*$,0O\`1W>?LR_LVZCJ,NKZA^SY\$+_`%:>8W$VJ7GPG\!W6HS3LVYI MI;V?0'N9)F;YC(\IE2PU;&J7-]6Q.)BXTY*E.K1K*E""\#@_P"C9QGP MGP]Q)PK@_$ZC@9XBO4POU6E'$9IB*U3%4,"X*/UK"X22 ME4BZL*->@ZTZC_AZ_P""/WPWO;/]K*W^(WC7P_JL>C?"OP3XN\?O'>:7>*MQ MJ&BZ7,]A&AG@0-*'4O'&NYG;9@9Q7QOXR\.?$7]I/]IO6]9A\.^)'N?BG\3; MVXM9+G2]2#+#XAUZ5;?)>`*GDV,\;!=V$5/FZ&O]#32/A'\*/#TES+H'PQ^' MNARWEM)9W"_#>FR75G,GERVER]EIL+3VTJ?))!*6B=/E92.*IV'P4^#6 ME7MKJ>E_"3X8Z;J-C,MQ9:A8>`O"MG>V=PA)6>UNK?2HY[>9225EBD1P2<-7 MJ4_I3X6EQ-GW$ZX0Q,L9F619;DF74YYM3<,MI8&>.Q-2;?U/]\L3CL73KU$H MTWRT(PN])1\FK]$?%5>%.'>$Y<9X:."RKB'-,_S.I#)ZBGFE7,(9?A:=.SQG M[IX7`8.KAZ;E*HN:O*:4=8NQ\(/!EI\._A;\/_!%C;K;0>&O".@Z4854*%N+ M;3K=+HD``!FN?-8^YKT:BBOY`Q%>IBL17Q-:3G5Q%:I7JR;; EX-31 3 vaso10qmarch2012-ex31.htm CERTIFICATION vaso10qmarch2012-ex31.htm

EXHIBIT 31.1

CERTIFICATION PURSUANT TO RULE 13a/15d OF THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Jun Ma, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Vasomedical, Inc. and subsidiaries (the “registrant”);

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c.	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s Board of Directors (or persons performing the equivalent functions):

a.	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize, and report financial information; and

b.	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

/s/ Jun Ma .

Jun Ma

President and Chief Executive Officer

Date: May 15, 2012

EXHIBIT 31.2

CERTIFICATION PURSUANT TO RULE 13a/15d OF THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Michael J. Beecher, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Vasomedical, Inc. and subsidiaries (the “registrant”);

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

c.	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s Board of Directors (or persons performing the equivalent functions):

a.	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize, and report financial information; and

b.	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

/s/ Michael J. Beecher .

Michael J. Beecher

Chief Financial Officer

Date: May 15, 2012

EX-32 4 vaso10qmarch2012-ex32.htm CERTIFICATION vaso10qmarch2012-ex32.htm

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Vasomedical, Inc. and subsidiaries (the “Company”) on Form 10-Q for the period ending March 31, 2012, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jun Ma, as President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Jun Ma .

Jun Ma

President and Chief Executive Officer

Dated: May 15, 2012

EXHIBIT 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Vasomedical, Inc. and subsidiaries (the “Company”) on Form 10-Q for the period ending March 31, 2012, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Michael J. Beecher, as Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Michael J. Beecher .

Michael J. Beecher

Dated: May 15, 2012 Chief Financial Officer

EX-101.INS 5 vaso-20120331.xml XBRL INSTANCE DOCUMENT 0000839087 2012-01-01 2012-03-31 0000839087 2012-05-10 0000839087 2012-03-31 0000839087 2011-12-31 0000839087 2011-01-01 2011-03-31 0000839087 2010-12-31 0000839087 2011-03-31 xbrli:shares iso4217:USD iso4217:USD xbrli:shares

-22000

1493000

1774000

60188000

60669000

2089000

2163000

31000

13331000

2294000

3101000

9706000

2000

4000

-162000

507000

84000

-226000

-1000

3000

43000

180000

89000

-788000

-278000

-243000

-158000

<div><div style="text-align: justify; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">NOTE N - COMMITMENTS AND CONTINGENCIES</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Sales representation agreement</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The GEHC Agreement is for an initial term of three years commencing July 1, 2010, subject to extension and also subject to earlier termination under certain circumstances.  These circumstances include not materially achieving certain sales goals, not maintaining a minimum number of sales representatives, and various legal and GEHC policy requirements.  Under the terms of the agreement, the Company is required to lease dedicated computer equipment from GEHC for connectivity to their network.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Facility Leases</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">On August 15, 2007, we sold our facility in Westbury, New York under a five-year leaseback agreement, which expires August 31, 2012.  VasoHealthcare also leases facilities in Greensboro, North Carolina pursuant to a lease which expires in May 2013.  In May 2012, the Company entered into a five year lease agreement, expiring in May 2017, for approximately 1,800 square feet of office space in New York, New York.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Vehicle Lease Agreement</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">In June 2011, the Company began taking deliveries under a closed-end master lease agreement for the provision of vehicles to the sales team of its Sales Representation segment.  Vehicles obtained under the terms of the agreement are leased generally for a 36 month term, and payments are fixed for each year of the agreement, subject to readjustment at the beginning of the second and third year.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"> Future rental payments under these operating leases aggregate approximately as follows:</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">For the years ended December 31:</div><div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> </div><div style="text-align: right; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="font-style: italic; display: inline; font-family: Times New Roman; font-size: 10pt;">                                                                                                                                                                   (in thousands)</font><br /></div><div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><div style="text-align: left;"><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr bgcolor="#cceeff"><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none;">  </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none; font-weight: bold;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; border-top: medium none;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Vehicles</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none; font-weight: bold;"> </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none; font-weight: bold;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; border-top: medium none;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Facilities</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none; font-weight: bold;"> </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none; font-weight: bold;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; border-top: medium none;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Total</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none; font-weight: bold;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 64%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">2012</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">217</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">178</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">395</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 64%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">2013</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">277</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">106</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">383</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 64%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">2014</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">154</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">44</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">198</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 64%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">2015</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">5</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">42</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">47</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 64%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">2016</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">42</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">42</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="padding-bottom: 2px; width: 64%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Thereafter</div></td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">18</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">18</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="white"><td valign="bottom" style="text-align: left; padding-bottom: 4px; text-indent: 18pt; width: 64%;"><div style="text-align: left; text-indent: 18pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Total</div></td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">653</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">430</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,083</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr></table></div><br /><br /><font style="font-style: italic; display: inline; font-family: Times New Roman; font-size: 10pt;">Employment Agreement</font></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">On March 21, 2011, the Company entered into an Employment Agreement with its President and Chief Executive Officer, for a three-year term ending on March 14, 2014 (the "Employment Agreement").  The Employment Agreement currently provides for annual compensation of $275,000, eligibility for annual bonuses and long-term incentive awards, and certain severance benefits in the event of termination prior to the expiration date of the Employment Agreement.</div></div>

250000000

158182110

153186295

158182110

153186295

153000

158000

-1366000

-593000

1862000

1589000

606000

394000

293000

265000

16679000

17146000

<div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">NOTE K - DEFERRED REVENUE</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The changes in the Company's deferred revenues are as follows:</div><div style="text-align: left; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"> </div><div style="text-align: right; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="font-style: italic; display: inline; font-family: Times New Roman; font-size: 10pt;">(in thousands)</font><br /></div><div style="text-indent: 0pt; display: block;"><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" style="width: 76%; font-family: times new roman; font-size: 10pt; border-top: medium none;">  </td><td valign="bottom" style="width: 1%; font-family: times new roman; font-size: 10pt; border-top: medium none;"> </td><td colspan="6" valign="bottom" style="text-align: center; border-top: medium none;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"> </font><font style="display: inline; font-family: times new roman; font-size: 10pt;">For the three months ended March 31,</font></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; border-top: medium none;"> </td></tr><tr><td valign="bottom" style="padding-bottom: 2px; width: 76%; font-family: times new roman; font-size: 10pt;">  </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">2011</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr><td valign="bottom" style="width: 76%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td colspan="2" valign="bottom" style="text-align: center; font-family: times new roman; font-size: 10pt;">(unaudited) </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td colspan="2" valign="bottom" style="width: 10%; display: inline; font-family: times new roman; font-size: 10pt;">             (unaudited)</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 76%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Deferred revenue at the beginning of the period</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">15,227</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">12,637</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 76%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Additions:</div></td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="text-indent: 9pt; width: 76%;"><div style="text-align: left; text-indent: 9pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Deferred extended service contracts</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">327</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">397</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="text-indent: 9pt; width: 76%;"><div style="text-align: left; text-indent: 9pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Deferred in-service and training</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">5</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">8</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="text-indent: 9pt; width: 76%;"><div style="text-align: left; text-indent: 9pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Deferred service arrangements</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">25</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">15</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="text-indent: 9pt; width: 76%;"><div style="text-align: left; text-indent: 9pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Deferred commission revenues</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,350</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,027</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 76%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Recognized as revenue:</div></td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="text-indent: 9pt; width: 76%;"><div style="text-align: left; text-indent: 9pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Deferred extended service contracts</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(275</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(314</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="text-indent: 9pt; width: 76%;"><div style="text-align: left; text-indent: 9pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Deferred in-service and training</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(3</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(8</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="text-indent: 9pt; width: 76%;"><div style="text-align: left; text-indent: 9pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Deferred service arrangements</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(22</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(16</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="padding-bottom: 2px; text-indent: 9pt; width: 76%;"><div style="text-align: left; text-indent: 9pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Deferred commission revenues</div></td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(1,853</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(2,954</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 76%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Deferred revenue at end of period</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">14,781</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">10,792</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="padding-bottom: 2px; text-indent: 9pt; width: 76%;"><div style="text-align: left; text-indent: 9pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Less: current portion</div></td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">11,311</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">7,585</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="padding-bottom: 4px; width: 76%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Long-term deferred revenue at end of period</div></td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">3,470</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">3,207</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr></table></div></div>

11311000

9484000

5743000

3470000

128000

-25000

126000

129000

4181000

3256000

-608000

-1786000

-4000

-5000

3939000

2185000

2421000

34306000

30618000

153000

-144000

-113000

-40000

11022000

6789000

-1344000

-465000

-1344000

-593000

11037000

6605000

-18000

14000

3000

1000

5884000

3543000

11000

16000

-1301000

-481000

-22000

282000

202000

2559000

2053000

1000000

0.01

150000

514000

429000

-202000

-74000

113000

40000

<div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">NOTE G - ACCOUNTS AND OTHER RECEIVABLES, NET</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The following table presents information regarding the Company's accounts and other receivables as of March 31, 2012 and December 31, 2011:</div><div style="text-align: left; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"> </div><div style="text-align: right; font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">              (in thousands)</div><div style="text-align: left; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr bgcolor="white"><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none;">  </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; border-top: medium none;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">March 31, 2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none;"> </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; border-top: medium none;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">December 31, 2011</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none;"> </td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="font-family: times new roman; font-size: 10pt; border-top: medium none;"> </td><td valign="bottom" style="font-family: times new roman; font-size: 10pt; border-top: medium none;"> </td><td colspan="2" valign="bottom" style="text-align: center; font-family: times new roman; font-size: 10pt; border-top: medium none;"> (unaudited)</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt; border-top: medium none;"> </td><td valign="bottom" style="font-family: times new roman; font-size: 10pt; border-top: medium none;"> </td><td colspan="2" valign="bottom" style="font-family: times new roman; font-size: 10pt; border-top: medium none;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt; border-top: medium none;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 76%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"><font style="letter-spacing: 9pt;">   </font><font style="letter-spacing: 9pt;">   </font><font style="letter-spacing: 9pt;">   </font><font style="letter-spacing: 9pt;">   </font><font style="letter-spacing: 9pt;">   </font><font style="letter-spacing: 9pt;">   </font></div><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Trade receivables</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">8,189</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">22,737</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 76%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Due from employees</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">128</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">121</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 76%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Allowance for doubtful accounts and</div></td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="padding-bottom: 2px; text-indent: 9pt; width: 76%;"><div style="text-align: left; text-indent: 9pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">commission adjustments</div></td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(2,089</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(2,163</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr><tr bgcolor="white"><td valign="bottom" style="padding-bottom: 4px; width: 76%; font-family: times new roman; font-size: 10pt;">  </td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">6,228</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">20,695</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr></table></div><div style="text-align: left; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"> </div><div style="text-align: left; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Trade receivables include amounts due for shipped products and services rendered.  Amounts currently due under the GEHC Agreement are subject to adjustment in subsequent periods should the underlying sales order amount, upon which the receivable is based, change.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Allowance for doubtful accounts and commission adjustments include estimated losses resulting from the inability of our customers to make required payments, and adjustments arising from subsequent changes in sales order amounts that may reduce the amount the Company will ultimately receive under the GEHC Agreement.  Due from employees primarily reflects commission advances made to sales personnel.</div></div>

<div><div style="text-align: justify; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 41.4pt;"><div style="text-align: justify; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 41.4pt;">NOTE L - RELATED-PARTY TRANSACTIONS</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">On June 21, 2007, we entered into a Securities Purchase Agreement with Kerns Manufacturing Corp. ("Kerns").  Pursuant to this agreement, a five-year warrant to purchase 4,285,714 shares of our common stock at an initial exercise price of $0.08 per share was issued to Kerns.  In March 2012, Kerns exercised its warrant and purchased 4,285,714 shares of common stock.  Concurrently with our entry into the Securities Purchase Agreement, we also entered into a Distribution Agreement and a Supplier Agreement with Living Data Technology Corporation ("Living Data"), an affiliate of Kerns.  Pursuant to the Distribution Agreement, as amended, we became the exclusive worldwide distributor of the AngioNew EECP<font style="display: inline; font-size: 70%; vertical-align: text-top;">®</font> systems manufactured through Living Data. The Distribution Agreement had an initial term extending through May 31, 2012.  Subsequent to August 31, 2011 the Company acquired Life Enhancement Technology (LET) (see Note I), the manufacturer of the AngioNew EECP<font style="display: inline; font-size: 70%; vertical-align: text-top;">®</font> system.  Consequently, the Distribution Agreement is no longer effective, and the Company wrote-off the remaining unamortized balance of Deferred Distributor Costs during the seven months ended December 31, 2011.</div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"> </div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">On February 28, 2011, David Lieberman and Edgar Rios were appointed by the Board of Directors as directors of the Company.  Mr. Lieberman, a practicing attorney in the State of New York, was appointed to serve as the Vice Chairman of the Board.  He is currently a senior partner at the law firm of Beckman, Lieberman & Barandes, LLP, which firm performs certain legal services for the Company.  Fees of approximately $67,000 were billed by the firm through the three months ended March 31, 2012, at which date no amounts were outstanding.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Mr. Rios currently is President of Edgary Consultants, LLC, and was appointed a director in conjunction with the Company's consulting agreement with Edgary Consultants, LLC.  The consulting agreement (the "Agreement") between the Company and Edgary Consultants, LLC ("Consultant") commenced on March 1, 2011 and runs for a two year term..  The Agreement provides for the engagement of Consultant to assist the Company in seeking broader reimbursement coverage of EECP<font style="display: inline; font-size: 70%; vertical-align: text-top;">®</font><font style="display: inline; font-size: 10pt;"> </font>therapy.  More specifically, Consultant will be assisting the Company in the following areas:</div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"> </div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr valign="top"><td align="right" style="width: 36pt;"><div style="display: inline; font-family: Times New Roman; font-size: 10pt;"><font style="display: inline; font-size: 10pt;">1.</font>  </div></td><td><div style="text-align: justify; text-indent: 0pt; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Engaging the adoption of EECP® therapy as a first line option for FDA cleared indications as it relates to CCS Class III/IV angina with a major commercial healthcare third-party payer.</div></td></tr></table></div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr valign="top"><td align="right" style="width: 36pt;"><div style="display: inline; font-family: Times New Roman; font-size: 10pt;"><font style="display: inline; font-size: 10pt;">2.</font>  </div></td><td><div style="text-align: justify; text-indent: 0pt; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Engaging a major commercial healthcare payer to formally collaborate and co-sponsor a study with Vasomedical for the efficacy, efficiency and/or cost effectiveness of the EECP® therapy for NYHA Class II/III heart failure.</div></td></tr></table></div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr valign="top"><td align="right" style="width: 36pt;"><div style="display: inline; font-family: Times New Roman; font-size: 10pt;"><font style="display: inline; font-size: 10pt;">3.</font>  </div></td><td><div style="text-align: justify; text-indent: 0pt; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Engaging final approval from the Centers for Medicare and Medicaid Services ("CMS") of EECP® therapy as a first line treatment for CCS Class III/IV angina.</div></td></tr></table></div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr valign="top"><td align="right" style="width: 36pt;"><div style="display: inline; font-family: Times New Roman; font-size: 10pt;"><font style="display: inline; font-size: 10pt;">4.</font>  </div></td><td><div style="text-align: justify; text-indent: 0pt; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Engaging final approval from CMS to extend coverage and provide for the reimbursement of EECP® therapy for CCS Class II angina; and</div></td></tr></table></div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr valign="top"><td align="right" style="width: 36pt;"><div style="display: inline; font-family: Times New Roman; font-size: 10pt;"><font style="display: inline; font-size: 10pt;">5.</font>  </div></td><td><div style="text-align: justify; text-indent: 0pt; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Engaging final approval from CMS to extend coverage and provide for the reimbursement of EECP® therapy for NYHA Class II/III heart failure.</div></td></tr></table></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">In consideration for the services to be provided by Consultant under the Agreement, the Company has agreed to issue to Consultant or its designees, approximately 10% of the outstanding capital stock of the Company, of which the substantial portion (in excess of 82%) is performance based as referenced above. In conjunction with the Agreement, 3,000,000 shares of restricted common stock valued at $1,020,000 were issued in March 2011.  In connection with the Agreement, Mr. Lieberman received 600,000 of these restricted shares.  The Company has recorded the fair value of the shares issued to Consultant as a prepaid expense and is amortizing the cost ratably over the two year agreement.  The unamortized value is reported as Deferred Related Party Consulting Expense in our accompanying consolidated condensed balance sheets as of March 31, 2012 and December 31, 2011.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">During the three months ended March 31, 2012, a director performed consulting services for the Company aggregating approximately $10,000.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Through the Company's acquisition of FGE in September 2011, it assumed the liability for $288,000 in unsecured notes payable to the President of LET and his spouse, of which $95,000 was repaid in December 2011, and $190,000, bearing interest at 6% per annum, was paid in March 2012.  In addition, receivables due from FGE management aggregating $158,000 were collected during the three months ended March 31, 2012.</div><br /></div></div>

294000

190000

-49065000

-50409000

13000

6043000

4845000

1453000

528000

533000

577000

<div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">NOTE H - INVENTORIES, NET</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Inventories, net of reserves, consist of the following:</div><div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> </div><div style="text-align: right; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="font-style: italic; display: inline; font-family: Times New Roman; font-size: 10pt;">                                                                                                                                                                          (in thousands)</font><br /></div><div style="text-align: right; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr bgcolor="#cceeff"><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none;">  </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; border-top: medium none;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">March 31, 2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none;"> </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; border-top: medium none;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">December 31, 2011</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none;"> </td></tr><tr bgcolor="white"><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">  </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"> </td><td colspan="2" valign="bottom" style="text-align: center; font-family: times new roman; font-size: 10pt;"> (unaudited)</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"> </td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 76%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Raw materials</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">896</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">842</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 76%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Work in process</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">577</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">528</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="padding-bottom: 2px; width: 76%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Finished goods</div></td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">712</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,051</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="white"><td valign="bottom" style="padding-bottom: 4px; width: 76%; font-family: times new roman; font-size: 10pt;">  </td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">2,185</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">2,421</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr></table></div><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">At March 31, 2012 and December 31, 2011, the Company had reserves for excess and obsolete inventory of $563,000 and $606,000, respectively.</div></div>

<div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">NOTE C - SEGMENT REPORTING AND CONCENTRATIONS</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The Company views its business in two segments - the Equipment segment and the Sales Representation segment.  The Equipment segment is engaged in designing, manufacturing, marketing and supporting EECP<font style="display: inline; font-size: 70%; vertical-align: text-top;">®</font> enhanced external counterpulsation systems both domestically and internationally, as well as the marketing of other medical devices.  The Sales Representation segment operates through the VasoHealthcare subsidiary and is currently engaged solely in the execution of the Company's responsibilities under our agreement with GEHC.  The Company evaluates segment performance based on operating income.  Administrative functions such as finance, human resources, and information technology are centralized and related expenses allocated to each segment.  There are no intersegment revenues.  Summary financial information for the segments is set forth below:</div><div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"> </div><div style="text-align: right; font-style: italic; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(in thousands)</div><div style="text-align: center; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><div style="text-align: left;"><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr bgcolor="#cceeff"><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none;">  </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none;"> </td><td colspan="14" valign="bottom" style="border-bottom: black 2px solid; text-align: center; border-top: medium none;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"> </font><font style="display: inline; font-family: times new roman; font-size: 10pt;">As of or for the three months ended March 31, 2012</font></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none;"> </td></tr><tr bgcolor="white"><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">  </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"> </td><td colspan="3" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Equipment Segment</div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"> </td><td colspan="3" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Sales Representation Segment</div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Corporate</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Consolidated</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">  </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"> </td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"> </td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"> </td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"> </td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Revenues from external customers</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,986</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">4,057</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">6,043</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Operating loss</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(157</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(796</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(348</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(1,301</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Total assets</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">9,227</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">8,381</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">13,010</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">30,618</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Accounts and other receivables, net</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,224</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">5,004</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">6,228</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Deferred commission expense</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">3,399</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">3,399</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="width: 52%; display: inline; font-family: times new roman; font-size: 10pt;">  </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="white"><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">  </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; font-family: times new roman; font-size: 10pt;"> </td><td colspan="13" valign="bottom" style="border-bottom: black 2px solid; text-align: center; font-family: times new roman; font-size: 10pt;">As of or for the three months ended March 31, 2011</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">  </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"> </td><td colspan="3" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Equipment Segment</div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"> </td><td colspan="3" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Sales Representation Segment</div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Corporate</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Consolidated</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="white"><td valign="bottom" style="width: 52%; display: inline; font-family: times new roman; font-size: 10pt;">  </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Revenues from external customers</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,105</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">3,740</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">4,845</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Operating loss</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(266</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(32</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(183</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(481</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Total assets</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">4,095</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">4,148</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">9,801</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">18,044</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Accounts and other receivables, net</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">454</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,874</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">2,328</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Deferred commission expense</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">2,270</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">2,270</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="white"><td valign="bottom" style="width: 52%; display: inline; font-family: times new roman; font-size: 10pt;">  </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr></table></div><div style="text-align: left;"> </div></div><div style="text-align: justify; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">For the three months ended March 31, 2012 and 2011, GE Healthcare accounted for 67% and 77% of revenue, respectively.  Also, GE Healthcare accounted for $4.9 million, or 76%, and $19.7 million, or 95%, of accounts and other receivables at March 31, 2012 and December 31, 2011, respectively.</div></div>

5330000

3629000

110000

<div><div style="text-align: justify; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">NOTE M - STOCKHOLDERS' EQUITY</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Common Stock</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">On June 17, 2010 the Board of Directors approved the 2010 Stock Plan (the "2010 Plan") for officers, directors, employees and consultants of the Company.  The stock issuable under the 2010 Plan shall be shares of the Company's authorized but unissued or reacquired common stock.  The maximum number of shares of common stock which may be issued under the 2010 Plan is 5,000,000 shares.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The 2010 Plan is comprised of two separate equity programs, the Options Grant Program, under which eligible persons may be granted options to purchase shares of common stock, and the Stock Issuance Program, under which eligible persons may be issued shares of common stock directly, either through the immediate purchase of such shares or as a bonus for services rendered to the Company.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The 2010 Plan provides that the Board of Directors, or a committee of the Board of Directors, will administer it with full authority to determine the identity of the recipients of the options or shares and the number of options or shares.  Options granted under the 2010 Plan may be either incentive stock options or non-qualified stock options.  The option price shall be 100% of the fair market value of the common stock on the date of the grant ( or in the case of incentive stock options granted to any individual stockholder possessing more than 10% of the total combined voting power of all voting stock of the Company, 110% of such fair market value).  The term of any option may be fixed by the Board of Directors, or its authorized committee, but in no event shall it exceed five years from the date of grant.  Options are exercisable upon payment in full of the exercise price, either in cash or in common stock valued at fair market value on the date of exercise of the option.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">As of March 31, 2012, 3,790,000 restricted shares of common stock were granted under the 2010 Plan to non-officer employees and consultants of the Company. As of March 31, 2012, 545,000 shares have been forfeited.  In March 2012, 500,000 restricted shares of common stock were granted under the 2010 Plan to an officer, of which 250,000 vested immediately with the remainder vesting over a one year period.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">No options were issued under the 2010 Plan during the three months ended March 31, 2012 and 2011.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">In September 2011, the Company issued 5,000,000 shares of restricted common stock and a two year common stock purchase warrant for 1,500,000 shares at an exercise price of $0.50 per share as partial consideration for the acquisition of FGE.  In addition, up to 2,400,000 shares of common stock are contingently issuable should FGE attain certain operating targets for the twelve months ending December 31, 2011.  The Company is completing its evaluation of FGE's calendar year 2011 results and believes it is likely that the targets have been met.  The aggregate value of the aforementioned noncash consideration relative to the FGE acquisition was $2,979,000.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Preferred Stock</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">On June 24, 2010, the Company filed a Certificate of Designations of Preferences and Rights of Series E Convertible Preferred Stock ("Certificate of Designations"), as authorized by the Board of Directors, designating 350,000 shares of its 1,000,000 shares of preferred stock as Series E Convertible Preferred Stock ("Series E Preferred"). The conversion rights of the Series E Preferred are that each share will be convertible at any time on or after January 1, 2011, at the holder's option into 100 shares of common stock (an exercise price of $.16 per share of common stock, the "Conversion Price"), subject to anti-dilution adjustment as set forth below.  Each share of outstanding Series E Preferred Stock shall automatically be converted into shares of common stock on or after July 1, 2011, at the then effective applicable conversion ratio, if, at any time following the Issuance Date, the price of the common stock for any 30 consecutive trading days equals or exceeds three times the Conversion Price and the average daily trading volume for the Company's common stock for the 30 consecutive trading days exceeds 250,000 shares.</div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"> </div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Pursuant to its conversion terms, the Series E Preferred was deemed automatically converted to common stock effective July 1, 2011.  As of March 31, 2012, 30,603,700 shares of common stock had been issued for 306,037 shares of Series E Preferred, with 64,750 shares of common stock yet to be issued.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">For the three months ended March 31, 2011, the Company sold 9,375 shares of Series E Preferred aggregating $150,000, and recorded dividends totaling $128,000.  Included in such dividends is the recognition of the value of the embedded beneficial conversion feature of the Series E Preferred, which reflects the difference between the conversion price and the market price at time of investment. The amounts included in the dividends reported attributable to this beneficial conversion feature are $65,000 for the three months ended March 31, 2011. These are noncash dividends requiring no payment and ceased on conversion of the Series E Preferred to common stock.</div></div>

<div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">NOTE J - GOODWILL AND OTHER INTANGIBLES</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Goodwill aggregating $3,939,000 was recorded on the Company's Consolidated Condensed Balance Sheets at March 31, 2012 and December 31, 2011, pursuant to the acquisition of FGE in September 2011.  All of the goodwill was allocated to the Company's Equipment segment.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The Company's other intangible assets consist of capitalized patent costs, as follows:</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: right; font-style: italic; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">                                                                                                                                                        (in thousands)</div><div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><div style="text-align: left;"><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr bgcolor="#cceeff"><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none;">  </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; border-top: medium none;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">March 31, 2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none;"> </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; border-top: medium none;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">December 31, 2011</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"> </td><td colspan="2" valign="bottom" style="text-align: center; font-family: times new roman; font-size: 10pt;"> (unaudited)</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"> </td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Patent Costs</div></td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"> </td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"> </td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="text-indent: 9pt; width: 76%;"><div style="text-align: left; text-indent: 9pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Costs</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">469</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$ </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">469</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="padding-bottom: 2px; text-indent: 9pt; width: 76%;"><div style="text-align: left; text-indent: 9pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Accumulated amortization</div></td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(420</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(413</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr><tr bgcolor="white"><td valign="bottom" style="padding-bottom: 4px; width: 76%; font-family: times new roman; font-size: 10pt;">  </td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">49</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">56</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr></table></div><div style="text-align: left; font-family: Times New Roman; font-size: 10pt;"> </div></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Patents are included in other assets in the accompanying Consolidated Condensed Balance Sheets.  Amortization expense amounted to $7,000 and $10,000 for the three months ended March 31, 2012 and 2011, respectively.</div></div>

186000

5000

25223000

28500000

152000

108000

30618000

34306000

20000

19000

141000

73000

<div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">NOTE D - SHARE-BASED COMPENSATION</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The Company complies with ASC Topic 718 "Compensation - Stock Compensation" ("ASC 718"), which requires all share-based awards to employees, including grants of employee stock options, to be recognized in the consolidated condensed financial statements based on their estimated fair values.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">During the three-month period ended March 31, 2012, the Company's Board of Directors granted 500,000 restricted shares of common stock, valued at $120,000 to an officer, of which half vested immediately and the remainder vests over one year. During the three-month period ended March 31, 2011, 200,000 shares of common stock valued at $62,000 were issued to two directors for joining the Board of Directors.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">During the three-month periods ended March 31, 2012 and 2011, the Company's Board of Directors did not grant any stock options.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Share-based compensation expense recognized for the three months ended March 31, 2012 and 2011 was $129,000 and $126,000, respectively.  These expenses are included in cost of revenues; selling, general, and administrative expenses; and research and development expenses in the consolidated condensed statements of operations.  Expense for share-based arrangements was $152,000 and $47,000 for the three months ended March 31, 2012 and 2011, respectively.  Unrecognized expense related to existing share-based arrangements is approximately $1.1 million at March 31, 2012 and will be recognized ratably through July 2013.</div></div>

<div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">NOTE F - FAIR VALUE MEASUREMENTS</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The Company complies with the provisions of ASC 820 "Fair Value Measurements and Disclosures" ("ASC 820").  Under ASC 820, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the "exit price") in an orderly transaction between market participants at the measurement date.</div><div style="text-align: left; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"> </div><div style="text-align: left; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The following tables present information about the Company's assets and liabilities measured at fair value as of <font style="display: inline; font-family: Times New Roman;">March 31, 2012 and December 31, 2011</font>:</div><div style="text-align: left; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"> </div><div style="text-align: right; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="font-style: italic; display: inline; font-family: Times New Roman; font-size: 10pt;">(in thousands)</font><br /></div><div style="text-indent: 0pt; display: block;"><div style="text-align: left;"><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr bgcolor="#cceeff"><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">  </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"> </td><td colspan="3" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Quoted Prices</div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">in Active</div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Markets for</div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Identical Assets</div></td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"> </td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Significant</div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Other</div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Observable</div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Inputs</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"> </td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Significant</div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Unobservable</div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Inputs</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"> </td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Balance</div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">as of</div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">March 31,</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="white"><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">  </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(Level 1)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(Level 2)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(Level 3)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"> </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"> </td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"> </td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"> </td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"> </td><td colspan="2" valign="bottom" style="text-align: center; font-family: times new roman; font-size: 10pt;">(unaudited) </td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Assets</div></td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"> </td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"> </td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"> </td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"> </td><td colspan="2" valign="bottom" style="text-align: center; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="text-indent: 9pt;"><div style="text-align: left; text-indent: 9pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Cash equivalents invested in money market funds </div><div style="text-align: left; text-indent: 9pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">     (included in cash and cash equivalents)</div></td><td align="right" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; font-family: times new roman; font-size: 10pt;">12,078</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="width: 0%; display: inline; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="width: 0%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="width: 0%; display: inline; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="width: 0%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; font-family: times new roman; font-size: 10pt;">12,078</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="padding-bottom: 2px; text-indent: 9pt;"><div style="text-align: left; text-indent: 9pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Investment in certificates of deposit </div><div style="text-align: left; text-indent: 9pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">     (included in short-term investments)</div></td><td align="right" valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; font-family: times new roman; font-size: 10pt;">110</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; font-family: times new roman; font-size: 10pt;">110</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="padding-bottom: 4px; width: 52%; font-family: times new roman; font-size: 10pt;">  </td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">12,188</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">12,188</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="white"><td valign="bottom" style="width: 52%; display: inline; font-family: times new roman; font-size: 10pt;">  </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">  </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"> </td><td colspan="3" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Quoted Prices</div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">in Active</div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Markets for</div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Identical Assets</div></td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"> </td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Significant</div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Other</div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Observable</div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Inputs</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"> </td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Significant</div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Unobservable</div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Inputs</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"> </td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Balance</div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">as of</div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">December 31,</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="white"><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">  </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(Level 1)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(Level 2)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(Level 3)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: center; font-family: times new roman; font-size: 10pt;">2011</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Assets</div></td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="text-indent: 9pt; width: 52%;"><div style="text-align: left; text-indent: 9pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Cash equivalents invested in money market funds</div><div style="text-align: left; text-indent: 9pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">     (included in cash and cash equivalents)</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,313</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$ </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,313</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="padding-bottom: 2px; text-indent: 9pt; width: 52%;"><div style="text-align: left; text-indent: 9pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Investment in certificates of deposit</div><div style="text-align: left; text-indent: 9pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">     (included in short-term investments)</div></td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">110</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">110</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="white"><td valign="bottom" style="padding-bottom: 4px; width: 52%; font-family: times new roman; font-size: 10pt;">  </td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,423</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,423</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr></table></div><br /></div><div style="text-align: left; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The fair values of the Company's cash equivalents invested in money market funds are determined through market, observable and corroborated sources.</div></div>

-1845000

-447000

931000

1337000

5482000

3737000

0.001

41000

196000

11276000

10396000

25000

-2000

-14543000

-10837000

<div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">NOTE E - LOSS PER COMMON SHARE</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"> Basic earnings per common share is computed as earnings applicable to common stockholders divided by the weighted-average number of common shares outstanding for the period.  Diluted earnings per common share reflects the potential dilution that could occur if securities or other contracts to issue common shares were exercised or converted to common stock.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Basic and diluted loss per common share was $0.01 for the three months ended March 31, 2012 and 2011.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The following table represents common stock equivalents that were excluded from the computation of diluted earnings per share for the three months ended March 31, 2012 and 2011, because the effect of their inclusion would be anti-dilutive.</div><div style="text-align: center; font-style: italic; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"> </div><div style="text-align: center; font-style: italic; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"> </div><div style="text-align: right; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="font-style: italic; display: inline; font-family: Times New Roman; font-size: 10pt;">      (in thousands)</font><br /></div><div style="text-indent: 0pt; display: block;"><div style="text-align: left;"><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr bgcolor="#cceeff"><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none;">  </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; border-top: medium none;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">March 31, 2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none;"> </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; border-top: medium none;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">March 31, 2011</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 76%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Stock options</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,810</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,864</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 76%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Warrants</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,500</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">4,286</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 76%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Contingently issuable shares</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">2,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 76%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Convertible preferred stock</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">31,855</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="padding-bottom: 2px; width: 76%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Common stock grants</div></td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">2,948</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">4,050</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="padding-bottom: 4px; width: 76%; font-family: times new roman; font-size: 10pt;">  </td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">8,258</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">42,055</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr></table></div><br /></div></div>

49000

39000

<div><div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">NOTE I- BUSINESS COMBINATION</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">On September 2, 2011, Vasomedical Global successfully completed the purchase of all the outstanding capital stock of privately-held Fast Growth Enterprises Limited ("FGE"), a British Virgin Islands company that owns subsidiaries which own and control Life Enhancement Technology Ltd ("LET") and Biox Instruments Co. Ltd. ("Biox"), respectively, as per the stock purchase agreement signed on August 19, 2011. The consideration of this acquisition includes a cash payment of $1 million as well as the issuance of 5 million restricted shares of the Company's common stock, up to 2.4 million shares of common stock contingently issuable upon the achievement of certain operating performance targets, and warrants covering 1.5 million shares of common stock.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">LET, based in Foshan, Guangdong, China, has been Vasomedical's supplier for its proprietary Enhanced External Counterpulsation (EECP<font style="display: inline; font-size: 70%; vertical-align: text-top;">®</font>) systems, including certain Lumenair systems and all AngioNew<font style="display: inline; font-size: 70%; vertical-align: text-top;">®</font><font style="display: inline; font-size: 10pt;"> </font>systems. Biox, a developer and manufacturer of ambulatory monitoring devices in China, is located in Wuxi, Jiangsu, China, and has been Vasomedical's partner on the BIOX series ECG Holter recorder and analysis software as well as ambulatory blood pressure monitoring systems. Vasomedical has obtained FDA clearance to market these products in the United States.  The acquisition of LET provides Vasomedical with consolidated technical and manufacturing capability in its EECP business which should significantly increase gross margins and enable the Company to meet anticipated increasing demand for its EECP systems.  The acquisition of Biox greatly enhances Vasomedical's distribution network, technology and product portfolio, and with combined market and sales efforts of the two companies, should help improve performance and profitability of Vasomedical's equipment segment.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The operating results of FGE are included in the accompanying Consolidated Condensed Statements of Operations and Comprehensive Loss and Cash Flows for the three months ended March 31, 2012.  The Consolidated Condensed Balance Sheet as of March 31, 2012 reflects the acquisition of FGE, effective September 2, 2011.  The acquisition date fair value of the total consideration transferred was $3.979 million, which consisted of the following:</div></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-indent: 0pt; display: block;"><div style="text-indent: 0pt; display: block;"> </div><div style="text-align: right; font-style: italic; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;">(in thousands)</div><div style="text-align: left; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 88%; border-top: medium none;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Cash</div></td><td align="right" valign="bottom" style="width: 1%; font-family: times new roman; font-size: 10pt; border-top: medium none;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; border-top: medium none;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt; border-top: medium none;">1,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; border-top: medium none;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 88%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Vasomedical, Inc. common stock ($0.42 per share)</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">2,100</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 88%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Vasomedical, Inc. warrants to purchase common stock</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">304</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="padding-bottom: 2px; width: 88%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Contingent issuance of Vasomedical, Inc. common stock ($0.42 per share)</div></td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">575</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="padding-bottom: 4px; text-indent: 9pt; width: 88%;"><div style="text-align: left; text-indent: 9pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Total purchase price</div></td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">3,979</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr></table></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">In accordance with Accounting Standards Codification ("ASC") 805, Business Combinations ("ASC 805"), the total purchase consideration is allocated to the net tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values as of September 2, 2011 (the acquisition date).  The purchase price was allocated based on the information currently available, and may be adjusted after obtaining more information regarding, among other things, asset valuations, liabilities assumed, and revisions of preliminary estimates.  The following table summarizes the estimated fair values of the assets acquired and liabilities assumed at the acquisition date:</div><div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"> </div><div style="text-align: right; font-style: italic; text-indent: 0pt; display: block; font-family: times new roman; font-size: 10pt;">(in thousands)</div><div style="text-align: left; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 88%; border-top: medium none;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Cash and cash equivalents</div></td><td align="right" valign="bottom" style="width: 1%; font-family: times new roman; font-size: 10pt; border-top: medium none;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; border-top: medium none;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt; border-top: medium none;">442</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; border-top: medium none;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 88%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Accounts receivable and other current assets</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">283</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 88%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Inventories</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">476</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 88%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Property and equipment</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">32</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 88%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Goodwill</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">3,939</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="padding-bottom: 2px; width: 88%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Accounts payable and other current liabilites</div></td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(1,193</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="padding-bottom: 4px; text-indent: 9pt; width: 88%;"><div style="text-align: left; text-indent: 9pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Net assets acquired</div></td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">3,979</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr></table></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"> </div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The goodwill is attributable to the synergies expected to arise after the Company's acquisition of FGE as well as FGE's projected growth and profitability.  The goodwill is not expected to be deductible for tax purposes.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">After elimination of intercompany transactions which reduce the income from FGE, the amounts of revenue and net income of FGE included in the Company's Consolidated Condensed Statement of Operations for the three months ended March 31, 2012 was $578,000 and $35,000, respectively.  The effect of FGE earnings on earnings per share was $0.00.</div></div><div style="text-indent: 0pt; display: block;"> </div><div style="text-indent: 0pt; display: block;"><div style="text-align: left; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The following supplemental pro forma information presents the financial results as if the acquisition of FGE had occurred June 1, 2009 (amounts in thousands, except per share amounts):</div><div style="text-align: left; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"> </div></div><div style="text-align: right; font-style: italic; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">                                                                                                                                          (in thousands except per share data)</div><div style="text-indent: 0pt; display: block;"><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr bgcolor="#cceeff"><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none;">  </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none;"> </td><td colspan="6" valign="bottom" style="border-bottom: black 2px solid; text-align: center; border-top: medium none;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"> </font><font style="display: inline; font-family: times new roman; font-size: 10pt;">Three months ended March 31,</font></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none;"> </td></tr><tr bgcolor="white"><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">  </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">2011</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 76%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Revenue</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">6,043</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">5,219</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="white"><td valign="bottom" style="width: 76%; display: inline; font-family: times new roman; font-size: 10pt;">  </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 76%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Net loss</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(1,170</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(274</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr><tr bgcolor="white"><td valign="bottom" style="width: 76%; display: inline; font-family: times new roman; font-size: 10pt;">  </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 76%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Basic and diluted loss per share</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(0.01</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(0.00</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr><tr bgcolor="white"><td valign="bottom" style="width: 76%; display: inline; font-family: times new roman; font-size: 10pt;">  </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr></table></div></div>

<div><div style="text-align: justify; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">NOTE A - ORGANIZATION AND PLAN OF OPERATIONS</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Vasomedical, Inc. was incorporated in Delaware in July 1987. Unless the context requires otherwise, all references to "we", "our", "us", "Company", "registrant", "Vasomedical" or "management" refer to Vasomedical, Inc. and its subsidiaries. Since 1995, we have been primarily engaged in designing, manufacturing, marketing and supporting EECP<font style="display: inline; font-size: 70%; vertical-align: text-top;">®</font> enhanced external counterpulsation systems based on our unique proprietary technology currently indicated for use in cases of stable or unstable angina (i.e., chest pain), congestive heart failure ("CHF"), acute myocardial infarction (i.e., heart attack, (MI)) and cardiogenic shock.  The Company, through its wholly-owned subsidiary Vaso Diagnostics, Inc. d/b/a VasoHealthcare, is the exclusive sales representative for GE Healthcare ("GEHC"), the healthcare business unit of General Electric Company (NYSE: GE), for the sale of select GE Healthcare Diagnostic Imaging products.  Under the GEHC Agreement, VasoHealthcare has been appointed the exclusive representative for these products to specific market segments in the 48 contiguous states of the United States and the District of Columbia.  The GEHC Agreement has an initial term of three years commencing July 1, 2010, subject to extension and also subject to earlier termination under certain circumstances.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">In September 2011, the Company acquired Fast Growth Enterprises Limited (FGE), a British Virgin Islands company which, through its subsidiaries, owns and controls two Chinese operating companies - Life Enhancement Technologies Ltd. and Biox Instruments Co. Ltd., respectively - to expand its technical and manufacturing capabilities and to enhance its distribution network, technology, and product portfolio.  Also in September 2011, the Company restructured to further align its business management structure and long-term growth strategy and now operates through three wholly-owned subsidiaries.  Vaso Diagnostics d/b/a VasoHealthcare continues as the operating subsidiary for the sales representation of GE Healthcare diagnostic imaging products; Vasomedical Global Corp. operates the Company's recently-acquired Chinese companies; and Vasomedical Solutions, Inc. manages and coordinates our EECP<font style="display: inline; font-size: 70%; vertical-align: text-top;">® </font>therapy business as well as other medical equipment operations.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">We report the operations of Vasomedical Global Corp. and Vasomedical Solutions, Inc. under our Equipment reportable segment.  VasoHealthcare activities are included under our Sales Representation reportable segment (See Note C).</div></div>

362000

273000

2270000

2531000

112000

2103000

3889000

3000

193000

399000

355000

101000

278000

-1319000

-467000

<div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">NOTE O - RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS</div><div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><br /></div><div style="text-align: justify; font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Other Comprehensive Income: Presentation of Comprehensive Income</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">In June 2011, new guidance was issued that amends the current comprehensive income guidance. The new guidance allows the option to present the total of comprehensive income, the components of net income, and the components of other comprehensive income either in a single or continuous statement of comprehensive income or in two separate but consecutive statements. The amendments in this update do not change the items that must be reported in other comprehensive income or when an item of other comprehensive income must be reclassified to net income. The new guidance is to be applied retrospectively and is effective for fiscal years, and interim periods, beginning after December 15, 2011, with early adoption permitted.  The Company does not expect that it will have a material impact on its consolidated condensed financial statements.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">In December 2011, the FASB issued authoritative guidance to defer the effective date for those aspects of the guidance relating to the presentation of reclassification adjustments out of accumulated other comprehensive income. The adoption of this new guidance will not have an impact on the Company's consolidated financial position, results of operations or cash flows as it only requires a change in the format of the current presentation of other comprehensive income.</div></div>

6228000

20695000

-2000

-177000

343000

<div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">NOTE B - BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Basis of Presentation and Use of Estimates</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The accompanying consolidated condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") and pursuant to the accounting and disclosure rules and regulations of the Securities and Exchange Commission (the "SEC"). Certain information and disclosures normally included in the consolidated condensed financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these consolidated condensed financial statements should be read in connection with the audited consolidated financial statements and related notes thereto included in the Company's Annual Report on Form 10-K for the transition period ended December 31, 2011, as filed with the SEC. These consolidated condensed financial statements include the accounts of the companies over which we exercise control. In the opinion of management, the accompanying consolidated condensed financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of interim results for the Company. The results of operations for any interim period are not necessarily indicative of results to be expected for any other interim period or the full year.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the consolidated condensed financial statements, the disclosure of contingent assets and liabilities in the consolidated condensed financial statements and the accompanying notes, and the reported amounts of revenues, expenses and cash flows during the periods presented. Actual amounts and results could differ from those estimates. The estimates and assumptions the Company makes are based on historical factors, current circumstances and the experience and judgment of the Company's management. The Company evaluates its estimates and assumptions on an ongoing basis.</div><div style="text-indent: 0pt; display: block;"> </div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Significant Accounting Policies</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Note B of the Notes to Consolidated Financial Statements, included in the Transition Report on Form 10-K for the seven months ended December 31, 2011, includes a summary of the significant accounting policies used in the preparation of the consolidated condensed financial statements.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Reclassifications</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Certain reclassifications have been made to prior period amounts to conform with the current period presentation.</div></div>

-28000

2000

-22000

91000

-69000

-414000

-481000

-68000

-0.01

128000

false --12-31 2012-03-31 No No Yes Smaller Reporting Company VASOMEDICAL INC 0000839087 158682110 2012 Q1 10-Q 0 1020000 0 101000 12000 62000 -47000 -152000 963000 930000 4057000 3740000 154377000 111937000 18000 31000 0 85000 467000 510000

EX-101.SCH 6 vaso-20120331.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 010000 - Statement - CONSOLIDATED CONDENSED BALANCE SHEETS (unaudited) link:presentationLink link:calculationLink link:definitionLink 010100 - Statement - CONSOLIDATED CONDENSED BALANCE SHEETS (unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 020000 - Statement - CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (unaudited) link:presentationLink link:calculationLink link:definitionLink 030000 - Statement - CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS (unaudited) link:presentationLink link:calculationLink link:definitionLink 060100 - Disclosure - ORGANIZATION AND PLAN OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 060200 - Disclosure - BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 060300 - Disclosure - SEGMENT REPORTING AND CONCENTRATIONS link:presentationLink link:calculationLink link:definitionLink 060400 - Disclosure - SHARE-BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 060500 - Disclosure - LOSS PER COMMON SHARE link:presentationLink link:calculationLink link:definitionLink 060600 - Disclosure - FAIR VALUE MEASUREMENTS link:presentationLink link:calculationLink link:definitionLink 060700 - Disclosure - ACCOUNTS AND OTHER RECEIVABLES, NET link:presentationLink link:calculationLink link:definitionLink 060800 - Disclosure - INVENTORIES, NET link:presentationLink link:calculationLink link:definitionLink 060900 - Disclosure - BUSINESS COMBINATION link:presentationLink link:calculationLink link:definitionLink 061000 - Disclosure - GOODWILL AND OTHER INTANGIBLES link:presentationLink link:calculationLink link:definitionLink 061100 - Disclosure - DEFERRED REVENUE link:presentationLink link:calculationLink link:definitionLink 061200 - Disclosure - RELATED-PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 061300 - Disclosure - STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 061400 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 061500 - Disclosure - RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 vaso-20120331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.LAB 8 vaso-20120331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Accumulated other comprehensive income PROPERTY AND EQUIPMENT, accumulated depreciation Additional paid-in capital Accounts and other receivables, allowance for doubtful accounts and commission adjustments Amortization of deferred distributor costs Other Amortization of Deferred Charges CONSOLIDATED CONDENSED BALANCE SHEETS (unaudited) [Abstract] Cash and cash equivalents Cash and cash equivalents - beginning of period Cash and cash equivalents - end of period Interest paid Deferred commission expense Increase (Decrease) in Deferred Charges Inventories, net Increase (Decrease) in Inventories Deferred tax liability Increase (Decrease) in Other Accrued Liabilities Sales tax payable Accounts payable Changes in operating assets and liabilities: Accrued expenses and other liabilities Trade payable due to related party Receivables due from related parties Increase (Decrease) in Due from Related Parties, Current COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Common stock, shares authorized (in shares) Common stock, shares issued (in shares) Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Common stock, $.001 par value; 250,000,000 shares authorized; 158,182,110 and 153,186,295 shares issued and outstanding at March 31, 2012 and December 31, 2011 Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Total cost of revenues Cost of Goods and Services Sold Cost of revenues Cost of sales, equipment Cost of equipment rentals and services Total current liabilities Liabilities, Current CURRENT LIABILITIES DEFERRED REVENUE Deferred Revenue Disclosure [Text Block] Deferred revenue - current portion Deferred revenue Deferred Revenue, Noncurrent Accrued preferred stock dividends Effect of exchange rate differences on cash Effect of Exchange Rate on Cash and Cash Equivalents Share-based compensation Gross profit Gross Profit CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS (unaudited) [Abstract] Accrued commissions Finance receivables Increase (Decrease) in Finance Receivables GOODWILL Inventories, net Inventory, Net Total Liabilities and stockholders' equity Liabilities and Equity LIABILITIES AND STOCKHOLDERS' EQUITY Net cash provided by (used in) financing activities Net Cash Provided by (Used in) Financing Activities Cash flows from financing activities Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Cash flows from investing activities Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from operating activities Net loss Net loss Net loss applicable to common stockholders Net Income (Loss) Available to Common Stockholders, Basic NET INCREASE IN CASH AND CASH EQUIVALENTS Cash and Cash Equivalents, Period Increase (Decrease) RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS [Abstract] Total other income, net Nonoperating Income (Expense) Other income (expenses) Interest and financing costs Interest and Debt Expense Total long-term liabilities Liabilities, Noncurrent LONG-TERM LIABILITIES FINANCING RECEIVABLES, net Operating loss Operating Income (Loss) Foreign currency translation loss Other comprehensive loss Other current assets Other Assets, Current Deferred commission expense Other Deferred Costs, Net Preferred stock, shares authorized (in shares) Preferred stock, shares issued (in shares) Preferred stock, shares outstanding (in shares) Preferred stock, par value (in dollars per share) Proceeds from issuance of preferred stock PROPERTY AND EQUIPMENT, net of accumulated depreciation of $1,493 at March 31, 2012 and $1,774 at December 31, 2011 Provision for doubtful accounts and commission adjustments Provision for Doubtful Accounts Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Purchases of short-term investments Payments to Acquire Short-term Investments ACCOUNTS AND OTHER RECEIVABLES, NET Loans, Notes, Trade and Other Receivables Disclosure [Text Block] RELATED-PARTY TRANSACTIONS Related Party Transactions Disclosure [Text Block] Repayment of note payable Repayments of Notes Payable Repayment of notes payable due to related party Repayments of Related Party Debt Accumulated deficit Amortization of deferred gain on sale-leaseback of building Amortization of deferred gain on sale-leaseback of building Total revenues Revenue, Net Revenues Revenue, Net [Abstract] Equipment sales Equipment rentals and services INVENTORIES, NET Inventory Disclosure [Text Block] SEGMENT REPORTING AND CONCENTRATIONS Segment Reporting Disclosure [Text Block] Selling, general and administrative Short-term investments CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) [Abstract] STOCKHOLDERS' EQUITY STOCKHOLDERS' EQUITY Stockholders' Equity Note Disclosure [Text Block] GOODWILL AND OTHER INTANGIBLES Goodwill and Intangible Assets Disclosure [Text Block] SUPPLEMENTAL DISCLOSURE OF CASH INFORMATION Income taxes paid Total current assets Assets, Current CURRENT ASSETS Research and development Total Assets Assets Financing receivables, net Other long-term liabilities Other Liabilities, Noncurrent SHARE-BASED COMPENSATION Disclosure of Compensation Related Costs, Share-based Payments [Text Block] ASSETS STOCKHOLDERS' EQUITY [Abstract] FAIR VALUE MEASUREMENTS Fair Value Disclosures [Text Block] Deferred revenue OTHER ASSETS Operating expenses Total operating expenses Operating Expenses Loss per common share LOSS PER COMMON SHARE [Abstract] Common stock, par value (in dollars per share) Receivables due from related parties Accounts Receivable, Related Parties Total stockholders' equity Stockholders' Equity Attributable to Parent Income tax benefit (expense), net Income Tax Expense (Benefit) Preferred stock, $.01 par value; 1,000,000 shares authorized; nil shares issued and outstanding at March 31, 2012, and December 31, 2011 Accounts and other receivables Increase (Decrease) in Accounts and Other Receivables LOSS PER COMMON SHARE Depreciation and amortization of property and equipment Depreciation, Depletion and Amortization BUSINESS COMBINATION Business Combination Disclosure [Text Block] COMMITMENTS AND CONTINGENCIES (NOTE N) Adjustments to reconcile net loss to net cash provided by (used in) operating activities ORGANIZATION AND PLAN OF OPERATIONS Nature of Operations [Text Block] Accounts payable Accounts Payable, Current Accrued expenses and other liabilities Accrued Liabilities, Current Deferred tax liability, net Accrued Professional Fees, Current Accrued commissions Accrued Sales Commission, Current Notes payable due to related party Sales tax payable Sales and Excise Tax Payable, Current Income taxes payable Taxes Payable, Current Loss before income taxes Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS Description of New Accounting Pronouncements Not yet Adopted [Text Block] Accounts and other receivables, net of an allowance for doubtful accounts and commission adjustments of $2,089 at March 31, 2012 and $2,163 at December 31, 2011 Income taxes payable Proceeds from exercise of warrant BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES Basis of Presentation and Significant Accounting Policies [Text Block] Interest and other income, net ORGANIZATION AND PLAN OF OPERATIONS [Abstract] BUSINESS COMBINATION [Abstract] COMMITMENTS AND CONTINGENCIES [Abstract] GOODWILL AND OTHER INTANGIBLES [Abstract] FAIR VALUE MEASUREMENTS [Abstract] INVENTORIES, NET [Abstract] SHARE-BASED COMPENSATION [Abstract] BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES [Abstract] DEFERRED REVENUE [Abstract] SEGMENT REPORTING AND CONCENTRATIONS [Abstract] RELATED-PARTY TRANSACTIONS [Abstract] Other current assets Increase (Decrease) in Other Current Assets Other assets Increase (Decrease) in Other Noncurrent Assets Other long-term liabilities - basic and diluted (in dollars per share) SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES Preferred stock dividends Preferred Stock Dividends, Income Statement Impact Weighted average common shares outstanding Amendment Flag Current Fiscal Year End Date Document Period End Date Entity Well-known Seasoned Issuer EX-101.PRE 9 vaso-20120331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 R9.htm IDEA: XBRL DOCUMENT

SHARE-BASED COMPENSATION	3 Months Ended
SHARE-BASED COMPENSATION	Mar. 31, 2012
SHARE-BASED COMPENSATION [Abstract]
SHARE-BASED COMPENSATION	NOTE D - SHARE-BASED COMPENSATION The Company complies with ASC Topic 718 "Compensation - Stock Compensation" ("ASC 718"), which requires all share-based awards to employees, including grants of employee stock options, to be recognized in the consolidated condensed financial statements based on their estimated fair values. During the three-month period ended March 31, 2012, the Company's Board of Directors granted 500,000 restricted shares of common stock, valued at $120,000 to an officer, of which half vested immediately and the remainder vests over one year. During the three-month period ended March 31, 2011, 200,000 shares of common stock valued at $62,000 were issued to two directors for joining the Board of Directors. During the three-month periods ended March 31, 2012 and 2011, the Company's Board of Directors did not grant any stock options. Share-based compensation expense recognized for the three months ended March 31, 2012 and 2011 was $129,000 and $126,000, respectively. These expenses are included in cost of revenues; selling, general, and administrative expenses; and research and development expenses in the consolidated condensed statements of operations. Expense for share-based arrangements was $152,000 and $47,000 for the three months ended March 31, 2012 and 2011, respectively. Unrecognized expense related to existing share-based arrangements is approximately $1.1 million at March 31, 2012 and will be recognized ratably through July 2013.

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Statement of Position (SOP)

-Number 93-6

-Paragraph 53

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph 64, 65, A240

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 40

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 50

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

EXCEL 12 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\T9C0X-3(Q,U]F-3`V7S0P,F)?8C%E,%\T,S1B M,&8W,F1A,C(B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-/3E-/3$E$051%1%]#3TY$14Y3141?4U1!5$5- M13$\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I7 M;W)K#I7;W)K#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D9!25)?5D%,545?345!4U5214U%3E13/"]X.DYA;64^#0H@ M("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I% M>&-E;%=O#I%>&-E;%=O#I7;W)K#I7;W)K#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I.86UE/@T* M("`@(#QX.E=O#I% M>&-E;%=O#I.86UE/E)%0T5.5$Q97TE34U5%1%]! M0T-/54Y424Y'7U!23SPO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O6QE#I!8W1I=F53:&5E=#X-"B`@/'@Z4')O M=&5C=%-T#I0#I0#I0&UL/CPA6V5N9&EF72TM/@T*/"]H96%D M/@T*("`\8F]D>3X-"B`@(#QP/E1H:7,@<&%G92!S:&]U;&0@8F4@;W!E;F5D M('=I=&@@36EC'1087)T7S1F-#@U,C$S7V8U M,#9?-#`R8E]B,64P7S0S-&(P9C'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$2!#96YT3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^,#`P,#@S M.3`X-SQS<&%N/CPO'0^+2TQ,BTS,3QS<&%N/CPO2!&:6QE'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!&:6QE3PO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^4VUA;&QE3QS<&%N/CPO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^9F%L'0^36%R(#,Q+`T*"0DR,#$R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%\T9C0X-3(Q,U]F-3`V7S0P,F)?8C%E,%\T,S1B,&8W M,F1A,C(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-&8T.#4R,3-? M9C4P-E\T,#)B7V(Q93!?-#,T8C!F-S)D83(R+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M M<#XR+#4U.3QS<&%N/CPO6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA M'!E;G-E"!P87EA8FQE M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS.3D\3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$F5D.R`Q-3@L,3@R+#$Q M,"!A;F0@,34S+#$X-BPR.34@'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQAF5D M("AI;B!S:&%R97,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ M+#`P,"PP,#`\'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA&-E<'0@4&5R(%-H87)E(&1A M=&$L('5N;&5S'!E;G-E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q M+#,Q.2D\3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%\T9C0X-3(Q,U]F-3`V7S0P,F)?8C%E,%\T,S1B M,&8W,F1A,C(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-&8T.#4R M,3-?9C4P-E\T,#)B7V(Q93!?-#,T8C!F-S)D83(R+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!A;F0@97%U:7!M96YT/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT.3QS<&%N/CPO'!E;G-E6%B;&4@9'5E('1O M(')E;&%T960@<&%R='D\+W1D/@T*("`@("`@("`\=&0@8VQA2!O<&5R871I;F<@86-T:79I=&EE2!A;F0@97%U:7!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M M/B@Q,3,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6%B;&4\+W1D/@T*("`@("`@("`\ M=&0@8VQA6UE;G0@;V8@;F]T97,@<&%Y M86)L92!D=64@=&\@3PO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$2!A;F0@97%U:7!M M96YT+"!A='1R:6)U=&%B;&4@=&\@;W!E7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA3L@=&5X="UI;F1E;G0Z(#,V<'0[(&1I3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@,'!T M.R!F;VYT+7-I>F4Z(#$P<'0[(&UA2(L(")R96=I3H@ M:6YL:6YE.R!F;VYT+7-I>F4Z(#'0M M=&]P.R<^)B,Q-S0[/"]F;VYT/B!E;FAA;F-E9"!E>'1E2!T96-H;F]L;V=Y(&-U2!I;F1I8V%T960@9F]R('5S92!I M;B!C87-E2UO=VYE9"!S=6)S:61I M87)Y(%9A&-L=7-I=F4@2`Q+"`R,#$P+"!S=6)J96-T('1O(&5X=&5N3H@8FQO8VL[)SX\8G(@+SX\+V1I M=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD M96YT.B`S-G!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S M($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T M.R!M87)G:6XM2!A8W%U:7)E9"!&87-T($=R;W=T:"!%;G1E2!W M:&EC:"P@=&AR;W5G:"!I=',@2P@86YD('!R;V1U8W0@<&]R=&9O;&EO+B8C,38P.R8C,38P.T%L2!A;F0@;F]W(&]P97)A M=&5S('1H3H@8FQO8VL[)SX\8G(@+SX\+V1I=CX\9&EV('-T>6QE M/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`S-G!T.R!D M:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@ M;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM'0O:F%V87-C3X-"B`@ M("`\=&%B;&4@8VQA3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I3H@8FQO8VL[ M(&9O;G0M9F%M:6QY.B!4:6UE&-H86YG92!#;VUM:7-S:6]N("AT:&4@(E-%0R(I+B!#97)T86EN(&EN M9F]R;6%T:6]N(&%N9"!D:7-C;&]S=7)E2!I;F-L=61E9"!I M;B!T:&4@8V]N&5R8VES92!C;VYT2X@5&AE(')E65A6QE/3-$)W1E M>'0M:6YD96YT.B`P<'0[(&1I3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE2!M86ME'!E2=S(&UA;F%G96UE;G0N(%1H M92!#;VUP86YY(&5V86QU871E3H@8FQO8VL[)SXF(S$V,#L\+V1I M=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT M.B`P<'0[(&1I3H@5&EM97,@3F5W M(%)O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&9O M;G0M=V5I9VAT.B!B;VQD.R!M87)G:6XM6QE/3-$)W1E M>'0M:6YD96YT.B`P<'0[(&1I3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE3H@8FQO8VL[)SX\ M8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%\T9C0X-3(Q,U]F-3`V7S0P,F)?8C%E,%\T,S1B,&8W,F1A,C(-"D-O M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-&8T.#4R,3-?9C4P-E\T,#)B M7V(Q93!?-#,T8C!F-S)D83(R+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^/&1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E M>'0M:6YD96YT.B`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`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM M;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T M;VT@'0M:6YD96YT M.B`P<'0[(&1I3H@=&EM97,@;F5W M(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA M3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!V86QI9VX],T1B;W1T;VT@#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE M.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@8V]L6QE/3-$)V)O"!S;VQI M9#LG/CQD:78@#L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q M-C`[/"]T9#X\+W1R/CQT6QE/3-$)V1I6QE/3-$)V1I6QE/3-$ M)V1I3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N M/3-$,B!V86QI9VX],T1B;W1T;VT@3H@:6YL:6YE M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY M.B!T:6UE3H@8FQO8VL[(&9O M;G0M9F%M:6QY.B!T:6UE6QE/3-$)W=I9'1H.B`Q)3L@ M9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B M;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W=I9'1H.B`Q)3L@9&ES M<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T M;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA M>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@ M3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1R:6=H="!V86QI M9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE M.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXI/"]T9#X\ M=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXI/"]T9#X\=&0@86QI9VX],T1R:6=H="!V M86QI9VX],T1B;W1T;VT@6QE/3-$ M)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY M.B!T:6UE6QE/3-$)W=I M9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V M86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T M:6UE6QE/3-$)W=I9'1H M.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI M9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q M,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT M+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXS,"PV,3@\+W1D/CQT9"!N M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT M6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\ M=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@ M86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS M1')I9VAT('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`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`Q,'!T.R!M87)G:6XM6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA M>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@ M3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1R:6=H="!V86QI M9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE M.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1R:6=H="!V86QI9VX] M,T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXS+#,Y.3PO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T M;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CPO='(^/'1R(&)G8V]L;W(],T0C8V-E969F/CQT9"!V86QI M9VX],T1B;W1T;VT@3H@:6YL M:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L@/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T M;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q M,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T M:6UE3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!N;W=R87`] M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE M.B`Q,'!T.R<^)B,Q-C`[(#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V M86QI9VX],T1B;W1T;VT@3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!C;VQS<&%N/3-$,3,@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O"!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SY!#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT6QE/3-$)W!A9&1I;F#L@9F]N="UF86UI;'DZ('1I M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\ M=&0@8V]L6QE/3-$)V)O"!S;VQI9#LG/CQD:78@6QE/3-$)W!A9&1I;F6QE/3-$ M)W1E>'0M86QI9VXZ(&-E;G1E3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('!A9&1I;F3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX] M,T1B;W1T;VT@'0M M:6YD96YT.B`P<'0[(&1I3H@=&EM M97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P M<'0[(&UA3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CPO='(^/'1R(&)G8V]L;W(],T1W:&ET93X\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`U,B4[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@ M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T M:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CPO='(^/'1R(&)G8V]L;W(],T0C8V-E969F M/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I M9'1H.B`U,B4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E M>'0M:6YD96YT.B`P<'0[(&1I3H@ M=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z M(#$P<'0[(&UA'1E M6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@ M=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXQ+#$P-3PO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V M86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1')I9VAT('9A;&EG M;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED M=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXS+#3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG M;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z M(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXM/"]T9#X\=&0@;F]W6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O M;G0M9F%M:6QY.B!T:6UE6QE/3-$)W=I9'1H.B`U,B4[)SX\ M9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P M<'0[(&1I3H@=&EM97,@;F5W(')O M;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q M,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT M+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXH,C8V/"]T9#X\=&0@;F]W M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO M=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R M:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXH,S(\+W1D/CQT9"!N;W=R87`],T1N;W=R M87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N M="US:7IE.B`Q,'!T.R<^*3PO=&0^/'1D(&%L:6=N/3-$6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T M:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q M,'!T.R<^*3PO=&0^/'1D(&%L:6=N/3-$6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O M;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^*3PO M=&0^/"]T3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^ M)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N M.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXT+#`Y-3PO=&0^/'1D(&YO=W)A<#TS M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1')I M9VAT('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO M=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R M:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXT+#$T.#PO=&0^/'1D(&YO=W)A<#TS1&YO M=W)A<"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1')I9VAT M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^ M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H M=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXY+#@P,3PO=&0^/'1D(&YO=W)A<#TS1&YO=W)A M<"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1')I9VAT('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@ M=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXQ."PP-#0\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT3H@8FQO8VL[(&9O;G0M9F%M:6QY M.B!T:6UE6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA M>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@ M3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1')I9VAT('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@ M=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXQ+#@W-#PO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V M86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1')I9VAT('9A;&EG M;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED M=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXM/"]T9#X\=&0@;F]W6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[ M(&9O;G0M9F%M:6QY.B!T:6UE3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXM/"]T9#X\=&0@;F]W6QE M/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M M:6QY.B!T:6UE6QE/3-$ M)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY M.B!T:6UE6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@ M86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT M3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!N;W=R M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[ M(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T M9#X\+W1R/CPO=&%B;&4^/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N M.B!L969T.R<^)B,Q-C`[/"]D:78^/"]D:78^/&1I=B!S='EL93TS1"=T97AT M+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B M;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE M9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$3H@8FQO8VL[)SX\8G(@+SX\+V1I=CX\9&EV('-T>6QE M/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`S-G!T.R!D M:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@ M;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM3L@=&5X M="UI;F1E;G0Z(#,V<'0[(&1I3H@ M5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z M(#$P<'0[(&UA2!A;F0@=&AE(')E;6%I;F1E3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4 M:6UE3L@=&5X="UI;F1E;G0Z(#,V M<'0[(&1I3H@5&EM97,@3F5W(%)O M;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA'!E;G-E(')E;&%T960@=&\@97AI&EM871E;'D@ M)#$N,2!M:6QL:6]N(&%T($UA2!T:')O=6=H($IU;'D@,C`Q,RX\+V1I=CX\+V1I M=CX\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I M3H@ M8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE3H@8FQO8VL[)SX\8G(@+SX\+V1I=CX\9&EV('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`S-G!T M.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA M;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM M3L@=&5X="UI;F1E M;G0Z(#,V<'0[(&1I3H@5&EM97,@ M3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[ M(&UA6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E3H@8FQO8VL[(&9O;G0M M9F%M:6QY.B!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E3H@8FQO8VL[ M(&9O;G0M9F%M:6QY.B!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!T97AT M+6EN9&5N=#H@,S9P=#L@9&ES<&QA>3H@8FQO8VL[(&UA3H@8FQO8VL[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[)SX\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!S M='EL93TS1"=W:61T:#H@,3`P)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/'1R(&)G8V]L;W(],T0C8V-E969F M/CQT9"!V86QI9VX],T1B;W1T;VT@#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE M.B`Q,'!T.R!B;W)D97(M=&]P.B!M961I=6T@;F]N93LG/B8C,38P.R`\+W1D M/CQT9"!V86QI9VX],T1B;W1T;VT@#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE M.B`Q,'!T.R!B;W)D97(M=&]P.B!M961I=6T@;F]N93LG/B8C,38P.SPO=&0^ M/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D M97(M8F]T=&]M.B!B;&%C:R`R<'@@'0M:6YD96YT.B`P<'0[(&1I3H@ M=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z M(#$P<'0[(&UA6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F#L@ M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T M.R!B;W)D97(M=&]P.B!M961I=6T@;F]N93LG/B8C,38P.SPO=&0^/'1D(&-O M;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T M=&]M.B!B;&%C:R`R<'@@'0M:6YD M96YT.B`P<'0[(&1I3H@=&EM97,@ M;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[ M(&UA6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W M:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQTF4Z(#$P<'0[)SXQ M+#4P,#PO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@ M3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O M;G0M9F%M:6QY.B!T:6UE6QE/3-$)W=I9'1H.B`W-B4[)SX\ M9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P M<'0[(&1I3H@=&EM97,@;F5W(')O M;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B M;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^ M)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@ M3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXM/"]T9#X\=&0@;F]W3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[ M(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q M-C`[/"]T9#X\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXS,2PX-34\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^ M)B,Q-C`[/"]T9#X\+W1R/CQT3H@8FQO8VL[(&9O M;G0M9F%M:6QY.B!T:6UE#L@=VED M=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M M:6QY.B!T:6UE6QE/3-$)W!A9&1I;F6QE/3-$)V)O"!S;VQI9#L@=&5X="UA M;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI M9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXT+#`U M,#PO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@#L@ M=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CPO='(^/'1R(&)G8V]L;W(],T0C M8V-E969F/CQT9"!V86QI9VX],T1B;W1T;VT@#L@=VED=&@Z(#6QE/3-$)W!A9&1I;F6QE/3-$)V)O"!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q M-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O"!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!W M:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W!A9&1I M;F6QE/3-$)V)O"!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^ M)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O"!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT M.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CPO='(^/"]T86)L93X\+V1I=CX\8G(@+SX\+V1I=CX\+V1I=CX\'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE3H@8FQO8VL[)SX\8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&IU'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y.B!B M;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE M9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F M;VYT+7-I>F4Z(#$P<'0[(&UA2=S(&%S'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R M9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL M93TS1"=F;VYT+7-T>6QE.B!I=&%L:6,[(&1I6QE/3-$)W=I9'1H.B`Q,#`E.R!F;VYT M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\ M='(@8F=C;VQO3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!C;VQS<&%N/3-$,R!V86QI9VX],T1B;W1T;VT^/&1I=B!S M='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([('1E>'0M:6YD96YT.B`P<'0[ M(&1I3H@=&EM97,@;F5W(')O;6%N M.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA'0M:6YD96YT.B`P<'0[(&1I3H@ M=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z M(#$P<'0[(&UA6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E3H@8FQO8VL[(&9O;G0M9F%M:6QY M.B!T:6UE'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM M;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)V1I'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G M:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@ M,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!V86QI9VX],T1B;W1T;VT@3H@:6YL:6YE M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T M;VT^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([('1E>'0M:6YD M96YT.B`P<'0[(&1I3H@=&EM97,@ M;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[ M(&UA'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F M;VYT+7-I>F4Z(#$P<'0[(&UAF4Z(#$P<'0[)SXF(S$V,#L\+W1D/CPO M='(^/'1R(&)G8V]L;W(],T1W:&ET93X\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W!A9&1I;F#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q M,'!T.R<^)B,Q-C`[/"]T9#X\=&0@8V]L6QE/3-$)V)O"!S;VQI9#LG M/CQD:78@#L@9F]N="UF86UI;'DZ M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE M XML 13 R8.htm IDEA: XBRL DOCUMENT

SEGMENT REPORTING AND CONCENTRATIONS

3 Months Ended

Mar. 31, 2012

SEGMENT REPORTING AND CONCENTRATIONS [Abstract]

SEGMENT REPORTING AND CONCENTRATIONS

NOTE C - SEGMENT REPORTING AND CONCENTRATIONS

The Company views its business in two segments - the Equipment segment and the Sales Representation segment. The Equipment segment is engaged in designing, manufacturing, marketing and supporting EECP® enhanced external counterpulsation systems both domestically and internationally, as well as the marketing of other medical devices. The Sales Representation segment operates through the VasoHealthcare subsidiary and is currently engaged solely in the execution of the Company's responsibilities under our agreement with GEHC. The Company evaluates segment performance based on operating income. Administrative functions such as finance, human resources, and information technology are centralized and related expenses allocated to each segment. There are no intersegment revenues. Summary financial information for the segments is set forth below:

(in thousands)

	As of or for the three months ended March 31, 2012
	Equipment Segment			Sales Representation Segment			Corporate			Consolidated

Revenues from external customers	$	1,986		$	4,057		$	-		$	6,043
Operating loss	$	(157	)	$	(796	)	$	(348	)	$	(1,301	)
Total assets	$	9,227		$	8,381		$	13,010		$	30,618
Accounts and other receivables, net	$	1,224		$	5,004		$	-		$	6,228
Deferred commission expense	$	-		$	3,399		$	-		$	3,399

		As of or for the three months ended March 31, 2011
	Equipment Segment			Sales Representation Segment			Corporate			Consolidated

Revenues from external customers	$	1,105		$	3,740		$	-		$	4,845
Operating loss	$	(266	)	$	(32	)	$	(183	)	$	(481	)
Total assets	$	4,095		$	4,148		$	9,801		$	18,044
Accounts and other receivables, net	$	454		$	1,874		$	-		$	2,328
Deferred commission expense	$	-		$	2,270		$	-		$	2,270

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8595-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8538-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 33

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 34

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8981-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 29

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8864-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8380-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 35

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8984-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 41

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 32

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 131

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8844-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 40

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9031-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 42

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9054-108599

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 31

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8924-108599

+ Details

XML 14 R2.htm IDEA: XBRL DOCUMENT

CONSOLIDATED CONDENSED BALANCE SHEETS (unaudited) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2012	Dec. 31, 2011
CURRENT ASSETS
Cash and cash equivalents	$ 13,331	$ 2,294
Short-term investments	110	110
Accounts and other receivables, net of an allowance for doubtful accounts and commission adjustments of $2,089 at March 31, 2012 and $2,163 at December 31, 2011	6,228	20,695
Receivables due from related parties	41	196
Inventories, net	2,185	2,421
Financing receivables, net	20	19
Deferred commission expense	2,559	2,053
Deferred related party consulting expense - current portion	467	510
Other current assets	282	202
Total current assets	25,223	28,500
PROPERTY AND EQUIPMENT, net of accumulated depreciation of $1,493 at March 31, 2012 and $1,774 at December 31, 2011	514	429
GOODWILL	3,939	3,939
FINANCING RECEIVABLES, net	11	16
DEFERRED RELATED PARTY CONSULTING EXPENSE	0	85
OTHER ASSETS	931	1,337
Total Assets	30,618	34,306
CURRENT LIABILITIES
Accounts payable	362	273
Accrued commissions	2,103	3,889
Accrued expenses and other liabilities	2,270	2,531
Sales tax payable	399	355
Income taxes payable	101	278
Deferred revenue - current portion	11,311	9,484
Deferred gain on sale-leaseback of building - current portion	18	31
Deferred tax liability, net	112	112
Notes payable due to related party	3	193
Total current liabilities	16,679	17,146
LONG-TERM LIABILITIES
Deferred revenue	3,470	5,743
Other long-term liabilities	73	141
Total long-term liabilities	3,543	5,884
COMMITMENTS AND CONTINGENCIES (NOTE N)
STOCKHOLDERS' EQUITY
Preferred stock, $.01 par value; 1,000,000 shares authorized; nil shares issued and outstanding at March 31, 2012, and December 31, 2011	0	0
Common stock, $.001 par value; 250,000,000 shares authorized; 158,182,110 and 153,186,295 shares issued and outstanding at March 31, 2012 and December 31, 2011	158	153
Additional paid-in capital	60,669	60,188
Accumulated deficit	(50,409)	(49,065)
Accumulated other comprehensive income	(22)	0
Total stockholders' equity	10,396	11,276
Total Liabilities and stockholders' equity	$ 30,618	$ 34,306

XML 15 R6.htm IDEA: XBRL DOCUMENT

ORGANIZATION AND PLAN OF OPERATIONS	3 Months Ended
ORGANIZATION AND PLAN OF OPERATIONS	Mar. 31, 2012
ORGANIZATION AND PLAN OF OPERATIONS [Abstract]
ORGANIZATION AND PLAN OF OPERATIONS	NOTE A - ORGANIZATION AND PLAN OF OPERATIONS Vasomedical, Inc. was incorporated in Delaware in July 1987. Unless the context requires otherwise, all references to "we", "our", "us", "Company", "registrant", "Vasomedical" or "management" refer to Vasomedical, Inc. and its subsidiaries. Since 1995, we have been primarily engaged in designing, manufacturing, marketing and supporting EECP® enhanced external counterpulsation systems based on our unique proprietary technology currently indicated for use in cases of stable or unstable angina (i.e., chest pain), congestive heart failure ("CHF"), acute myocardial infarction (i.e., heart attack, (MI)) and cardiogenic shock. The Company, through its wholly-owned subsidiary Vaso Diagnostics, Inc. d/b/a VasoHealthcare, is the exclusive sales representative for GE Healthcare ("GEHC"), the healthcare business unit of General Electric Company (NYSE: GE), for the sale of select GE Healthcare Diagnostic Imaging products. Under the GEHC Agreement, VasoHealthcare has been appointed the exclusive representative for these products to specific market segments in the 48 contiguous states of the United States and the District of Columbia. The GEHC Agreement has an initial term of three years commencing July 1, 2010, subject to extension and also subject to earlier termination under certain circumstances. In September 2011, the Company acquired Fast Growth Enterprises Limited (FGE), a British Virgin Islands company which, through its subsidiaries, owns and controls two Chinese operating companies - Life Enhancement Technologies Ltd. and Biox Instruments Co. Ltd., respectively - to expand its technical and manufacturing capabilities and to enhance its distribution network, technology, and product portfolio. Also in September 2011, the Company restructured to further align its business management structure and long-term growth strategy and now operates through three wholly-owned subsidiaries. Vaso Diagnostics d/b/a VasoHealthcare continues as the operating subsidiary for the sales representation of GE Healthcare diagnostic imaging products; Vasomedical Global Corp. operates the Company's recently-acquired Chinese companies; and Vasomedical Solutions, Inc. manages and coordinates our EECP® therapy business as well as other medical equipment operations. We report the operations of Vasomedical Global Corp. and Vasomedical Solutions, Inc. under our Equipment reportable segment. VasoHealthcare activities are included under our Sales Representation reportable segment (See Note C).

XML 16 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.1.0.1 * */ var moreDialog = null; var Show = { Default:'raw', more:function( obj ){ var bClosed = false; if( moreDialog != null ) { try { bClosed = moreDialog.closed; } catch(e) { //Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control // that somtimes causes it to throw when checking the closed property on a child window that has been //closed. So if the exception occurs we assume the window is closed and move on from there. bClosed = true; } if( !bClosed ){ moreDialog.close(); } } obj = obj.parentNode.getElementsByTagName( 'pre' )[0]; var hasHtmlTag = false; var objHtml = ''; var raw = ''; //Check for raw HTML var nodes = obj.getElementsByTagName( '*' ); if( nodes.length ){ objHtml = obj.innerHTML; }else{ if( obj.innerText ){ raw = obj.innerText; }else{ raw = obj.textContent; } var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g ); if( matches && matches.length ){ objHtml = raw; //If there is an html node it will be 1st or 2nd, // but we can check a little further. var n = Math.min( 5, matches.length ); for( var i = 0; i < n; i++ ){ var el = matches[ i ].toString().toLowerCase(); if( el.indexOf( '= 0 ){ hasHtmlTag = true; break; } } } } if( objHtml.length ){ var html = ''; if( hasHtmlTag ){ html = objHtml; }else{ html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ objHtml + "\n"+''+ "\n"+''; } moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write( html ); moreDialog.document.close(); if( !hasHtmlTag ){ moreDialog.document.body.style.margin = '0.5em'; } } else { //default view logic var lines = raw.split( "\n" ); var longest = 0; if( lines.length > 0 ){ for( var p = 0; p < lines.length; p++ ){ longest = Math.max( longest, lines[p].length ); } } //Decide on the default view this.Default = longest < 120 ? 'raw' : 'formatted'; //Build formatted view var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ; var formatted = ''; if( text.length > 0 ){ if( text.length == 1 ){ text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ; formatted = "

"+ text.join( "

\n" ) +"

"; }else{ for( var p = 0; p < text.length; p++ ){ formatted += "

" + text[p] + "

\n"; } } }else{ formatted = '

' + raw + '

'; } html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+'

'+ "\n"+' formatted: '+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +''+ "\n"+'

'+ "\n"+' '+ "\n"+'

'+ "\n"+'

'+raw+'

'+ "\n"+'

'+ "\n"+''+ "\n"+''; moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write(html); moreDialog.document.close(); this.toggle( moreDialog ); } moreDialog.document.title = 'Report Preview Details'; }, toggle:function( win, domLink ){ var domId = this.Default; var doc = win.document; var domEl = doc.getElementById( domId ); domEl.style.display = 'block'; this.Default = domId == 'raw' ? 'formatted' : 'raw'; if( domLink ){ domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed'; } var domElOpposite = doc.getElementById( this.Default ); domElOpposite.style.display = 'none'; }, LastAR : null, showAR : function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }, toggleNext : function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }, hideAR : function(){ Show.LastAR.style.display = 'none'; } } XML 17 R7.htm IDEA: XBRL DOCUMENT

BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES	3 Months Ended
BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES	Mar. 31, 2012
BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES [Abstract]
BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES	NOTE B - BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES Basis of Presentation and Use of Estimates The accompanying consolidated condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") and pursuant to the accounting and disclosure rules and regulations of the Securities and Exchange Commission (the "SEC"). Certain information and disclosures normally included in the consolidated condensed financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these consolidated condensed financial statements should be read in connection with the audited consolidated financial statements and related notes thereto included in the Company's Annual Report on Form 10-K for the transition period ended December 31, 2011, as filed with the SEC. These consolidated condensed financial statements include the accounts of the companies over which we exercise control. In the opinion of management, the accompanying consolidated condensed financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of interim results for the Company. The results of operations for any interim period are not necessarily indicative of results to be expected for any other interim period or the full year. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the consolidated condensed financial statements, the disclosure of contingent assets and liabilities in the consolidated condensed financial statements and the accompanying notes, and the reported amounts of revenues, expenses and cash flows during the periods presented. Actual amounts and results could differ from those estimates. The estimates and assumptions the Company makes are based on historical factors, current circumstances and the experience and judgment of the Company's management. The Company evaluates its estimates and assumptions on an ongoing basis. Significant Accounting Policies Note B of the Notes to Consolidated Financial Statements, included in the Transition Report on Form 10-K for the seven months ended December 31, 2011, includes a summary of the significant accounting policies used in the preparation of the consolidated condensed financial statements. Reclassifications Certain reclassifications have been made to prior period amounts to conform with the current period presentation.

XML 18 R3.htm IDEA: XBRL DOCUMENT

CONSOLIDATED CONDENSED BALANCE SHEETS (unaudited) (Parenthetical) (USD $) In Thousands, except Share data, unless otherwise specified	Mar. 31, 2012	Dec. 31, 2011
CURRENT ASSETS
Accounts and other receivables, allowance for doubtful accounts and commission adjustments	$ 2,089	$ 2,163
PROPERTY AND EQUIPMENT, accumulated depreciation	$ 1,493	$ 1,774
STOCKHOLDERS' EQUITY
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	1,000,000	1,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	250,000,000	250,000,000
Common stock, shares issued (in shares)	158,182,110	153,186,295
Common stock, shares outstanding (in shares)	158,182,110	153,186,295

XML 19 R17.htm IDEA: XBRL DOCUMENT

RELATED-PARTY TRANSACTIONS

3 Months Ended

Mar. 31, 2012

RELATED-PARTY TRANSACTIONS

NOTE L - RELATED-PARTY TRANSACTIONS

On June 21, 2007, we entered into a Securities Purchase Agreement with Kerns Manufacturing Corp. ("Kerns"). Pursuant to this agreement, a five-year warrant to purchase 4,285,714 shares of our common stock at an initial exercise price of $0.08 per share was issued to Kerns. In March 2012, Kerns exercised its warrant and purchased 4,285,714 shares of common stock. Concurrently with our entry into the Securities Purchase Agreement, we also entered into a Distribution Agreement and a Supplier Agreement with Living Data Technology Corporation ("Living Data"), an affiliate of Kerns. Pursuant to the Distribution Agreement, as amended, we became the exclusive worldwide distributor of the AngioNew EECP® systems manufactured through Living Data. The Distribution Agreement had an initial term extending through May 31, 2012. Subsequent to August 31, 2011 the Company acquired Life Enhancement Technology (LET) (see Note I), the manufacturer of the AngioNew EECP® system. Consequently, the Distribution Agreement is no longer effective, and the Company wrote-off the remaining unamortized balance of Deferred Distributor Costs during the seven months ended December 31, 2011.

Mr. Rios currently is President of Edgary Consultants, LLC, and was appointed a director in conjunction with the Company's consulting agreement with Edgary Consultants, LLC. The consulting agreement (the "Agreement") between the Company and Edgary Consultants, LLC ("Consultant") commenced on March 1, 2011 and runs for a two year term.. The Agreement provides for the engagement of Consultant to assist the Company in seeking broader reimbursement coverage of EECP® therapy. More specifically, Consultant will be assisting the Company in the following areas:

1.	Engaging the adoption of EECP® therapy as a first line option for FDA cleared indications as it relates to CCS Class III/IV angina with a major commercial healthcare third-party payer.

2.	Engaging a major commercial healthcare payer to formally collaborate and co-sponsor a study with Vasomedical for the efficacy, efficiency and/or cost effectiveness of the EECP® therapy for NYHA Class II/III heart failure.

3.	Engaging final approval from the Centers for Medicare and Medicaid Services ("CMS") of EECP® therapy as a first line treatment for CCS Class III/IV angina.

4.	Engaging final approval from CMS to extend coverage and provide for the reimbursement of EECP® therapy for CCS Class II angina; and

5.	Engaging final approval from CMS to extend coverage and provide for the reimbursement of EECP® therapy for NYHA Class II/III heart failure.

During the three months ended March 31, 2012, a director performed consulting services for the Company aggregating approximately $10,000.

Through the Company's acquisition of FGE in September 2011, it assumed the liability for $288,000 in unsecured notes payable to the President of LET and his spouse, of which $95,000 was repaid in December 2011, and $190,000, bearing interest at 6% per annum, was paid in March 2012. In addition, receivables due from FGE management aggregating $158,000 were collected during the three months ended March 31, 2012.

- Definition

The entire disclosure for related party transactions, including the nature of the relationship(s), a description of the transactions, the amount of the transactions, the effects of any change in the method of establishing the terms of the transaction from the previous period, stated interest rate, expiration date, terms and manner of settlement per the agreement with the related party, and amounts due to or from related parties. If the entity and one or more other entities are under common ownership or management control and this control affects the operating results or financial position, disclosure includes the nature of the control relationship even if there are no transactions between the entities. Disclosure may also include the aggregate amount of current and deferred tax expense for each statement of earnings presented where the entity is a member of a group that files a consolidated tax return, the amount of any tax related balances due to or from affiliates as of the date of each statement of financial position presented, the principal provisions of the method by which the consolidated amount of current and deferred tax expense is allocated to the members of the group and the nature and effect of any changes in that method. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 3A

-Section 04

-Paragraph b

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 57

-Paragraph 1-4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 4

-Section 08

-Paragraph k

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

+ Details

XML 20 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information	3 Months Ended
Document and Entity Information	Mar. 31, 2012	May 10, 2012
Document and Entity Information [Abstract]
Entity Registrant Name	VASOMEDICAL INC
Entity Central Index Key	0000839087
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		158,682,110
Document Fiscal Year Focus	2012
Document Fiscal Period Focus	Q1
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2012

XML 21 R18.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY	3 Months Ended
STOCKHOLDERS' EQUITY	Mar. 31, 2012
STOCKHOLDERS' EQUITY [Abstract]
STOCKHOLDERS' EQUITY	NOTE M - STOCKHOLDERS' EQUITY Common Stock On June 17, 2010 the Board of Directors approved the 2010 Stock Plan (the "2010 Plan") for officers, directors, employees and consultants of the Company. The stock issuable under the 2010 Plan shall be shares of the Company's authorized but unissued or reacquired common stock. The maximum number of shares of common stock which may be issued under the 2010 Plan is 5,000,000 shares. The 2010 Plan is comprised of two separate equity programs, the Options Grant Program, under which eligible persons may be granted options to purchase shares of common stock, and the Stock Issuance Program, under which eligible persons may be issued shares of common stock directly, either through the immediate purchase of such shares or as a bonus for services rendered to the Company. The 2010 Plan provides that the Board of Directors, or a committee of the Board of Directors, will administer it with full authority to determine the identity of the recipients of the options or shares and the number of options or shares. Options granted under the 2010 Plan may be either incentive stock options or non-qualified stock options. The option price shall be 100% of the fair market value of the common stock on the date of the grant ( or in the case of incentive stock options granted to any individual stockholder possessing more than 10% of the total combined voting power of all voting stock of the Company, 110% of such fair market value). The term of any option may be fixed by the Board of Directors, or its authorized committee, but in no event shall it exceed five years from the date of grant. Options are exercisable upon payment in full of the exercise price, either in cash or in common stock valued at fair market value on the date of exercise of the option. As of March 31, 2012, 3,790,000 restricted shares of common stock were granted under the 2010 Plan to non-officer employees and consultants of the Company. As of March 31, 2012, 545,000 shares have been forfeited. In March 2012, 500,000 restricted shares of common stock were granted under the 2010 Plan to an officer, of which 250,000 vested immediately with the remainder vesting over a one year period. No options were issued under the 2010 Plan during the three months ended March 31, 2012 and 2011. In September 2011, the Company issued 5,000,000 shares of restricted common stock and a two year common stock purchase warrant for 1,500,000 shares at an exercise price of $0.50 per share as partial consideration for the acquisition of FGE. In addition, up to 2,400,000 shares of common stock are contingently issuable should FGE attain certain operating targets for the twelve months ending December 31, 2011. The Company is completing its evaluation of FGE's calendar year 2011 results and believes it is likely that the targets have been met. The aggregate value of the aforementioned noncash consideration relative to the FGE acquisition was $2,979,000. Preferred Stock On June 24, 2010, the Company filed a Certificate of Designations of Preferences and Rights of Series E Convertible Preferred Stock ("Certificate of Designations"), as authorized by the Board of Directors, designating 350,000 shares of its 1,000,000 shares of preferred stock as Series E Convertible Preferred Stock ("Series E Preferred"). The conversion rights of the Series E Preferred are that each share will be convertible at any time on or after January 1, 2011, at the holder's option into 100 shares of common stock (an exercise price of $.16 per share of common stock, the "Conversion Price"), subject to anti-dilution adjustment as set forth below. Each share of outstanding Series E Preferred Stock shall automatically be converted into shares of common stock on or after July 1, 2011, at the then effective applicable conversion ratio, if, at any time following the Issuance Date, the price of the common stock for any 30 consecutive trading days equals or exceeds three times the Conversion Price and the average daily trading volume for the Company's common stock for the 30 consecutive trading days exceeds 250,000 shares. Pursuant to its conversion terms, the Series E Preferred was deemed automatically converted to common stock effective July 1, 2011. As of March 31, 2012, 30,603,700 shares of common stock had been issued for 306,037 shares of Series E Preferred, with 64,750 shares of common stock yet to be issued. For the three months ended March 31, 2011, the Company sold 9,375 shares of Series E Preferred aggregating $150,000, and recorded dividends totaling $128,000. Included in such dividends is the recognition of the value of the embedded beneficial conversion feature of the Series E Preferred, which reflects the difference between the conversion price and the market price at time of investment. The amounts included in the dividends reported attributable to this beneficial conversion feature are $65,000 for the three months ended March 31, 2011. These are noncash dividends requiring no payment and ceased on conversion of the Series E Preferred to common stock.

- Definition

The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable). Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187143-122770

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 2, 3, 4, 5, 6, 7, 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Preferred Stock

-URI http://asc.fasb.org/extlink&oid=6521494

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 5

-Paragraph 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Article 4

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 4

-Section 08

-Paragraph d

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 17: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 18: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d),(e))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 19: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Chapter 1

-Section B

-Paragraph 7, 11A

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 20: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 21: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 22: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 23: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

XML 22 R4.htm IDEA: XBRL DOCUMENT

CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (unaudited) (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended
	Mar. 31, 2012	Mar. 31, 2011
Revenues
Equipment sales	$ 1,453	$ 528
Equipment rentals and services	533	577
Commissions	4,057	3,740
Total revenues	6,043	4,845
Cost of revenues
Cost of sales, equipment	606	394
Cost of equipment rentals and services	293	265
Cost of commissions	963	930
Total cost of revenues	1,862	1,589
Gross profit	4,181	3,256
Operating expenses
Selling, general and administrative	5,330	3,629
Research and development	152	108
Total operating expenses	5,482	3,737
Operating loss	(1,301)	(481)
Other income (expenses)
Interest and financing costs	(3)	(1)
Interest and other income, net	(28)	2
Amortization of deferred gain on sale-leaseback of building	13	13
Total other income, net	(18)	14
Loss before income taxes	(1,319)	(467)
Income tax benefit (expense), net	(25)	2
Net loss	(1,344)	(465)
Preferred stock dividends	0	(128)
Net loss applicable to common stockholders	(1,344)	(593)
Other comprehensive loss
Foreign currency translation loss	(22)	0
Comprehensive loss	$ (1,366)	$ (593)
Loss per common share
- basic and diluted (in dollars per share)	$ (0.01)	$ (0.01)
Weighted average common shares outstanding
- basic and diluted (in shares)	154,377	111,937

XML 23 R12.htm IDEA: XBRL DOCUMENT

ACCOUNTS AND OTHER RECEIVABLES, NET

3 Months Ended

Mar. 31, 2012

ACCOUNTS AND OTHER RECEIVABLES, NET [Abstract]

ACCOUNTS AND OTHER RECEIVABLES, NET

NOTE G - ACCOUNTS AND OTHER RECEIVABLES, NET

The following table presents information regarding the Company's accounts and other receivables as of March 31, 2012 and December 31, 2011:

(in thousands)

	March 31, 2012			December 31, 2011
	(unaudited)
Trade receivables	$	8,189		$	22,737
Due from employees		128			121
Allowance for doubtful accounts and
commission adjustments		(2,089	)		(2,163	)
	$	6,228		$	20,695

- Definition

The entire disclosure for claims held for amounts due a company. Examples include trade accounts receivables, notes receivables, loans receivables.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6965416&loc=d3e5066-111524

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 7

-Article 9

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Statement of Position (SOP)

-Number 01-6

-Paragraph 13

-Subparagraph d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6965416&loc=d3e5162-111524

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3, 4

-Article 5

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3,4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 4

-Section 08

-Paragraph k

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6965416&loc=d3e5074-111524

+ Details

XML 24 R11.htm IDEA: XBRL DOCUMENT

FAIR VALUE MEASUREMENTS

3 Months Ended

Mar. 31, 2012

FAIR VALUE MEASUREMENTS [Abstract]

FAIR VALUE MEASUREMENTS

NOTE F - FAIR VALUE MEASUREMENTS

The Company complies with the provisions of ASC 820 "Fair Value Measurements and Disclosures" ("ASC 820"). Under ASC 820, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the "exit price") in an orderly transaction between market participants at the measurement date.

The following tables present information about the Company's assets and liabilities measured at fair value as of March 31, 2012 and December 31, 2011:

(in thousands)

	Quoted Prices in Active Markets for Identical Assets		Significant Other Observable Inputs		Significant Unobservable Inputs		Balance as of March 31,
	(Level 1)		(Level 2)		(Level 3)		2012
							(unaudited)
Assets
Cash equivalents invested in money market funds (included in cash and cash equivalents)	$	12,078	$		$		$	12,078
Investment in certificates of deposit (included in short-term investments)		110						110
	$	12,188	$	-	$	-	$	12,188

	Quoted Prices in Active Markets for Identical Assets		Significant Other Observable Inputs		Significant Unobservable Inputs		Balance as of December 31,
	(Level 1)		(Level 2)		(Level 3)			2011
Assets
Cash equivalents invested in money market funds (included in cash and cash equivalents)	$	1,313	$		$		$	1,313
Investment in certificates of deposit (included in short-term investments)		110						110
	$	1,423	$	-	$	-	$	1,423

The fair values of the Company's cash equivalents invested in money market funds are determined through market, observable and corroborated sources.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6925170&loc=d3e19296-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 159

-Paragraph 17-22, 27, 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=6947722&loc=d3e13433-108611

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 15C, 15D

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=6947722&loc=d3e13504-108611

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 15A

-Subparagraph a-d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-URI http://asc.fasb.org/extlink&oid=6947722&loc=d3e13537-108611

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 133

-Paragraph 44A, 44B

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6925170&loc=d3e19207-110258

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 3, 10, 14, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 15B

-Subparagraph a, b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 157

-Paragraph 32, 33, 34

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

XML 25 R19.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTINGENCIES

3 Months Ended

Mar. 31, 2012

COMMITMENTS AND CONTINGENCIES [Abstract]

COMMITMENTS AND CONTINGENCIES

NOTE N - COMMITMENTS AND CONTINGENCIES

Sales representation agreement

Facility Leases

Vehicle Lease Agreement

Future rental payments under these operating leases aggregate approximately as follows:

For the years ended December 31:

(in thousands)

	Vehicles		Facilities		Total
2012	$	217	$	178	$	395
2013		277		106		383
2014		154		44		198
2015		5		42		47
2016		-		42		42
Thereafter		-		18		18
Total	$	653	$	430	$	1,083

Employment Agreement

On March 21, 2011, the Company entered into an Employment Agreement with its President and Chief Executive Officer, for a three-year term ending on March 14, 2014 (the "Employment Agreement"). The Employment Agreement currently provides for annual compensation of $275,000, eligibility for annual bonuses and long-term incentive awards, and certain severance benefits in the event of termination prior to the expiration date of the Employment Agreement.

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14435-108349

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Interpretation (FIN)

-Number 14

-Paragraph 3

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 440

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 5

-Paragraph 9, 10, 11, 12

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

+ Details

XML 26 R15.htm IDEA: XBRL DOCUMENT

GOODWILL AND OTHER INTANGIBLES

3 Months Ended

Mar. 31, 2012

GOODWILL AND OTHER INTANGIBLES [Abstract]

GOODWILL AND OTHER INTANGIBLES

NOTE J - GOODWILL AND OTHER INTANGIBLES

Goodwill aggregating $3,939,000 was recorded on the Company's Consolidated Condensed Balance Sheets at March 31, 2012 and December 31, 2011, pursuant to the acquisition of FGE in September 2011. All of the goodwill was allocated to the Company's Equipment segment.

The Company's other intangible assets consist of capitalized patent costs, as follows:

(in thousands)

	March 31, 2012			December 31, 2011
	(unaudited)
Patent Costs
Costs	$	469		$	469
Accumulated amortization		(420	)		(413	)
	$	49		$	56

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References+ Details

XML 27 R13.htm IDEA: XBRL DOCUMENT

INVENTORIES, NET

3 Months Ended

Mar. 31, 2012

INVENTORIES, NET [Abstract]

INVENTORIES, NET

NOTE H - INVENTORIES, NET

Inventories, net of reserves, consist of the following:

(in thousands)

	March 31, 2012		December 31, 2011
	(unaudited)
Raw materials	$	896	$	842
Work in process		577		528
Finished goods		712		1,051
	$	2,185	$	2,421

At March 31, 2012 and December 31, 2011, the Company had reserves for excess and obsolete inventory of $563,000 and $606,000, respectively.

- Definition

The entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income.

+ References+ Details

XML 28 R14.htm IDEA: XBRL DOCUMENT

BUSINESS COMBINATION

3 Months Ended

Mar. 31, 2012

BUSINESS COMBINATION [Abstract]

BUSINESS COMBINATION

NOTE I- BUSINESS COMBINATION

On September 2, 2011, Vasomedical Global successfully completed the purchase of all the outstanding capital stock of privately-held Fast Growth Enterprises Limited ("FGE"), a British Virgin Islands company that owns subsidiaries which own and control Life Enhancement Technology Ltd ("LET") and Biox Instruments Co. Ltd. ("Biox"), respectively, as per the stock purchase agreement signed on August 19, 2011. The consideration of this acquisition includes a cash payment of $1 million as well as the issuance of 5 million restricted shares of the Company's common stock, up to 2.4 million shares of common stock contingently issuable upon the achievement of certain operating performance targets, and warrants covering 1.5 million shares of common stock.

LET, based in Foshan, Guangdong, China, has been Vasomedical's supplier for its proprietary Enhanced External Counterpulsation (EECP®) systems, including certain Lumenair systems and all AngioNew® systems. Biox, a developer and manufacturer of ambulatory monitoring devices in China, is located in Wuxi, Jiangsu, China, and has been Vasomedical's partner on the BIOX series ECG Holter recorder and analysis software as well as ambulatory blood pressure monitoring systems. Vasomedical has obtained FDA clearance to market these products in the United States. The acquisition of LET provides Vasomedical with consolidated technical and manufacturing capability in its EECP business which should significantly increase gross margins and enable the Company to meet anticipated increasing demand for its EECP systems. The acquisition of Biox greatly enhances Vasomedical's distribution network, technology and product portfolio, and with combined market and sales efforts of the two companies, should help improve performance and profitability of Vasomedical's equipment segment.

(in thousands)

Cash	$	1,000
Vasomedical, Inc. common stock ($0.42 per share)		2,100
Vasomedical, Inc. warrants to purchase common stock		304
Contingent issuance of Vasomedical, Inc. common stock ($0.42 per share)		575
Total purchase price	$	3,979

(in thousands)

Cash and cash equivalents	$	442
Accounts receivable and other current assets		283
Inventories		476
Property and equipment		32
Goodwill		3,939
Accounts payable and other current liabilites		(1,193	)
Net assets acquired	$	3,979

The goodwill is attributable to the synergies expected to arise after the Company's acquisition of FGE as well as FGE's projected growth and profitability. The goodwill is not expected to be deductible for tax purposes.

After elimination of intercompany transactions which reduce the income from FGE, the amounts of revenue and net income of FGE included in the Company's Consolidated Condensed Statement of Operations for the three months ended March 31, 2012 was $578,000 and $35,000, respectively. The effect of FGE earnings on earnings per share was $0.00.

The following supplemental pro forma information presents the financial results as if the acquisition of FGE had occurred June 1, 2009 (amounts in thousands, except per share amounts):

(in thousands except per share data)

	Three months ended March 31,
	2012			2011
Revenue	$	6,043		$	5,219

Net loss		(1,170	)		(274	)

Basic and diluted loss per share	$	(0.01	)	$	(0.00	)

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 141

-Paragraph 51, 52

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6909870&loc=d3e1500-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6911361&loc=d3e7000-128479

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6911361&loc=d3e6927-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6911361&loc=d3e7008-128479

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6909870&loc=d3e1490-128463

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6911361&loc=d3e6996-128479

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4922-128472

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4934-128472

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 141R

-Appendix F

-Paragraph F4

-Subparagraph e

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4926-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6909870&loc=d3e1383-128463

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6909870&loc=d3e1392-128463

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6909870&loc=d3e1497-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 141R

-Paragraph 67-73

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 7

-URI http://asc.fasb.org/extlink&oid=6909870&loc=d3e1524-128463

Reference 17: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 88-16

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 18: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6909870&loc=d3e1486-128463

Reference 19: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4845-128472

+ Details

XML 29 R16.htm IDEA: XBRL DOCUMENT

DEFERRED REVENUE

3 Months Ended

Mar. 31, 2012

DEFERRED REVENUE [Abstract]

DEFERRED REVENUE

NOTE K - DEFERRED REVENUE

The changes in the Company's deferred revenues are as follows:

(in thousands)

	For the three months ended March 31,
	2012			2011
	(unaudited)			(unaudited)
Deferred revenue at the beginning of the period	$	15,227		$	12,637
Additions:
Deferred extended service contracts		327			397
Deferred in-service and training		5			8
Deferred service arrangements		25			15
Deferred commission revenues		1,350			1,027
Recognized as revenue:
Deferred extended service contracts		(275	)		(314	)
Deferred in-service and training		(3	)		(8	)
Deferred service arrangements		(22	)		(16	)
Deferred commission revenues		(1,853	)		(2,954	)
Deferred revenue at end of period		14,781			10,792
Less: current portion		11,311			7,585
Long-term deferred revenue at end of period	$	3,470		$	3,207

- Definition

The entire disclosure for deferred revenues at the end of the reporting period, and description and amounts of significant changes that occurred during the reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References+ Details

XML 30 R5.htm IDEA: XBRL DOCUMENT

CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS (unaudited) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2012	Mar. 31, 2011
Cash flows from operating activities
Net loss	$ (1,344)	$ (465)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities
Depreciation and amortization of property and equipment	49	39
Amortization of deferred gain on sale-leaseback of building	(13)	(13)
Provision for doubtful accounts and commission adjustments	(74)	(202)
Amortization of deferred distributor costs	0	31
Share-based compensation	129	126
Amortization of deferred consulting expense	152	47
Changes in operating assets and liabilities:
Accounts and other receivables	14,543	10,837
Receivables due from related parties	158	0
Inventories, net	226	(84)
Finance receivables	5	4
Deferred commission expense	(507)	162
Other current assets	(91)	22
Other assets	414	69
Accounts payable	89	180
Accrued commissions	(1,786)	(608)
Accrued expenses and other liabilities	(278)	(788)
Sales tax payable	43	3
Income taxes payable	(177)	(2)
Deferred revenue	(447)	(1,845)
Deferred tax liability	(1)	0
Trade payable due to related party	0	(243)
Other long-term liabilities	(68)	(481)
Net cash provided by operating activities	11,022	6,789
Cash flows from investing activities
Purchases of property and equipment	(113)	0
Purchases of short-term investments	0	(40)
Net cash used in investing activities	(113)	(40)
Cash flows from financing activities
Proceeds from exercise of warrant	343	0
Repayment of note payable	0	(294)
Repayment of notes payable due to related party	(190)	0
Proceeds from issuance of preferred stock	0	150
Net cash provided by (used in) financing activities	153	(144)
Effect of exchange rate differences on cash	(25)	0
NET INCREASE IN CASH AND CASH EQUIVALENTS	11,037	6,605
Cash and cash equivalents - beginning of period	2,294	3,101
Cash and cash equivalents - end of period	13,331	9,706
SUPPLEMENTAL DISCLOSURE OF CASH INFORMATION
Interest paid	2	4
Income taxes paid	186	5
SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES
Inventories transferred to property and equipment, attributable to operating leases, net	12	62
Accrued preferred stock dividends	0	128
Issuance of preferred stock in satisfaction of accrued dividend	0	101
Common shares issued for consulting agreements	$ 0	$ 1,020

XML 31 R10.htm IDEA: XBRL DOCUMENT

LOSS PER COMMON SHARE

3 Months Ended

Mar. 31, 2012

LOSS PER COMMON SHARE [Abstract]

LOSS PER COMMON SHARE

NOTE E - LOSS PER COMMON SHARE

Basic and diluted loss per common share was $0.01 for the three months ended March 31, 2012 and 2011.

(in thousands)

	March 31, 2012		March 31, 2011
Stock options		1,810		1,864
Warrants		1,500		4,286
Contingently issuable shares		2,000		-
Convertible preferred stock		-		31,855
Common stock grants		2,948		4,050
		8,258		42,055

- Definition

The entire disclosure for earnings per share.

+ References+ Details

ZIP 32 0001201800-12-000013-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001201800-12-000013-xbrl.zip M4$L#!!0````(`).$KT`.%OZ$LV```+5\!``1`!P`=F%S;RTR,#$R,#,S,2YX M;6Q55`D``U6^LD]5OK)/=7@+``$$)0X```0Y`0``[#UK=]I(LM_O.?L?^GIG M9I-S($:\[4RRA\$DRVX"7IMD[YP]^Z&1&M,S0F+4DFWVU]^JE@1"")!`@+"5 M+\%2U[.KJJL?ZOKYK\\3G3PR2W#3^'"AO"M=$&:HIL:-AP\7CBA2H7)^\=>/ M?_J?G_^W6/S,#&91FVED.".#L3D1ID'NF&,#`M)25:8#2!$;/P\MG0!N0USC M3_[A8FS;T^O+RZ>GIW?XY)UI/5R62Z7*)3>$30V577CM=6[\OJ$YOAY2,6_^ MO-+^J2);*U=75Y?R[;RIX%$-`:UR^7]?O]RK8S:AQ3`_2%Y;``:YJ5^Z+_VF M7)C5LM+8)*S;8@Y@/#)A+^,63'WW8#Y>NN\`3%&*):5847P@T/$#I=,YU(B* MH:3@O8@`T1B/)@(O(IH;SB1:!LVV+NW9E%U""V9Q=0Y@&C%@3*,8@E--Q["M M631OWLL(_E3'LM;`P!LPX"@@@W)51$/)5Q$@@JO1`/`BJKD]7<,6OHD`8,_J M.!H`WT0`/%)AS@'PCPG3N$KU=ZHYP>;E4F7>.([+@:L2\C/ZR+60UG_'1D3Z MS#5VV8<+P2=3'5U!/AM;;/3A`ND6?6+OGH5V02Y=1-+5H5,-FSW;A&L?+E39 M3BDIMCEG3[:=MV:&S>V9]VS^E&OX?,29121C;$D:7TOM[C\N/I;@7[-R56HV M?KX,`_ND+B-H>92F8(^F%J8/^K'L&PAU'Y%M[(22XF-9O`L!,4,+@%2@WQ:$ MM0"`_S1`VG_DZ6ZS.FM*Z2R4Z)J9[>FC5E1*<^3>FW3T<2Y&M:R/H'VDJ0]% M*9^?/I0BJ.1`^IB''^5L+&4I_"C)PX]RN/!3.D?S*AW2O,[%J);<+;7PXQC< M5<8W2*-#>I@P*AR+??0,=TPM)GQ4_KL@>L2U#G=Y#6XOH[[^=G^S*^I*"+7& M'T'=8?4A1`_35VJ;UOQE4GZ""H[&&"!WPPQSPHW-!+C=UAJKD8SPAR(I])6R`:4_F$ZI#E%J'[(+'8D=R)A?,2 M]HW"%U=_[9S-_B5M'HWI///;]W;KYW>H$!H0'*-`2J54YO#9&V] MK#>!9O!;9_BC96BMB6G9_+_R^:UE0@2Q9[]I#2;RX)%8S\@GW',LUZJUZ^2\:G*]0U!J.$''.@EQA_I4&<"S$[7S2>< MI).1:1'-=(;VR-'1&A=@X.H3+G#MCE#M-T?8V&-B14X?TR?3NO'P^-3OYB3; M!)T%.).2(W;,2@G4;:,.H_L!7Q M)%00J#_R03R(59E"LZ3-TE64)=FVTSN^0.%5I]@)1`)AVE2,7:O#'PQBYB/5 MH^P-&T)4Q?\ZBU8MNTTM:\:-A^]4=]ANXV*E$NJ,6+2.)4(L5RE?5;,K02F& M!!7TGLQ*$,>AKQJE^AX2=($B3#]L=\@-<>V_Q'%P3S==3H2#B%-@)5D(K,9A M1;5@(L;(FQOF_GH+TXBMP,1 MS-VT>!Q9`HWW[)EFV*@VD#J:",FZ`B:K]?2$\+(%5;4Q@M!+'I,P3A&::UVZ7P)Z`PYDCL`_K, MQ*T+O6^RNJ7+-I$^FDC)S+":BDSS^59LD7P(#]/`HMJ^O:/@]'ZC+%%$#RU# MLNX(S7Z3BR"]GCU/F2%8`8B.T]A*'YBG$2CI$-?80R[47S]J( M!OFV;1*+N>N#4PH^%R/[<=C`O'-A;@$$\*]=:TC68^6MD6$][5.)N/-,?2?A MUJ6P(.7(,B?$@R8>>(%X"&*)_`DP'*)?MPF]EF[6Q$Z:;=6V>6HLX=NX*.BN M!,HHU`:N8`[+#!6CR0T7JF[B?AGY]P"W=G_13?7W_ZQ,OA=(<&(<1+'`@/`2 M?*OD'W_2[?<:?_SIP7[O_23"GNGLPP7"%:G.'XQK@DN8?#1[3^1#;N`V\#4I M3>WW1.-BJM/9-1DBP?=D!!2+(SKA.CP;\`F(UF-/Y,Z<4.,]F<#$AQM%G8U\ M>-E>\/^R:Z+(!UX3BS^,O387R%VO/^B0'BF2=O_KU^X`=T7NY29)N]\;='N? M.[UVMW./,EQND&<3ZQ<^T-`BE_[O3R-\=?4:4`D%G*A#A#']CJHVC$XB%^Y^H9_!O""#F MTEMJZ7CL`K'CSC>V$=0>&2L.T06K`#B(`@U0=<_:(_/KHA;2(!Q,8*WBMN8%OL!$EP!2? M.!-B.),A,`7RBQ43>I0[("#<([6XZ0BBLP=0&#Z16IV:8/4S`/G#X994;[0< MWZ31AU%"1NAQ"-'GH%$<+W"+'T]]RT=+= MO92CB>0(NQ:BH`&=P!^Y/4,$@)M;Q&#VDVG]_BZ/&7/O^$15S#1GY`NJ6+S6 M(-$W2,MY`$:(4D,W+S4*Y(D18>HP=W`L,O+5!$[U+R;LH6/-"I+TKV!0GE-3 M,@)W*6+T<"UV2&%`#ECXTYBK8YR8@%T+GV#%C2OE2*_Y3H7Y-T9U>ZQ2R!-D M@)&HA<\2E_&`?`8BAAB:E@ELF98])FUJ@6L:E$P=2SC4D!&)>JZTS`G`?Z4S MY*(2R45W_KZ\[*9,+C]K@$#B1O')0OR@Z)(41IT%+5"QC,+3J64^L%A(N!F:7?+69I@#X@S.@;X*,TA M#MW@;LZ6L92@\TAV-?(@OYW"]$`Z&^B?3$!Y8PGJCNPPX_;F*.AS_!F@L"V# M?,+UYM6Q.I#DP(1H?N"!4%NV!.5R0R89'JA@,")KDIH]YI8F\9YV'#ZA52[Z M]I-CX_P/9XWRX)#7$?,.!H/#!56*AT$DQJ\73'N+Z=-'P MA)F,YXYN\@Y^"V8,\W4F4]N*LE4G"<58971K9\?D0")(EP4@AFKTJ44-67/D MW("L@6WKIW"OA$7-?^6_\E_YK_Q7_BNE7V]@YF>/34=`%BG>RL$41Z$#IRN) M!ME-M.:-;'E"_DW3G#]OSTT3URSQSC&EGX,#DWPDW%<:S0AN0AE"T3VF:V=EBFWY1-S^W5HZEID`K?$)F@5 M.@WX+%^L8]DCYW,\U'%1"/C&Q26N;=/1>J-2Y>)+XHQ[13\Q,NY5Q6Q9?EA9 M1US6FF$^67B1A/O_6LVMNFO6NC^WTK.TTD_SI=/<3K/$9FZGH:U+$R;GK\%$ M+VTK*EEY&G.;!5,53SB48*VH7L94K_X8+R\[1I>OZ5_<4-GQ;QIHQ-F)!X.6-LI5\E$V?A72&VT8^W.8FLGG<+=5S$\E- M9.,`W*QDWT1>[R2WF@^_&74?I; MR\??C+K.&:P;Y09RTM&WG%M(;B$;+>0,%M!>[]2WG@^]&?6;8O;=)C>0?.C- M+22WD.S,>R-/C9W1B#P8,XO1D6=M>4J:2Z&YZ>6F]PI,+^[JP,[,5Y'YI:1#:4[M?1,7%T>V/P_8R:6KV7%I M8$467-%9^CX=_\!H(M92\>5Z+\?LXD#B:'E77;HWC#KWA$I+YUEAB;O2?,94JJ2H2IY@PQ=1%&^>+ONIMAH1E7W6FI] MYEY5IS'_^EO#D64')WA1_KPFV@_E1JU0*I4*A$%_\:%[[V4`8&@:CG^OOFZ" MJTDYN(&?T*+`](E:FG=I[/PB6O;(+%E";\@,-D*MR=L\&&%8E$5>$Q>X)'=J M<;S-R[U"3UX=Z3[7\-8S[TJY*%%7;I3S?P<*3"6Z3GOI*F^\I\^&AP7B5KTE MU+''I@76IA&\G,1]^C;J`F_3N$?(>]FBM0"+47I-"=Y.7KKX6*Z5W'_+,JVA M<&P!(@JO'5(`+H23D/FN"[*#YI5:4VF6%643XR[V8S$=0]M*K:(TZ^6K6F*F M[UVFW28%TG=LO']:#J[;V`VT/92B`R2.Q'A*RM[`N&!T9^ M\!@9D4MX-6[8<]\34%,U2`8I-R`L7"W2K68\\(Z7K50%:P$O,O+F0N+(@(;F$Y!R_5PJ=-E[*ESE[!:7;@8[A;N%I47 MW,N+71L0GKJC>9U;R)[56%=<+8C\L)PF4VJY7HO#::#>U]H"2($V^Y1,5^KU MQK*_K").FZ]8V4!#J=;C\C6O^WJ'LT<88F.64O+A/+`#ED\Z]678/:R=]`]2 M)#>=3YV[N\X-N>M\[_2^=4ZQX!.AC..7`%+'U,"*O]ZR@[?2\Q=R;P_?EX4@KE2E=[AK+?$]P`>OVE7>/3J.>F$SZMZSNO%P> MEY553N97_]5CK?7[U_5MO>XO:+L'./D:M-&T2?D%#=R:9+)HAU_78#XO75W, M/_%AU!TM8.D(R'8#W70Z90;.=R*>Q9FF%V0S<^9* MVX])9<)^E!=@/PD#8C#VG>@#CR-^8A+#IJ.,<@.@YR%0:&GJQ__7,3FNJO+50%OK5`NG\'7[KEQG,(XRH5ZY0R,XP!7(9Q#Z&U!ZHQ'N%:74[.6MIS:0([H M,WE*F]O&2["-=!/:I2!Y%?A.;,W62%!*O8UNN;-I4=7>4O/HE68N M67"Y2I[RVY;>2VD>>Z^2[F^^[ MG;^#9=:]AFQ^#";;=GXDCXO`A/EM(7F06M'I-#5NX;YW.HR:W7EPE4MS:61(UC=*_T0 M+^H;:(8WWX[RKYZSG8\IU4*CJ60F)EP_-S2\^CXU"K9GFQG<6*XCN,I14 M0W=+9CW!_S(OR12^V?@0J7Y>42]-UM+Y1KA0;>2%''.S.[K9E4MIG@+/7"'' MU5IRV^L)K)8L\&-Q,9S;;RE6L%?1!P42RZ7B"M'(#\]MG%(05]5F=2=FO?<% MTC,--;I:10C5HN%.G-8:UL/<_[M&WQXSRRV?R]@=T\&LM4"UI7TKX=5+ MRS$Q,0/'E2YI&<-&LYZ2>#XD>>/#OL7R1)^X(2LEWS&507B!422&U!Y0`&;? M;JQND7*5XJD$2]B#M=T%^]SOW_RK^^7+BM>;IO;$=7VWQ.RJLAP)?6R[DXV3 MO&XGVS6P-K=IS62IS=6N\MYB&HT,9^3--R$_YWCK!1&\J[VEVI!M(\*P2(`",?@(?IDAM._8`+J`W#>' M"=4PCD\X(^(F'!.4:O7`\J+["7LG>>>@J75O45%B]6\$Y8S(N\.8?U!Q^U-F MT=W$G8.FY[U*J5R.(W`$Z8P(G*Q_ZXU0K>0=Y=5A(A(AA%OE&HMS[U\K?#70 M++#OR4M2GPC5\%W/RE)YR#PUZ!P&27JQMYG^,8F($*\!X" M"7Y836^GGST%[%FW?5?YUZYE%+3D6M++GQXHK)_\*LTEHM3 M)R">(;$3AL!ZJ;:_U#W3,.>!W;?ZSC.N6JU*%VSLMO5:[NV[RQGV6CJ'9COA M&F4U(===K-X&"8A/=TX=([%?AR#4.J[L]]?"6,RYPCS MWE^.+.FDIJ5EM4?0.`2;2;/69GPN/YD6XP^&M\6OSO">#$/H[B9/5'XM%[AQ ME\9B8P@J_)&Y6#U$;0_/`-%0%=%`OPX62%O:;XZP\;MPZ-W^:$"?#Y+B%$.S MNV.Q?8:*W7F/].@ZE01)2PB&.68[>E20C=PV^YR;*3ILQ5JS+B5D M:W[HI&T*9"]B(5TV]-O)9CLOZ]=J5ZOLA5$?BL-X^@LMVV[F\';Y7$F!"-RI M%H0Z]MBTY+6:;[CA/5V)[7-H.764F]RBM8",H6$ER'_)3?.6V-],XC1R1/3# MH>7@0CC)9>BZ4#OTPQ;.7<3'Y3J&UM/AVG1L8<,D!U.;A*SW`Z#I:SV`_51" M[-\)L8284@L/TSI,\JZ9NDXM@0?[73FVB'%+K;YU;^/1A.^(!$9=23M.EU2" MTG1[GT">=R5EG4CK*)U` MZWI@_=$R=07S'Y9,]T>34&C5`5=69./),$/`!^E"Y.Q^`=S\HA>I5!3_3^4HM=4PJ M2H%@Y\GE)'C9:%3Q)>3$;#($=_#>*Q%J!&^Q9[7.80_F- M_;;[+@N$IPZ;:!V%_X0S^L:*'<9@G\[D%72X#=52H8-@+/#[K4!DSQ7FYV-D MYZU(Y&$8F![\VF[?>U-F>6(2GW`VI-UY&2$E0>]AKF"['S^ZAQ0F4:?)5XA) ML`%`!8!2'$SCD#N96,FZ+'1`))EH=X M[%E;R2)8[$-+;$G,4"3#)NW1O]^JZN9-HF3)EBW*Z@!))(OLKN[ZZM*7JOK] MNGM'=O:F^Z5S6]S3O^YTIT/9IH>T:`!IO',O9!_+XN*6GY_FT6M.4'A_2A(#QP-;-E8.1RB&/*2E'*`';RH$W)O\)-%#448+0>H32,,< M2+E$5Z7$09EQ2V9JK3QWRF8G9;XGIL'!EHZ.?D6B9FF""03^`%&-N='0CR7_ M6-SW?!SV!5X*V&1VBJ*Z7)R`8KVI1UZ+O09R%8/%9YJ[RNWF;"&3&QO+YWN\MFNUI[,ZL2JGYQ6 M/XFNP<8&L-%H6,=-4^^ZNMKU(A;JYH'0.3B,>GT!$M:3\[A1G<)N1LM6%"); M4/-@1Y=99WBZ1G>[\&:(G=P,R1^<+5:]1I),*?D5I\5@8]>Q84J'+-;*N9I_ M/`VO,F7_*DKBN@JPU=:Z86'*_AG4+8.Z^M&6%9MP MG>40CJS&6O-YX:U190/',*">OHOAOC MK?RQVK^Q8[6S(T=.$%")!=^.^_I&M!3AO=.'MT(!Y(?"/BP[GCW33>D,+NZ$ M&HWQ#;IN_;GSY9R=#4,A**($`S5EW/L+2P9$?F[]@@FDX0H_3+X%`F](FJA$`V*7O><*=0>9L3:(GQ<2D(3HZ6SW[QD-@3RYKR](Q M.;H%:B#__@M&XI2+SFM$*+3JAZW\E:-*$WB-`4-7[(#==J[.NIV+@V]G&)W; MO3V[OCL[[U[>7-_MJN*[\=AOL2=8@VX(UXXM]@"JC!+H81I?-$3L3H`)4UEX MO\4A:!DI@+:PS!S MLGC1",P13]H%M<<&H'<.)H*'[(&'H7XL2$AH68V3MG5<;Z59+;1.50E752DD MCAD)82!`/G>9^"'"OB,Q&LI18?GO:H>UDRS#`G24)B:!OHCT4L(O/1W_A")K MZ?$GS_!#UP:G7:!$J5;`P$/W^-B9-W1\%*-.Y_P;"FK^4E[Y$8L2J6,, M);H78>3TN9N(,TEQY`<%I_BX5;RFQ^1$1F*,=BZ1%83:*/3C86%>#UEW[M#9 MB-MY6%-\+/0N/!W+IUK["K8^B3B[S'?`F-MX"`HIC14H.`6\K[V2*V<@ M6,<;H;$F4G+LW[_J=#^P?2D$1;JR2^`Z-I(;:@6F?IZ`Z9EP)]8"T*''[/G@ MX8&C!0)(9;(`9LI'*WA1(!#^I79T7@&(?J?5$"#1]"*)]!6*$L1 M:1V,$_*G'WZWR.YE9*'_#6M<@53@"W^@M3P?<8>&I*DAHDMI^4(KR\QB<6C- M:*(6C$=(6.R[G'INZ34&88QA_Z/Y)US[NC8ZM6JRF. MP:K-S=A%/2=:%O\`GT'I%02S&.YGX9`5V3;./>B09%E&[><2PI$>`L>O`9N=+H+!S.)3NS=($JC9&)D/"& M?*A^`U9D9-!N%:SB97$?`7OF7S4H#IH&9)9(#;?I!D0R.UD,HQT^)&"S\TPJ!Q<)Z8 M?@$5U:>+,]9W0<_1"M<&R5-[>+BLCT`!X18=;;:>G]^Q7GZ\_`/T M)9#`E;+G0.E?OMI*P"4]>!0CP=UHU,<]@FCDA/9!0!N%`9^(<'9S0^W8H0^NCB0`8@!>0(RBFV]B_0'ESY& MU()]RLS\`.U5'\P5?7(H?3LT\I'Z!Y%+5[V>D.G29(ZD8J/7?WXY2T7M(T@; MTAY&;,`=-PYGSYR,\&Q`>)IO5W@&H-9=M;B[1YPGAW'GM!.J_-NO)`2ADA;U MQ;'97;**!*_[ZQVXV\N;I`@<-G5ZB\W/,38&^E6`?FNWH`](1ENAMHNS11B= M4J@E7VH*BNNU^>"?AKB&]W\]$@5C(/Y:$&\;B*\!XJ_@R.S$1M\E;[:`O-Z(N$5;;OFMDZRBRBYL\#\[LF(ZW-DVLBFTUQ5B#-M`O<"\6A% M2)@4(61^`[&P"5ROO4\\W'S-A#X/,#>D/F,N[LY;^#V[;87W<[!/]-D#//G! MLU''PR-*[3Z?--Y_P)U.O95-1T)T*PN=BC35.GSK`9`/V>6<3$EG/D&% MPXGD1I'-CC25:@*ER!.I*)^[3YGG-;2'-YW4`1P(8U)#0?.E6&ZD"`1RVX)0 M!.CN"5V+$/4$7D50!W7)O@2M?0"P(+T3ABI%[?PGVZI\X7VH+MW2RX[^%($. MTHZ@4+Q.#P&+=Y'.LYWDI%HB\`0O`.#U-)H&78R#HAVX8C%*MLP=,LJ1$-$J MJ5MW]ASB(CMP7>9<)SM>T`*LIC]AV;R3*`#,$-/OJA."XLE3G<1B9QG0S9VL MY7,2_QT[TDFV!C]][J`8W(D@4KA5Y[`.RK2,QUH;N$YRX1*G_UWCY(04#KP8 M@W3TZ?*%AU<&<1,EJ=B,+Q:.G:XZ79(1O*`D`S^6(J?DWYVVEX@P!)Y(SFSS>WM7;)YFBQ]TB04K77@'Z,_"Q%S.31FP$]J)];7V+[>3V\*+6KY:MOG!8+1JQ(A_XGEW=8BO2S0D$8W'0MH19O-PB[PT.\1R1S MKURH-YY4U>6@=5H[:D]-]F,]O3#=2Y5#:==:M=,GTZW\L+3HCITX7D.\0>*K MZ_-@N<`)[W'EX/=BQZ5HH*GQW<&35\F#.5VFRU&JDIZ?H=E;<%*'WIS*ARL) M1[%0RA,(J.H\K%B\:GWS<(OWZF)16GP3VY7Z@?(B4JLP[ZC6FB4[U_Q:2%JQ ML,E)J[T425GQ&XK-6$359]^WYY1170GJK?;\V4KZ6"M]JTU=NW'R%/(0C]!& M(91L$;7),<3S)[3=G#^?N5Y>F.85)_GX>"6:L?Z.!\NQR;)Q.^D+;[UDSA=V MP"ZO_^A<=V]N+S=8'V=S04&Y+4C%"[]T MQN-7J9`V1445"J$]5455@!\O34(E.+"SM4QN^0/#"S&APUU3QJ2,A$U6B3H] M6J.\F.HE;P@9K4;UD;&C14O^QP^_XXVR(/3Q\K%1JNLG82TRU#[>@B)K!B(; MA<@VE`][A7(E6Z1]/SF>(T=XNPJOAJQ!^9KR$"]`XEJD\[B^3B?HE?ELL+?5 MV*M;M?8ZZP:^)J=-B1)3*^)5:D58]9-M+15A8+?%L&NMM:1KY2J4;&&PX5FT M5#3L=(2YG5X7I?SU\YU ME]UVOMW<=B^O/[.SZPMV?G-]#G^]/=OIV@#Y./M[1SQ(2IK0BZ5#F;_P!M0# M)@H>JJB[`Y4(+(O"T#A,4F/3Q7U$)4J.%ZFH(_W0W*#YV>8Q*/0$Z'SSH M\!%8GC&6D:%TH2H-@4?OX9,JA2C'A,&NFR1FS@:)Q0\P60E+\KG9@D(CYL[L M(G8P/\#<')B)(Q>+C=GBOF1IYS"SA6,[F*969TS($O;1M!`"$RS0`)(1S6;70#)HF"H4 MNP]S7U['R1[CSDV$3]X+-M"9-Z#I&,P&,`)3T$"S%AO%*KV%!++[0E?N<3SJ MEX8=9D1?,8!92>FE" M3C+X4(7+E(/A+AZ/D8EJ&)BG)$]REIM%BSG&P`M*:P;,Z`G7?WA>6$2Y3GOQ MN(BRX(4-ZMJ2^Z2/#V7YZU*KWAN=:[.S5;BY4;KE-TKKK2??[RL#X:-W_AZW MM\]:JN2O7Z^[JS-57"A,M>&CV3%F2-KU>X-K('R3\K:\6#6?*E75OQR;.>-Z MJ;CX$,MPXT6Y4>K`;PUCGGRYO/J,2M*%G^ M=H<))=C)J^N&`X8#A@.&`Y4,H'G.7>]VH_JW#76&)*G+L*?G#TG!^<5>QX[> M[-U@W$3=.CTQ,34&&V5=MZQ:VT0$&&R4=7U@<&%P4=+UD55K-:N/C1<);]X& M_^PFO7K@^B84KVK2LU^OD,$M20YA$/'JB#BN4,B[0405$-%L52<&TR"B"HBH M6\W:.B_XKQ<3.[H3UO6Q5!N74D3&SZJ8Q)Q:C49U'"VS@JT2-DZLYDEUE*G! M1I6P46]:M7K-@,.`HZ3K9LTZJE?'-3=[7S,QEWT*@]+QDA2UE*M@2`4YC*-6 M+9FJ@Z/6JKY(&6QL`!M8_]1@PV##'$\:7"Q_/-G8X@QV;WW++*U$W_?'8T=* MC"S10G!AL&&T9G&%R\+9WQ[,"SG">V9M0L'X3V M]H#[3!+6@N!%-%0-Q@8;!AL&&P8;!AL&&Z^]7[6C27J>EDZB)$?QFNG*&,ZPX0Y5A"VSR1AYT)2##8,-@PV##8,-@PV7L`Q^ACA65KZ M+;=ALVC+J:SY_%[/X\W\%2WS]V\^K1DMJ\&'3]BVB^+ M?>ZP+X*[T:C/0\&X.I^$%S!SV-'Q>WKR&/[O#UBH0BHM^"`#T8^<>^%.#G.3 MEGXZ%SXZ;0-/T'_?.'A*>-1 MV2@OX(EQ#QY-,IU-DS^'T__\&,N#(>?!SSJ-T:T(_!!#%BXB"YS^ M%5GZRW_^!V/__,?!P9T`LKVAQ8;"$R'>O`,2N#UV/$=&&/%P+PX.U--9\_3* M9_7"F6>?%1[OJ,U'U@=N0G>W8O"OO3Z.KE:OU2.?/C6;]3T6>X[Z]?=:K;'' M;-%WQMR5_]H[:.[]TFXV:_!/?E#+]+J!<=73<=67&%?SJ''ZK'&-@*<'D0C' M8##NA8R0TW)F*/A4%QZZS)XI8(UJ/`_T7KY.JKY^N;;H=] M90?LKGMS_N\O-U<7G=L[F+W__OVR^^=C5F81Q>G2OQ>RCT\Q66H$^``X3A'\ MVM_D/)W[XS&FCT.(;'1:"CTTCUYS#FX\]EOL"58_)JM5([O^J\]#&RWAA0.& M+_)#,'I!$/KW8%3Q=WJ0IHU]<[G']O&/>_17_+[W@4RO/Q@X?1`["P:CF[&8 M&`>N/Q%"&5>0.1F[$4==`MUA,\"4@'OEYKX+OTOJUI$R1FL,J@8D.R.*R)$C M[KJL)_`#V."IEG^"KN,(E`Y,CLUZ<83J"IJ#+SX:>MX'-9&!)@?4K+/(2",?5._67K: M%4,$C-9!(`6`5'Q6)W2K)N$2(>GVQ6K\: M&7-`I`3)G8`<.>27@@?NQ\,1=>N,Q\)V<#)22A&.,?26-!!/T8@-8OR[TDZ`9N"%+=`Q$7> M*J8GJ,PTU,PSI=HM$9Y$$LJ4E0:M!J/C89))\'XU6G/]>+YW\'<,_!TXB.[\ MSW-5J_H=YAX`FNET\![?)X,=<"=$!GX7$>X,Q.F<%X0&/N#?,.]D\CN-B>TC M98[ZM:_%9=X8DED`EH!8P&.`7<>&$:GGE(?)`E]*(27&FX_]$'D&DU3/"(XH M2@JHZP%';7;O4VAZX#\HQN`0]=]T[P7+9;&Z;HN$>F;T'^9.)3GWV`&0KJ=5 MLV[@_$`K.%D$:BX9(\TEP#-XD=?X`H<)W(B>*C3(^7Y M0#.Z$'FXFA<_1-AWI++U`<*!3R@;,W1+TJ*G2#\G%%RL#)+(V9%F=`$6-&4V MKN9+8%2$3-IX0JK._%/1"+-:WC4^6U@$:)@`O1?#L&>!<+%0N(&:H, M[4(N[S6R&A#1P`5(1="L1+3[>D6ZFM67Q>^ZG: M)D8L\+;M.,0)7&TS1VN=4>YPYX4OF>7KYHK9T4Y$I"`IM[Y$G M3\`M_)9ZL0\\)'N-#FO=:A<;!_W-O2GUCSV^JQVV:R@)ZD%T?&&I$#ED?ST) MGE2HLLFP!8*O>Y"ST`:X@_V##R$K2O4L4]6,>`Z9=H\Z%!U_F. MJBKUDA/2,X4[%N4V'RGCPV$HAFAS"\XI&+H7!IXS59 MO]",YCCZ`/Q_U[!.CT^149N5X&KM@GT+DZO(9B,,#&BCI3;"BJIMX+CH*[)S MD$Y8P_2U8W@A)`R`ZV7.@*FY%%Y?>RJWV`G]<@VP$I7]JZMG^ MWH+V]SY8M'K/[5W-]]KMY$40[69[6CFAL-=+M'20TJ/UEER6[O2Q]*>]#X>L M2TLQ?(_NMX?I;-`NR;%JHI7(O:4?U3SI_0F>YZ*KCNGN`R^C? MN!?SXYZY[V>?*$>-4^5`F3+_D!'T*A[N`U;$5?."Y[]@8832YYN' MAFD%1(=F(.?3=0:FVN-TQ(&6!U+5>J,%T`&1,IU@<<2<# MMH$=X@-G6=9$F4]4,G$V9LQ$8G8#:WIJX?\P5_V^>.=$,S&(,SK:U(5'#JXQ MLU]++%W?L6"B"$OZO19!C:Q$.3 MH&:1]4'<1CVIX@D7`+&[DXL5V4K@N'*U`5X`33S.9*LOCA40V6[*GCQ%&OX\ MES1)4/-D*3MOB<3E;!>&$A/]$+C(8[033?%\&:X_6DBDU3AC)Z'V8'!00HS4 M1HIW$3298(-X3ZC[)MN+(?L^7:^=UN%2/5M,#35#*%52\4;.:]5/:_76F5)E M>C@U<9<\/:Z=G>O(ZNZ0N0QZ<.>RBUCH[F;L6D=*+LN%+ M0\@#\90`ASFF_#$8F1JA1T_8#T7)YKE09#.O*+H5&"39A:4P;L#T0KNQ,["C MNPY^E5"Y\2IA8`O/W.:@CLA;4[A9^ESS`Y?//LEKTIP!?UNP"T2GAMF7RA$T M"Y<8+BVO<;OCA!"6%CGYI2^/^[[BI"`T#&TDO'5,9=BBOW#4+KG4D+$/;J'/ M`7ENB9L"3,C\,>)1^^54F(]R9SDDPCQ1.;ROJ.3@"R,NH^U$]DPR;'&-WK9L ME9#9ZE)*Y.1Q,&&$K;=N(VQ!- M;-`58Z48SZ+],/[!#MFW^_OK/[JWMZQ]=\WNGW[K/++NW5/[[EOW\K;3VU7! M&K.6*@);M8L6W='IT(UDH+3(QSJ7FDT,_S#0W\I@EYI%2F1OR)$_<_OJC175 M(-L:A&(E:?U2A"]KQT\1@W!<.`#0$AQ=\Z<>5F$$<69)3WC^;>6(S=@D[__2 M&D^*(Y]M(D$C(`6%M+*8NWZ7):+SZ\E8L5S*6F[JX?CJN*Q*O M=4LQNION-L<.R.+:M:C8#VPM,-!1+B,'QLILMC/KL6D22K$"Q6#Y;<*F6Z`$ M?A`&IRLT.,T7OA4W5O)@IU>@R*,\L>$OQC'`P]GI2EB?%^\I,W((BPJ);8F> MBX%;/[TH<-]4&'V%<\9Z-.P.CQ0+H9QY\_O0TK>MZ\$HL.@-5ALAM,J_R:&V M`(&<.5GO#LBTR-Q1`LRH94@L*$E@LTB8S0TL]*JY)"N>*R_/-8I,5?H./+0E3;(<7DV")#"#"=XMGCQ.R2_*KT4:<7H446J4>^\ MOA7/?4R>.RDRL_Q[KN_:$),+/,GR4%,$(N4[AW:0759@1JB.X,*?4#H12L=P MQ'=BK=0Q]SNOQQK1!#*.<3J3-BMH]G>8U3XCOMK M;<0D\R_LY%T(SX6R>K$BX?=T8-Z:VK-IF;Z)1-\YMIXM8*BP4C8NN1K1QXT$ MU;.;WSBY>9CCK+4LM4JXE-.GJ`?8T4*!>.265$$HE*&',8.'SQ0/]B!"Q+RY M(59QT_=]M6'9+C5+C5YBFV&3GS/FZAJQ;W]K/W8.+]N]SC6[NO_^T+GKM9^Z M]W>+=-K/&FVE0K\0[@M&$U(<<+MWQ9ZA)J*@4\B8!7R;S:J^92Y&H,XE63&CI*1P+)HMC8\."EX#YX">Q<9[#N$JH:+H,8;-&5(^@WRCT=7=15J]3 M&%B'="V1(&*9EY-:*I(M`R\X!#_+C9E64P#YOH#,H5JS8-*&FM7/PD@+0X>3 M$&F>`$@+X=&.V-(CIO_.A7A2B#]MBO!%!7H,8_]>G1@'F>Z!?SFF'9(Q/8,5 M.V8MSL++\D+&-$RT`_D2`I0B]9-HI#LZ[:K"H:M'0&C94"3P\E8,@;_5:%XH M%I'FJ<`Z6)CE0\322SJF33P8_*FD#?%^9EXJBT0M(XU$U-[/$FPA^QH8=SO_ MV%$.&T+8E;ADV9:C\-;8#Q%XP[,2<>X&LADQ8R?->,:.SPJR(660],-6UC=> M9OIL":G$FO*4'BW^AH!6'\I7'4"/.KS`C$#L&=E+YAWN!F,HF0K0D] M!2JTTLDL%LW5J@6#DOIA="Q*'F?-ZLLSV%R;YS#1E&[","*(B9 M*-2VH-L#S#U)T9)F:HM+BEC1XGZ"F-4]!U"*,M5="GA2;CYLO8INCY$25 MBPSF")V%)E=27V"G>WV"F;7D%7?"]LTC?B2!ST!`2*R6O0.4E:BWX9N/P,^" MC:C3:1(BOX3@+@C)J9MCN@1(2+%1/!N$P)P7%FOK2`:S'U'*2C$RKH+")O); MC?$L)(1M.&E&0@G0GIW`3V?1$'8_Y%U(C[<3*0N'R.T.F1 M9H3=9>-YT/QC4UAA(1;$LJN1/P!V68:0+Y]%!^&J,YZ%3K'<*LSP?ID..PX7 M8!FIGNN(^$Q!Q=O*C_QN41"M94-\MA]F^:_`0;67,"&G'/=+2S5LP#:I^!^& MXN^D!)`UY,/0W*44++IF20BT^6[$V]Y\TR%(I9_@'M!!$,AP>'P4IJ"GGX]# M[3.F?2+7HH]"!XOV6BF"WJH]ORM[_H?M5/NHVD>E6E[IM?AAV)&,`A^& MVLCR\`'V3\&A'2L`P&P3T>H=4(3*+PSV;_$9BS6F,.#*`Q*T102JBD5B%FE6 M+%*QR'P6:54L4K'(#!8I-_SA>Z(GK'DW$5^\VM]#Y9@^$6=G)?^(SW&5H*A6H%J!:@7*L0(% M'9:E7X1B;WU3V'9EA\2[PGR$&+#W@MG="1@C#*:R,:"`3T+_W'Z`"0MSOM!L M>UA9SM%9G]A^(GP$)X.R+Z9F98'%*Q^$O*[).2+1*S/!Z1<=DVQ&^7:)E6) MNSZYZ?DB`M[@8\J;6X+EN3S93)J'BCXHV*-RK>>&?K7(725KZPPPJEK4)IJU#:*L2FW#17*&T5NE2UYW=K MSU?R<"JBM8I%\+%(!M54L4@&U54ZX MR]&U1B1_E$SG@_!0L8']BD/$"H%:F]G]],6F`7&J%[-=?S&K>*/BC8HW*MZH M>*/BC3*&UT]'D:^GK)49?RFGZ77;HU+6O2SP2Y]/YJR%U[&F:WRMU6B57\KL MT@GT);^Q?J=/GIWBB8HEBHS1JAAD]XZ08JV(^9"@/I+^F@L5ZE-KK>\,"E6. MF-"YSQZE)K$8X;5Y1))WG\1R4%%QVS9AE2JFJYCN$S%==D[@ZMP[ MFC+SRL]__RGP#@>:-OYZ`Q3_C@1?FYYN.5[@!05@#P;U^:1]W_9T]%9 MNP[_\QWZU&HU]EA@F^+7'_5Z3.!!/('I`H,)VK\$A(,47/B+!V659FNLQJ,R\(8BC M@S3AHG8/*S]H[KW;\U'\D#QYX&X/Z^1AR98Z@.[=S=ZO]:-ZO1'3GZ.?+8XH M@Z$+'5%;UYT`#XQ'KG.31'X-/ELDZJ&V;TZS5%@GKB(KR/(K28KCI*!8U,?[ M#B"76+DX76T$M%!#QP(ES_L;Z\`A[D]8V_==\SD@#8;Y#HX$A%)Z(&I567$E MTAO-LR3QTPV_$[EY6`7$U$5N7-*N\CJ9*,$+ZD1-9HB`IQ@%\W MTI,3T47<0>)OI=VA3$5&DY]B&O*P<,X-ZDF$::2>%2!/:4 M@)Y68\/Z;=N@VDKE=77HQO')<6N!%CVG^S*-?-F;3_V\M>C^D&?DM_>]'GL` MU?WJ_OOW^SO6^ZW]V$F/K*.Y-O"Q%ZH@T4UPX?K]*J_FR]_2%T>?%GA)O[M_ MZK`..V29T['(U#"/Y+T5[19_!9YO]B=;-5W$AII+S3-UQB4;D)ZL2WV:5%\3 M^7DT#E!QT[RXH#8>6Z8>:A:ZHH++$Q_&\F*B3]KSA,PB(C"8&X?:"UQ-!IS9 M`4E(IY_HT$N(U[[C4F4@RW2,HRSOMVO3(N)F#P'DHL5UV.O4DN,C_J)F`7U0 MT812_E##PSFP0+3K<-%D9I]Y'#Z8I'8""0X)"-P1KD8-.>(\2%'^RJ$W_L9= MW?2`(H>JP&B1O-0D31EJ=H7S!+^AU#7DPEF.E[%HK\!L7^IX6(<\X`]=SM%L MY@^!#VUDK>312ZVBE-W9R26+)-QXG5?)/,CRH#)NR2M`,D]TI/ MTK[KC&C:Q>[7:*>@"VW6=A-+MOQ"U=@SU[7`XU2/]_NP3:49U81MB%ZM'O;[ M2IOS&>V>OGDH-NX+7[C,)FH6#=`; MTAMVES5%\V,DIB9DT0/'TI_0'`57B\`#[I?^V-C'LN(FE^R:IXS%#C\D'W1N M6?(IZ)>]^A[][8TU/?P[%6Q2KZ_X-+0X8F%S$#M,OM;YSO@K&W'##$;,=H`' MM@DPEY>H:9H*R*8ZO^_%,FA[8%+)HV1^6,,VT8!67]Z*Y#712KZ1LQ21S:3BN-<]/R\\D.ZK.7D$YN#]`Q]:$ M7B?(NB->)BJY6](MU43/@_)OJ8I)MLDD1<::5)IMX5(7'WA-E+7CI*]1)72K M_50)W(_((*U&[?SDI/Q<4J2F.P^.X&,(8L6W85"4M:$"XR@K&$>S=G%\ONGG MEY(%X5;<5Q;N.Z[53SX9&,SJ#AG'J:-B/6HK.)A2T5C(=CFO-4\V*:PKQ(2* M_^:*ZR;(ZR(5^@^#G3`=_S\SXD.)GQ^[7#?)Y;?&X"^+D_NVV1X[KF_^F MW]*Q)&J]J%;;-M0Z:X8%'5\D`F/R]+B=82T9OKW&L"X##Z[[GH>X$\^F+\DMY_I8Y]*A[R"Y_]+IWG5X/(X\N MNW?MI^[]77J?[DJ$PKW->GSLB^#(9DU&`?RN>0[ZJ^F:Q;Y9SC/\XP6@CWI> M/["L"<4@P"X@3!3.QH&K#S&DS^G#T6S1=VK0D*Z-T>=;V@*@T-@U7S2?6Y/# M(;<,=J-Y/OOF.J_^D'70MQ!^1PB&6W-D8A_[>S??.GL'-::Q2XP!\H;L=Q-' MP[J>A<[;1(]F3T3T#NLV<:IN9BQ-#KT-2'^+W$:;%]U[&@^3Z'_H:8 M8)T`RI^X/K1!^1Y,V*V/W=YVGO8.J,ZEZ;RQKNWY;D#PW;"YC[#0$93"WY`Z MEWMCKF,@A#6I86P61F+@7(AQ1[.D#5PN.O2`#3`NR6;M8`#,P!H78@6.V!-% M>M@P!L*-$+$>_M#TF*;_=V!Z)GTG<<;A2X%M,]8FU#"4_=)@P"P6"52,A()U MT43$%;U%PIBQU$E4"*CW75,G[!H9]S4%GY/`=0C&&$/5/#J.FHCK)0);],R' MT&!,D5XP'?K0Y"\\I!LAXC586B?"[(`/?<<=$.;=5 M&?`WW$\87P@,C4%%)LSYV'5@FW)8D$FXB0S6>8/=:\-6O\)H6-C(@>4)[MWO M=*X><(J0WG".LDWD8C!G&-=`3SE`0#B1-'^^,TYH:&?'8AVP,GY]P+R)!Q(- MN$3L#Y)!DJUN<(*ACZAA7;X><`+(&6%*3 M\%A_!&]FC?W#!'[Q@HA;L/T9'#/67-_&'L4VO^S>_Q_F<9+'G:MO[#?'`@8! ML:/3[4.L`[#.Q(-^/:?OOV((FR*Z%+)AJS@&/N]YI%$IHXBF0CW!D$#G&9)GAKD\DPF*1#!,, M6PT;PFA;+T'(JPDG'$IUM(+1Q/IXY-!OR962QZ;V;%J(_P'4X)[#/<2>0_U2 MG&K>D&+Q\"BAS!I"RH9!]@,7@SF%2!"\#MQ/,<*Q9*=)X#`%&,RGFV.YXM2" MX(P15@PW/A$1SG/.&:'C$XX]#8GC0EIX*7Z!+2#04;".S?U7QX53QH_/9"1" MK@\;@^+=AUETY$D@)A:59FZ$*XH_>!H"`/`^$.]')QHT+34&8,9:.(.@BHR9 M.<*%XXDS1_;;!QU&+@>TDZ0=8S?'XDCG`_QW9X\97/SXZ(8=&EABXD&%(SP] M-36*./ZE\H;EK]2]`7\8B*0BMY_0NZ`E":7E2(9&+G;Y$$J"YL5ND=_I:]2' M;BSGU6.YXV!GLO,,NBXUBSBD-Z3M0]2E(FL3L>ZI70%34I-!MDCZE!Z>:W LL8\;& M&7RE&,O%E58,E!5[8>EXW]Q7Z(S`U`+1-Y>ZR9HS;UE_/ M07H5ZZ^TW'H4'BQ9H)E[/FW;25DWGZ9&6;Q*RQ.0B+NS[)M0T?%JK&OK1TF[ MQOZ7^M%Q4T&RK!P,2^H_UJPURK'_MN"T^S$W6F3:@[MI9#A5=U^UUTJZUUKU MCQOX6;BCYD?8?'&<4N)E8`N'7^5>5U;WNI.S33IKE,.Y;I6]?CPW/_.*N_]= M^W>U=X!.Z^?U%B6BY(GBF`!=&:(;C!"JEMZKQ0NBZ3(.DS^B#M4T/\+N/F4]9_MIDSN:R@]F&M63,I`,Y/$` M54)@(/0V)/S,1!X4:\*T%\VT1&(%\98W(8!,`UD&A]C'YT[Q#(GK-'+<9$LN M'\"RF?@4KX&>-9`@M_X0G0-K8LIHR&*Y:ED3)KIV^8OIT9*2KPVWS!$LLCN) MYF_VNUT:K!1:!2X$GA0/&-D+(-\)\BZJYD\]AN#*3+TNO*O7VJ:>`E90Y3-% M8_4F4+T)X(LF.;"ETIA5#P6?Y:'@^+A9!N-)]4RPS+Z,4E>X4=('D99$@-3+ M'&SB=*S,EB4U6S;/BTSE^2&,&1]HBW7M%^C40>?!:@>5=`<=G^TF%ME'V#\/ M+OKD^<*',G)6K+922;=2JQ1:8'469>ZE;XYCO)J65>V>LNZ>VD6K2$/W!SB* M/OH;='2%&FN3&?>GT))8B`98O327]:5YOU%K7!1Y%=O`4A]4;\S+Q5US/_TX M4#TQ5T_,G^")N42OPDN_8)6!:'QR'$A]FEZ44PG2*7I^8G.HC&%\;QA?+YZ; M-80(D(^JR2CUZ2`K-8H4_OP;!2__)9H:"-B!J1B_F2^D*KFVXR>(>N;,X!B? M2(_<%':FO>'#\MCQ\-%U1QT6VK1*\ADZ7!<3X\,CW`:,3--TX8<@PM!Y6BHP$?K9US%T M;*C)A,;H'?&/P.:,&*9^P?9#;E9?^6N8_)6/?66Q9;&#O+X2&W``F,D7&X^? M?(>3L_I4?:H^59^J3P5_2KBO39]KH()I"YW:R:\W?CZV79.$0OAW'@UE8^**-RK>J'3& M#'\BR_&J4)"R[B)TXCLK#^!:VE^O8HZM,D?SK#P(83E=.2NE<=>Y]B,I!A5O M5+Q1*8TII?%2\TR=G/$,TPK0XP]5R/@-NE(FRV5EVJ\?U1NEV4^5"ED2EBCO MK:)2'4O(K95Z4*F.%6^\8X34='[C?#EMH_2Y5_??OW>?OG?NGGJL?7?-KN[O MGKIWWSIW5]U.C^W?80[7NX-TXEQH?&3ZE"*J;1L1I+6.84-3J8`;S8P$P&^> M^=4V+9A/-^![[*=W)"@[T?),@NXT3.67"DZ9EU585+CO*\4WFD%XL5Y?H/<^ MS7^;';+[QV_MN^[_I6R^M%`/M^T[=G_#[A\ZC_1M+\VLNQ*`E95?P:,P*7?L MN&&&QVMN::\B11O[1V!-6./B_.R(_;`MA(KU14):'`5S.47Q>B)$_]7T$//4 MPBB8/G^`)_*T*LD48]Q:8$E3@-QB@%O@T?KKFB>`73WA4(V_V/(S M@OC:&MLWC_A1C>E#[OELK)GV00T99(`8L3#=0ZZY/L+$6BBL]O>N?KNA%,XZ MW+W9:.+H"'8+@S'MON;J`J-8M"AJ:KZO89KA_>_=@P,)>PDU'!"B<(_WAI3+ M-\/3_"D.\<-`0=<)!D/BD->A8UF30^<54T1&[#(AGF+7IC:P':!<]R1C&3\] M_Z31C[]QS?*'T#NGG*B$@_NF6P'E&Q0))ETNX\(T&CM.Y+<.BRO"^+]U?KL* M@96'\0]1-D^4_CCAW[@-4MIB'4P;Z,)0PRR=^W=_]CI?H5UH)`Q%Q-YIE3B6 M3O49CXEU1]J`4BG+]*:9,_?#-F0P+=+*VF&:ZEIJ%N*$KQKL!XSC-%*3DC$= MJ?2JL)!$[@(1_Z,=1P(BTK,0=^>VV*%-98 MZLJQ`M`WM)D\DAPCC4G#A-JFCUP)VVLD.D,7ZPEPI$A_C2F#C^AG;+PK3Q%'&5(3*>65W/$>Y9#%',C(U7&^ MTRBK+.@CL]/+X^^4.WYN9OEDL#`T2.PU#@^\7)F#S7!W..$Q0G47I=JM9>?: MS=Q+;>1Q<_Z"46[Y@#)0$RW]P"5L'V(YHB@2@_&QSZ(Z`DDRTB"7$:44,$,VUZ$6D"PBS7\_860J[(]K# MBY10:EKHN(<>;9O'Y+:9[HSM]V"7WSF@5EX=S`1!B.T1T[?AZ&8=P9`]"!BR M&KL2:G+Z1AT6E.5DJ9P7>P/TGA&H!K_L';;V?FV=-NOU>DQ>=M,;(S';&)(D ML7G66I)$-X"5O(US/\RC$LLJ1=>9RV;SK)ZF-+OY#1.;:U9/6HT5B7UPG3X( M0N!=V*(W?#'):@4LO\XDP]BRR)[1Q?O1GF?.UZ1=2"0R[5'I1:13^;CX6JS= MJ$]MPME=O!?E>>:\=7Y^L0+E*-!C/$@C(#PHEUMDJ1AKKC^9,G-B#2F3'D7! M!RB'^\C2H(^^R8VU)'5B%$OTMJ4QY=H0%^N/2O`6:@Z=-QU1N9ZTMX7'$U5J MVX:H`C6*.$HODHRVH(_W'4"NK7)RLM(`X!>^6".@4@5,/+-Y!P);3+S2!'CS4IY*GGD?4W7)\M1D#1@%;I_B1@07O2Y: M7VN@@]K2/F!A&UVT2,#--SU:T1+V>P.]QIW&?5Y2EZ(<=9CHCGI+]A5VM?!= M9_[\'39:C>06VB"M.[82C6@E&GE6XOCT[-T7XII[NFN.0_,$WD*5Q(*@)-GP M61BS/+QPL0GW6=MPQGA\S7N`5!J^[T.S<:O)1J'-/[D?MEC0&^5*CH=%/U#> MLT/VV+GJW#W=_LFZO=Z/SC5K7UW=_Z"W9/;P>'\'GZ\Z],RTM0;O4&%P*"933A4'=\&/`[Z/!1GSP&=!1[7`WH,BQKQQ(S0/"H/7Z;' M@C%"DC+#(8!9?:C9`PF$2J^\-/TCX!;$FQ7V,/&./6=L0-CK$%_L;&IDP4S$ MC>N1UH]K$T]OQFJ:GH3`U<9C"RNX'$X:Y06#7BX\B6X:O@OV30_MC/3")M:, M@&'-$7IFFPZB8#YS8%7*F2K@?J^Y+AX:&B&PU507S'3IL\([Y><"#2&Z4]=>KB&ROC6*!XP=!5+5@^Q9..F8ZA0 MA0%V6,Q$BQB_%MVT>Y>AB-$"?^BXIGQ`CG@,&,P0OB`13"[^3MM%O+8XB`I- M3!<]%D>UZ:9-N6T%LG3Z/29F=YDT623O%9O3"6C;:[H>C`)Q8Y^]@^36#EF1 M"#&]E$!%ID)F$XQE*PR5?,M)L%;,1V-'H,O6(O!9W-2*F=\5B4+[)&11>F/; MUB3VWM%"V2)?W`7*;3AMH51/S]*<42\VOJ^D"4X;O^/T(''.1:]&\@G7R!9' M"TTSL@4"WOO]P**\V5$#>F1[2BYTGWUIUNKG%YBH.`7L3%C.S5KCM(4_1CPL M?V_,LL'#%9XTDL>8V#ONKW,'/VTVSS-M\G.[VK&)S&4RJ)]>G*PQD_(RZI.= M0UKV,JZ9+M<\#L.D?[NV-(&J]HEU+XS-]'5Q<9?O,(AE[0]G4[?>)88!(D3G M')12LB'P-^Z2-0_X\%5ST=$P/::P`EZI_Q!%.K+68A?9!::\XZ1A=5Y7[S2` MY1AJ6=HQOH[V?.)^A?N\A\Z5>*;"%E7M"7"FD3OT/,L!M7K?5]N$?:FTJ!P@ MLKW(I?Q3&1`NV2&[;/>Z/?1H?GCL]#IW3[&K\]5C]ZE[U;Y-V!3N;[OHHKX- M)?/=IHR^>.5BQIX=RY@;_YG-GS_$%NN`7HS*_12LR*YHY:2RZM(G3GBS9=UI M6-95)N%BC5=?<2/%YMQ0W<4T*_'V'[N@-)IC?'D9")=7O+SI"`P=Y^I(^GG" M(K5'\([>!RX7H`B1BKW2EG!/=V/'NIVKO8,C=B4=-]4<$0%F6;B[WG3G)7=JV M'4`KC\(%"OJ]@56`#7#XS\@OC[+.F*&QP'0,":(\I8[6\/K4-RWX+:(>UI]N M>4M.C2189=&(]V+O4>>%NS(/SBN/%0%IO#]B75M:S4Q;WLIBO\E:U/9*&]GE M??(EQW@.59O?QT9,CS846MJ(I_'6``HQ;;*X[`%U:!HZ`ZI842` M.W6G#&T^X4TV7"&YG.(ZG7W-I5;M2+D.NS?C2`>\L-)M7S0GC%91 M&J>P/4<:`Q.M2K+@!B1,5CMKP7D2YA.R<\X+16"RXL#Z+%$G^4+&`*AFAPFR#Z#=L*J[0T58CBU&T M[7+O#K&WE+.$#,$RML^?U>T*TCXT7B>V,8F^V+"=-7"9"HMR!XVQ?7E#CPU! MAG`1)_N7L+"&NY$;*/A]E)IABT+PBGVBDTPWS#[:W^B"(JQMT4J)73IOX6*/ M<%QCX?@9Q2P-0;@X+GF=HB>[@_;@Z&5!#8N()@"'Z)JNHZNCA%3WP8I)28G])R;;=$[-&G=TOX24J_0"C7BM'FL'% M^[`)3!]J>?*<@N^EFA$KZ-'[A2BJJIPY'BK6,3PI=E7I#!2;V".) MTJ'A65IEUS2IIMX)LCO9+,7+&1[3ANP%]`K#,-L/3<0'**>D_X?D@#:I98L- MVE1+5A)UUC;*+[+*3W>YM:$MQU<7C0V-#'W45AE<7*^8I3N=[CVW))3M-B_,5AG9(5Y@D M&"(FZ#,*2T1O?L*[-%]/@E`U8GJYQ>NHN.8Q,OPG*%JB!J+ZH M'546==?DQL0;8?Y>RS+8Y<1*(Z5)K33B=NCMQVXL;1".QN#FU^@7_&'QTV4? MZ.)__VFJ9@Q;)0^8&^%@]R?77-:!+7(-A*G]RG*B&):"0EAF,0F'AXWF8:LA MB)C53.Q<[N@$<,`>A#Z>14M81A3)30A^.JRW(EHRFXD(Z8#2[D_8']RR#O_+ M=EX1ND#S'$0'Z*+SF:M2)`ICV7]BT;"D*+B8LCM'4#2WF31EOSL67"SP=GYC M6MSUINF)2H@"R]*1JI[N/^0<87!`.P!RK*;29-% MQ+(KQ'QPW,DT,?1[^/-B&GKX)`<-QJ.45D&5LD2;:8(>(P`K=J>-^#1%<0'\ M?3%)O[=[]]\[U_20W[V[4@E)-C6U8C![B!G4A=O[&_LGSY@=681*0('%Q&`@ M]7GKHGY^EEBJ9#-3A#BCD6,+:5YC=-!Y[#[PT7)+"?2FZ:(:5$$45TIG$'G2 MJ"?%=$,5TW60TB?GI^=-$.@)JN=T,BV@5(EY`U]Z62(J%G14))^02HJG5!,S M"9$"+.VS4#_^5[!+KQ8>5PC=""HN' M.+28!A;MS@BJ*9J#%Q"B7Y6E%?5N'#>N%5=:7]-9JKMMCFQ)M:;>%)@)JXT/ M2Y$C@M-'$YM4YSP:+BCA"%#GX7..M!9K,A[=D.I28L1A6V1V4W2KKMU3FKGO M2Q_`4.4J:&E7[+W4,[$L*S1B3EA[.NP78!0'@9:$HX6<$#+AXON]+R)"(LR> M&D+^$2H5>9)"N1A4R<*[K9>P00HBXTZ>XCZ>G`?9`\9.A^VWE=:?G/NP[5MJ M&E-*K<=&$EFB<+(^T80NQXVGFY]0::(+C2?P0<[I%6@)`P(?$DY'#RHV@Z0H M:7@)J\J:"G;"M*ZUK#GK3)V(W-UN?YS+.G^?--<;Z)7C^>R^K_CJX M#WG9#DLUV%R8/(T"!CO_P%7>`Q/CFW/F*2^(JZQ@.*!-KQC-N[+&=MF\=B(0L]%"$#DG)TOGU!2A0(DA<*4I<>OH21^3N`KO[X;98 M@%]_6GZR2$]1&A!R\LO?__B'KW\Z/?V& M8YR@#(>#\7KP,J6SE,:#)[S(F(#!11#@B+&<W#V^?/M#D=?CQ[&PT_/<_[I^#*9ZA4Q*G&8H#?#)@]%_2 M_.$]#5"6U[#$OAHG42'@TW!;EI:"_SHMR$[YH]/1Q]-/HP^K-#P15>2O'0HI MR%J'3Z//GS\/\[9:4"2(&T5NUF?4&@XW]$AKA)SP9\+\_GNZVW$N4TAD. M28"B#P&=#?G[X16-4QJ1D+N'_3_$<8K#YXS]G.$X2Q\F5RB=WD;T+?T1HT5( M&!FK6UY.MI[C\Y.4S.81+IY-$SPY/^$E,5.-/IY]VACJIT;%#`^FU,.<`Y)! M([V(&<5LGN`I(R)+?$_3`VOJ7':[ZE^BB`/E>8IQ=@`-=>++2K!*!HLHU_V> M_9:*QJL,,U';"G%%VM,RKT11C8@&4M$1[R9H(JLM2LY;VP2EX[S)L6[J%:$Y M:WJCT1!'65H\X08:G9Z-1+_PDWC\GWN"QB0B&<'K6B&H*[H(Y*E:K[95"7-\CH0">')@RO8@KQALGK-!,_NO1ULF!=-HJ8`G0V(RF? MY6A=;J?=>=Y$"Q@`SBJZX<`D3L#A(S@X6#LT*YT,`WOW!@X"5M7(R"7U\2%*2R*;K%E@F@AEF>)6F*HN/%2 MTGV^J)4G,/$S'$Q\I]EVE'O"$8]./:(D5RM"3(4)P:$:(`TXA2&].*%"I[GZ M#CCR$E[$),XLJ.K(=N;0('6(K>D,II3,S6=8KP&*W%CCJ]:(*J@8*NO[%K-% MCM6';(H3::_@+@[H+-\Q^(ZSAPF;6]>'FR;RCJ`QD4FO+#' M11B2+)^#/2(2WL57:$XR%%4['C-5T<'HJ*#"P$TMEPY#)PA>`)0'Z&F$[&TUCK40"%,H:2`ZE:[.@Z>50IQ MG/M"72!8Y\'>"P251'C]64F3[S0.;(D)=9IZ;D*9IC.]\HFGBW)V0J&AB1`$ MQA4UIQ[ZZ0"^8^"H-HF#-XVOA-VU(+#2J;@(!5^W<$&"0YCC`0QT#]FDE M+G&B!J8ZYE(F37&65E=EQ5S9Z"ZIU4\>YSYWAF+\]T97\X4)8H MXGFP%]D52I(U6_PJ5Q8^/,5RPXVGN]:I=A9MIJW4-"7)^7+$32+`$.Z4)MD+ M3F9W\1*G69XR70WB&DB*,*Z2!*#G'70Q.UHM`&!_*](_&2CS2=43#C"#Y3C" M/#)JSJ=UXJFDUUIX`$*AB;9F;#A*A+=,*RJ^J["\9:?!B8V\`A$].6!T..KH M!@R],'BQ9]Z_Q4SVFD&WXG_5*V$'^15`OQKJ;O:AS`AO,9ION+.>YYZBN`0T M;6?O3%].>3#3`W2WKY9F##A(:S/EKL585;&LOJ)IEM9;M)&F'*&JTP!TNHLV M9D=K)+29$*?)I]P6.D7)*TY+X\3:G!AK9ZA$F4P,`)WJK:?9PR[BX.6ZY;@T MQ2?T!.56;(Q4@/"V50^']EMA%][\#"A\6(E_47-\2:%R/KE4J@DHQ/"8T#EF M[>HQ0G'&SYW\MB!SOG"NCT,NI-N-41,I))]Z**5QL5D"O.##-TK#-Q)5$U6J MCX72N\>0O*:IK,9#.VIXJWO]K%6[8^7#8ET?P-C'JGNX@9(:[[M):G/-Z#][ MM.Y..O'8YY!0O=U$38V['44!70IN]#!G+.AHZI-(J.YV44/C7@VK9?'W=5C5 M^I[]/NYE+$UNO>DPU;&:MJU)K'>@W"5`ZBF[&W]QMDM+OU@B$O'!X8664AC% MOOXE2DE0'8J;<1>CLB\W#"N9;L--X>5&)6]8EL2:9D7A!XM==.[S$$YH( M6.9'LV]668)8MT)BE*SO6,O-^QO&R5HXJ]_K79SA!*?U\/O!2]I&\P]84G>C MX*;VO"X:O!DHBA%01=&]1C>K.1\(M/I4WU>UV;WO+B$!YSC97&$8L;'K(IR1 MF*09K^$2BQI64Q2\F(JD!4>F[J8U>K_1ACI+4YZ:^#S!P5$LO#C3$TXQLRK/ MP[G&2QS1/$2B!HP3[?8LE9$6*#Q\-+2CPB(-8&JFJ0^G]BY1;9*=K'RA4)>A M:A6G'0?C^)T._#Q_[52AXDT1DBN_Z?8ZJ"(1N!8KUKPM7_=4?@M""QXF5&R_ MFD@4^NQ(.CP(I+$^==)&/@8DB]I>4543`6_(*=?S&2=+$F"+>Q54"@]+5."= MK-?)Q\^2E#;W-#2QTMUEB/H^QDA3.G6IH`'I-1=];#[3R'#<]SBF(53C&[4- M')+Z)0E5N`+MD7BRRL,D[S/YH1'1IIYI%-:@;2/9'U@4#I M+CV9Y#@563]<:%70VYDJB?T97YU'%M-0:Q*B0KAJD0THW*!?:KL$&B1N@+&6 M8^Q(4)>PO&3,`]9*BOZ4:P-O0&4*4+FFZHBHE6Z;YZ.EZW#O;>.6/#HYUH1\ MS43;'2\U47=MR^X7ZJB;U#BT8C=G7=3B`$8W2U7-\S8VNNA=KR"JNUXBZH_K M];HUX^8Y$)_8@30O-+C9]P0%]C\CNN+A/WD&"Y?]HH`3B@]K>* M.]H:E05P)GRD"9#K&'W,:9"A3@!GJNI,(GK,I!JY=93KL^E_#U@/>+/3K1H" M-)Z;LTN M*=G5ENN=NUP)FVI+K+5CEY+@M73=9>:W;+0GKV)*'*Q+LV2V1LM_":>'_UUL M+B0J#+.9/C,I"9]B7^/-WTHO<>QBRT=(CE(L^%;2D0=\FM?QJFA9,T`[9:/X MBC:L:_^<^H`FK,9+`-W:XG%/E_`J/B:4#[;AY?H'<^1=?,O63''`UD@7#+1+ MHKCKRI]Q=R[%F;'#E.DY6@LHEX\Q\JAOQ1`NI-N$:1-II[-%7U]2+\6K$T/' MTC8)UJ92``;>RQ4N?^S)`!L5F0(R,EF?X6)0N"6HR"6X+OR/>_E'@'&81[/^ MA1(V)6P>L-DGSI\8,.4O1($V'R%]QF%C8[6$4)_R!78A?3VPT8R:[C'=E%=S M'J6+Z(ESJ?`")YK:;RYH;C"W-S":Y_9*QN[Z3S%)>*$7`0-!@AVN^O;B*7I' M-QYPG:')S;29*5SZ/D6Q>=_G5AS$&5ZUYMK;RFQ@LS+J$&=@[#WL7(W2)O8, M98+`Z"W,KG' M4;Q^5]XVOS_JE[_F"0Y(KAS[?X3%EL?%C`W:Y/?\>04%/BS;6_9<6/J&F0:& MV`-*;J7!6]3\/[OU2'!L.]W5"YW[Y+^"6@-P=?EYM5N:7-/%.)LLHN*C)_6( MG)5T%W]BPPKQ>8[ZW*'Q]4?TBH&;,6D6;F_D/2PSBM M8M)PSN.I9 MM'!2L?0?559#M`HN56D%QB#EMBKZ66-,PIE>/S[V/2+A:X)V1T%-/&($*49: MK_;F5,UFL):_8*/%E9Y%"RT52__1935$JP!3E59@S)H*T3W&V,HE6>#PGJ`Q MB52;\]Y\9K2I^-X)Y*PF:1]WJB+A?7]<4_G=%[1\>C@=EQEV=:YW`CJ+.=J' M7+W`?O1V18A&G(AY25!8OPO,A\D:8I.9^H\W!V,<)*@FEU>@#="&DJ:EW,SF M$5UC+"(PWD.LG=_Y_SO>-.]0RS MO!&@3\C6*UXDBQ?;(OF=9.K#P,V8M;`S,_6'1P&/K^=X;\NRF.$3?I\;9SY!Q5D0>U1]`<*:WQH4!?!*A[;BPP[<2VHH+ M5S^B,/H,&E,+_$(;[]%;6$T[]%K6=P`Z5\.TO3NO+;7(X@9TJL4:#/)>W1I9 M78-Y[VQ9X6R80X;U5,N,C[;C+ST^TVD_9GB(,YW*4N'EX-],)CC('B8WJV"* MXE?\Q/JKAUAM@TJ[;\(J#.['VC\D[F&:O;#H5Z[E;*7VOD7Q@O\S9@6S)_\# M4$L#!!0````(`).$KT#:ZB1;+4$``$1<`P`5`!P`=F%S;RTR,#$R,#,S,5]L M86(N>&UL550)``-5OK)/5;ZR3W5X"P`!!"4.```$.0$``.U]^Y/;N)7N[[?J M_@^XLZF*7=4]MGHVV!)K[OX``$#O[RGY\?0_`$XR1`T5^_&WW_^CL`HRW: M!=']7[\[)I=^L@V"[_[3^]__ZR__Y_+R+8Q@[*=P!^Z>P>8!/28H`BMX3+$! M,-YN88A5+HEP&$2__D3^OSL_@0`[B9*?/B?!7[][2-/#3Z]>??KTZ?M//WR/ MXOM75Z]?CU[]]_O;]?8!/OJ7092D?K2%WP$L_U-"?[Q%6S^E+:RH?[Z+P\+` M#Z]*7UP)\K\N"[%+\M/EZ.KRA]'WGY/==WD3R6,%)X7XYY9\_C>-?OSQQU?T M:2F*#04"T^6?C=\>`-G[BU$(5W`/R'\_K&9<[1]?$8E7$4QO_3L88I=4/7T^ MP+]^EP2/AQ`6OSW$<,^V$\9Q:8:\G1_)VQG]D;R=?SM9?F72O'L"G0U*_=!. M.ZF]=EM;;LP;/;?U:D5-GMM\RYB1\`QON>+&O-%+&`=H-XUV_3>\ZI M'Y\!*FUGYG]`_ZUF-#4D/]WB?]7\PL\IC'9P5W@FM@6QD[JFP99:+FVC;Q>Y]_X"MCT:O8)@FQ2^7Y)?+UZ-\V/BW_.=_X+'O M^'@,R1^Y2!]@/$&/AQ@^P"@)GN`,#ZB/\!8E"6;X8K_Q/Q=-H'_]7[_KJ)T& M*7DMVMJOZF^)M*'VGF*8H&.\A8U6=OQ;_Q'>A5K]6(-A]B>:N7X,\9]`\AD8 M77Y8?P>"G9E%KZ($$-$"VZH:"*C>7UZ=WE[[C8_C.CC]>%O\T?B?DA>52[S: M(IPQ'-++VCO;Q^BQ.Z:0E8[.^XVVZR>@:0BD"!BUX=4`PL`UQ.W*;XV?1_CL'A$48I/SY8,=L.'(9F[444 MHX;T%&ILM$DQ!IF[\I:KQ7*ZVOP"QO-K,/VO#[/E^^E\P&7G@1#P+K787"G>[@+3/#Y=^L)M%$_\0X!E9,[*)I8I`Q9,R MC3MLNU;#B-"%,"H(-+W30W#`3R^#"&RSYX[I+.E/I/7R&V1C*]2X([+IC@IA MB#Z1M9T;%%^CXUVZ/X:8Y>@8IKBF9=+Q9 MI5@'QT+B:=OSBL?`CXH905Q*)GCL+4R"/8K!+C=*AN23&DYE'X.$K,,"?_?/ M8Y*2()XXIG,G]"$+H&A07\=,+2#H^W<6)NC\ICJT+_;7<`]QTW:3!S^^ATF# M>>H*^=M443",`G(7NM1_@O$=:JYEUB.`LE,1[16->%41@/8XE\Z$P"Y(TCBX M.V)X8#(GKKFK@0[4M?_J+)7K5JFIZNDL@!S9&HS4W9EC2CBA.;V:&&/Q$CE= M;M;@Q3'RCWBR`GW-&UXF?/(RC'?D/ M68YY\D.2RH_3B1_'ST%T_]$/CTU^:.GD;U!1QY"Q2EYL4E;'H8BSZG8\(I/- MPL@_X$G:+2/U0($,^JS.227U*BDU_)T+C5HIW8'W\;XC,F4)GH8A/C;!);B# M]T$48062]F5_Q->.6$[*UQ]DVXE?;YB]TL=L:[=,1\1>V4+LE1BQD*R0?2M8 MO3HW5J\<9CVS*(68""E9>F\0@?4H?R7U1X9$JQJSF9$P[(JXTA+WBE_HUQJW MJ&?V!9*_PSJ$JU)5I+:U'>)Q&T,_@=RL)IDDJG6&*?DY!_2LK9HJ M>S-&W8C$XNPY>%%(O@1!-+!%T_X@R,F?[6/0Y8)INX&SZ`GG3"@.%.(^0Y8; M\VNRUDE7L7Z66-_VI\>XIKY7^>$"1#`=&JM872UD%*='9&2JJ(F)U++?-Z9Z M#.(,3T9PX@?OBN#7AC#E>-T58L.*T]G'N.TV/N+8%?AW01BD*C%;HL>-WUP] MZ[SC>-*=IZ;MDUTR'HH]ZU%29.N4T:?^9Q#F3Y^'QD@95(3L5.A%&5$Y)L2D M%?H])U9['"\D7JT!E3^.Y/LI,BU04?M6,*P\VM@&\;!&H6)7_3C*CAUM_,\P M6?K/9+>@="A24>:.1V)EZT07N;.[@MK!LQ[AI0:]M1\2A.*QZ9#]/#16*R%' M2&W5_I316V1'S'%Y"P;$\V(O<-Z^3>SOY/P6*7%YS5:RSF>6FWYY+/"HQU^N MH=/V^H'25@@((5UEW26C*4M?3$^^QP'1`G"+_V8M)%])+6+*G_+A$#5_B=LKK-^ MB2OUJ_E96VS.R[+`/%<&NVPK69S)XY_CX:W(*@!(_)E;J6.E'[RY5B3?OB7> MAT7R&]P'G6DN51817:#`&W6BPUZIP/-"64]85N-]P,.^4D\KL)]K1\I_20O.#N\^=V8IN+:+;,&>K0+EN2[(E2]`KO[MP5U]>U=O M>'?Y*6="MI)FI3/(AGD4D3DQC+:XA==!L@U1 MIK+IF1(M=ST47>C4`.$)$WV#WF3Q_OUL0PJJ!#T3K%35D_^)A4XV/Z@.+@-]@\?*4@61G"N)(6>,VQ M;?7LN-2-C*\B;2\3``F1N``)E0%^*01>X*0T^_6E>T;*.AUI]TZ;:ARE)J^$ MMH?#H5F2'.7\J4OQN%-(V>9-9K=7SM1<:/&EHLGF2D`%!LR31N>*.-+N"0D_ M,@4A-ZHVA\.+Q3$EMY/L\(`H(P=#E,>0FJAMFE2,]S3YD;C3XDU3G4T>=)(: M,(-8"!#1B--3$BY5M(2$:EGO&6A69R,R1R88&Y4@6V<@RZ0N0$7NZT*68,9@ M`UH#F0TPBTMQ'KDUGZ:,__(#_]Q\OKG[\0R/7H=LH*I#R M4_`>H_\!_#"Z`+@_KZC$-=S"QSL8%[^.!L,]?AD402]S*=:N;<*TXI))S0M& M.+?V*$B>^,67-*<:S[;VR;+VS6PMZDE\25@HU/9J`B!$B>OJ:PH=C+1[HL4, MGE*#)&+;_:+(9E(C\V,`H5$30YD(>$&N"'IY`;`LJ3V%I2_`.,V*-1<'&I:^ M^^^%=@''3W)*S&UA,H>O4^3UC4G%(KA$XR.KK>3*/0OTNV))EEX.G6NB"WW"B&+L5GF MICM^:&3.H$-%:,I;"`$B]?4@B1MWS:$TS*C+.9VCKB"-PM9.X\A=V)VJ*GKK M1JS&J9LO)#2+3M3H=8\JOU@G:%0]#8%NXLQ&G,[8SF&Z)"Z*%-%/5$[920'^ MQ*?W+<'B$KS!D$!A*%'.1`1C!C?G.#=P"T8Q<=M\6(/MZ:$5U!;F[(.V85F. MV9I""=D2JX!,0/TPRXV27'8(`&YU5PN_K)?,@F^9\;706[?@#+R5`UKL4Q%\ M@?SO90D8`KEMTOK4D>M"A&J.4C%5S+<2#^;LH*#KD.K+KH.Z+5L%-L]2+VBP M-@ODF]>'`I[U51X,9%.^"0PX4[LN.'`YE6NWB#.%DPMRHYZU*1O?M,TA7>I% M#_V-J=F'U6HZWX#;V?C-[':V<;XW7:%?A5R0S\;X.F)J#&3V510R7&63:?G1 M$76%_#VI*!@R1^ZBAYU1RDY%A%(TXEU/;Z:86M=@-?TXG7^8NF65!@90UUZJ MLTRN6V6;JJ>SP,Y:PJ+NSAQQHTJ)TUQRF`--A4FQV6!,H7JL%E.54\D"M8430HZ@CF"/(.$#*$,540 M61P*$>;XU:EPH2W'ID-5SBXC3I;[SW-:OC3HT=!M,610?&!T*Y\2[!X0LN*D M(B!&TVZ?N.DK46E[Z0P91EIR`4XB7PM^U!*/#@!RFF8$3\$.1KNB(.?XD93G M;(96H5`15SE"IN1@FK6:9H@\"$G!5RRKV1WB@AETHS?8%3J.62'N4:3S_AMT M8,K7N""PZ(P'T_T>;M/%?OIY2\N'KOP4+B+VQ9<-I'91S=^9GJHADW2<6?_" MT\&YB'K:YKQ,@W[QS'5`C)4P(?$#'(G)9T$4T2MCW5*S$YR0>3?7::QCI4IN M?>]G1K6U?*J+8YN0'E4Q72@!HD5P7-Z!3/]14?VVP,W)V9'3TD^,9/ MX([LI8=1XI/%C0:+Q$+Y2^,)&3*7;=9F9B?T(.*B0-&CSR[OR$-RF9!?W**6U15(^@[K^*P(54'9TK7;G];2"(9=C9#%?+VYG MU^/-E-93O)[.U_A?ZPW^(2NTN+@!B^5T-=[,L"AX<8S\XRY(X>XE^'MARO'G M3UG?(ZV.:E5292DT2J;R;0ZH&CB]GVOZ>`C1,X1Y.5?M.U?E^N*[5T7Z_=QK MR?=HF9Z=G'>XY5)BLUP+W9(*ATF"<\/!U0%7A9+\7DNUWE6ZWI)O2N&:2UD[ M!A0';H+(QWU5J1\OI3Y?A=*'/:I-H_UZT>FSEFO/QW$)\>#(W` M`D`(.2ON,!E-V]IB9O*\G0F'/9;EYSNT`4%^"?X"FJMO!9K*!?;M8-/E1(L< M*?P4A&$#]X5 MO]`C5!%T?J<)HU>0_&TVH^5)JAX5F]J6.]?B"-PVK-.OHU/'/M/*5%]6MW)' M0;5^'P*>D#A#L8)^7B8/C>0I"K>/@G'$;=W'H[IH,^SP2*'B@?D M^";R<\/5638]"5^1_CT]+>_Z_D)E1+#/T$E[C7N2CJG).4\G\'(&`/9Q'%GH MS!1]]:/*%'C3KQAJ\H/,5K`VY#`O/_*LI*88]OLX#BUTU-/A:!6?)ERL?XNJ M')BFUWNM-XO)W]XM;J^GJ_7OP?2_/LPVOPR;H(KGJI6[4H^ODC/7"EZ=T1%:H"[9_#B2'9R!=%+L"_T@%\JNJ5W!S`ATVZN4US=1I7D MNI[/BF=KR:&^6WM@'F5HIKM[EU4T?RC07"J"\3>(9DZ&>0XXN\PZU5O*R3^[ M&]`>QJSEI/HN;6:GG;W;"0:-W5,D'NQ#]"G)+J;^DHYJUN5=8P(KG^W: MDJ&%"+)$FJ0=,EN!HC@D,!7["04,5^?*;/FN._"?9^R4V>;)+/Y_N>30B2^" MCYSPDHY5(CK#A@+!N9[/BN"^>RI>+0<]E>T*R7RUJ%\P!S649+ M]7)9!0/:`U??N:S`Y1ER6;EW.\%`G,M^R4-:AUQ6LNCD%T%(3GI)YRJ1G6%# M@>1CY;"]HULMGK<)Y@/DLHZ5Z^:R"`>W!J^]\ M5N#R#/FLW+N=8"#.9[_D(:U#/JO8Y5UC@D8^*VV)RQ"1'=XE-\:VV=]^=B)V M]9DY9T_6+-.Q95C"M(8\'5C=7\W,[@ND\`I;\#Z)-9#;U+?=J5JIELJ,H6U> MJV]'7V[G\A,:Q=YUG):<&C-^\H.0'/[:H`EZ?$11=8/6&S\)MJ*HI*[-BELJ MVC9)(/?7Q[RZ@W]E&BE:+'D&_,,A#+;%'>1;JE/;\3X@)FJ`B\=5O1X7D%EN MB$MWU3:<'^DVY]Y=?%N&>3Z>9&K@!5%\"4I5TC^9,JAJ7P"J_RW"7F40ZQWW M3F^89I9Q7,(X0+OF<>D&Z[JH%K>.:JF:WDFJX3&@%XV06566":!L<0L$*M#6+Y0S0@D7C7-FX#797R6PU M1YQ1V_'BK:83/&;>_@)FZ_6'Z3483R:+#_/-;/X6+%>+.?[W)"_<.)3RC#91 MC'J#43,--S9>3\TMM=5=<,-M+M;QLUG&]#.I/=TDN52N"$1\.=/PPK-L?WE) MXDD8#X2Z>7$$1"H+@H`^'D`Q&'G?(LUN:)".IU*CDMANG^"QMV(C\](9.605 MIO*\7([)11PGH_8`Q%L],4:0TP22US!>>J@J+XNY]E([F0>KB9NBLTYDJB== MBTH@!B]@)I(,E4W"K$FGAQ3)Q(972TYG8K%J70//U\KE>B*+[2]SKCR`\B0ZFVI'X'E_IJ^?6,6)?WRNPUQ=(^BAA MIW?GLT"Q6JQN.%<]F\-#7I=.$Q^#BX[RLG-\65&T[*/`7-MZ3U7EN(ZTZ=&H M'[>8O[W<3%?O0:62W``YHE@E3MP?"I21U(/CV7>X_I'2*G6WR(^24V'\.4RY MZ8:.2KD*HJ)BO!`B=V)W+439GW@Y1-&,=S.;C^<3\M6)?)":?1R_N9VN![%& MK0$(U+W#FDLCI+/]R$B#T_+ M.QT_=+_;7M1I2/DMU]'/$*Z"G6NK'R18R^0%]CO`8%3%06V7[)<,"$X&WPT1 M+K-WNL)/[E..X0.,DN`)9FV[03$,[J,)C#&#C*NB1O.61ZR9U`2[W4,]A3) MU9MPCABMW9HNT5?32;[[8%LU-.!PV@&D"H&R&TS40J"Z;97@IMM2MV%KG"0P M32;,Q36^0#6L-`1LA(F:25W:*US2QW4B97-;J6!GOLCC4X$!,)/=;TVF<=\T M@SDUV183&)9Z@8*]Z3W7O#X*1@4,LB<78#*$#W0F..!-[#L`P?FT_AKN(6[- M;D)V'\U;-X\*9:J1KBUC`^%-JWW%.XX?*=B9>E[Q*ZUB$"0)F>+!(>S;$?=F M$_>BE\]`?E.\!7ZVO;Y@8C<6\CQT0D@9$4N@T*<#N/O4'""BV-@)(2XCY#+. M&T0+!*P??`S&\3%]0''P&]PU$*DFG+\6F;`A*\3F;4X6E3R)6*)@P"MELH(P M%R"A8L`OY<"+(,I_=?S-0!$&J$MGU3DEUJN22\7#H$@V2Y*C$L'J@@)R%8(] M$"LSW3>I:EYT"551YI(IH#+#)E*CNR4D:G>,G$"9CHP\5DRJFF!2RMT$APVMUA@D!",TV-REE44951K M^1@(WY9^O(C7*3E!]-$/CW`)8]I@(>UD2DSV\96LDI#GIC\N2CRJ4U)HJ,W, M@Q^#)R)'";E#8>C'"3C@"1DEYZ"X*44,EZ(J_2EB*D^?3UBQ1X>\15L(=\D- M?KUDX/;QJU_LZTT?1[OL!X@?TE]:/#8Q4O*ZFQ%CGG=Q:Y?W!BT0QX'.AKU" M-[_2)]<&:`\.]8CA.AX8(0_9Q$$S7G2Q5X\?W5OD,I[@L2)]7F)4DE.(I/C6 M(=^(T8X:4M%3;!"(FD<`KG'+/)?YD;!9K.XM5XOE=+7YA=9*)&42EZ2>$]U; M3XCK;[?'QV-(1B"P@YC&VR#;886?_6YT\>\__@#\%+S'K'L`/XPN`.[A*WJV M%C_\C__X=_+P&F[AXQW.!?+G(^?LER,(Z?=TB\E?`3L@Q*9E69+!T'8"'HF*+Z\$&F'=M@K[*-&IV#FC45G0/.@QJGU`XK3#8P?LYN)Z4/9 M$"72X8U.;!W;M&9Y.<>8)/"KQ6BNG?I(E!"QK*!0;==%6O(S.?;AP7;C)"';((@D:AIR[F:@6@NK?'%1WLU>8S M:4$O3""U_8CN159"Z`)0?3KARK;/5TR`DPWP=V(%4#..;_=P3Q1>%4%G3'$Y MXJX@_3*X]/',LG*N7F&<[:"9OW`M3<,@HN&KAY%4W[LH:NA:\U;3V_%F>GVY M')//PYO5>+X>3S:SQ=QQE<,NT$'&?5JGNX:1*LFU?9\7O]:&O@Y^+4(7#W.Y M!J`JH*HSS''MO)CFC&'G`;7;\>J03V07>SK6XGDM&5M;@Y-8K!R)>&+&M&4; M[F'A4.)*S$J!JE<^)RD M*VA&%=30564J`)9?$VZXH=<,.$,)JM6Q@-PE(0BL/%%&<&V+6J1)TWC/09;C M3I4S3/5VL$V*:`MV1PJB.$^(#D1Q.%3B@H!#)U%G\1G5U.*QBFV]9ZSU$I9Y MCDQ@U@K/]22;B'U=P%*(U2;(DGI\=_[VU\HT.2]=E=7N>XO_AA7KWO@1Q6GP6WF29E>*#H8JT:.SFUQ0PQKZ:*!_QXX,?H7*4P!,016N,QI29.3%7R"T1&V#XYR MGE9&QMI3"^2NV-/-0Z5WQK#MRWC9U,@O@XRS7QUOAN-U$%)ZJVWP5P2;P&[9 ML-_;5L,TP[9F5].Y._UA`#41N_6T(,ZI=_6`XA.G&K]$BAVOK-7-Y]CM87.# MV),&O.O5ZU=#C&6B$O0*;UP(>%:Q>*'-_A#25\QK^N@(CD8,!'\O'CK^]F\' M+&KA41,M0PF7;Q':,6IIBT08@?(D8I$#A5&;2XT"^ZK8KZEYIS-B9`XUH.#8 MZC4.V%EOF0_T0IJ'\KJU02!\#>.G8`LE(&=(,7!>D[((]8K=OM#>=J$*^*9F M!?-DPNJ'6;6,)!<;#@58?DT%T!0]D=3ZZEP=G#8TB>5'1 M,$UDY#[Z6.50]BK,.OI6U*]#ZRFR\5J,YN_I2<>)XOY!/^Z&@_@\(8. M.%#GWFMD1'+E6G:DZNL\B+2WJJ+NSP(8\2"02X)2=)B#0;^0Y*W+]())MP-% MB&W>OX41C/UP'.W&N\<@"LAB4AH\P6EV75=KK-!1*H<+-25C?JJXL3H3UO$H MYJBR(2^7O0#WF32=)OLU>=?\U,((,NG!)DE5].L\5??HCJGR"DL*!95ZJ9]D M5"Y)A6'=RB+QJR"M!UCX2+6*C%Y9(UF)&.6B16<$.KDY@31DL9_XR<--B#XE MO,^N"J(%\(6BI@00&+=*!+D?(2%DZAZ>=*P7M[-K>K.8_.W=XO9ZNEK_GM;JW_SB MFBK2CD6Z7="D"4^G3A*QY0%1A)S<5%A#T]7C$HBK9YU/'$]]K*II^M8CGV\7B^N?9[6VEWN5LOAG/W\Y(O4NW3.^()F2CC^N4U[-3Y7V7 M%IP=V-;&L6ZN[6(:CVB%$EV?/JF!3&^8PYH+L',&N'.BW>EGJ./A$-(%$S\L M%DQFT1[%C_1@(6^%0D^KF&VI:IGFKVI^K"YD:+D49JX:EKSUA^7REJX4CF_! M]6P]N5VL/ZRFY:KA;'ZS6+VG&QD<)ZR:@$%&O=G(5=4,U#)5'9\.=X!NT2/< M^)]);:N@6?^`\[3^48-IPA-AL&\T/1#20QG^5_9^.9(59KUJR?-699%X&U+9^? M,]YF/P&?"KA%*[MSD,([K2.U)E;%*4/?=B];R_"9EK6ZF)1OH+]=@/S7+ZU[ M.6FS>O^Z3'IKC>&DN$(95EBREKXRK=H<4$4.E&'<^'S]8;4B.VG'Z_5TXWC) M1-QS/%#+\TBF.!?C`\D15S"!^)T]X-GH-7R"(:)GO-B["Y5DRWIU0EGC4G4" MZS:IH.)(7*!.IN\5(G0A9G<2+Y@#!'-$ ML#0$])2:*D?Z:C(Z'DP2RH_DLM#=CM46$\T>,DSUU+*64PZ_DX3)([N77*:+ MM'HXCDOTSJ'3#4-SF+)GLLKR^9^O(&$4:D'FV.JJC,1K-5L>#=!Y$=;V;R3"Z8 MOR61H"&S^*9[^%HN=2:BE$39RZZT"U%TG^W/#T^B;LFDT,U(MT/J].'K5'DC ML]PKDJRE%G(WW4$T*E!4D2"7)Q8R7P^..!F,#2"YS'1.'Z@7^PEZ)',O^L$K MK\<_04F:K!_\&+[Q$U*>/[_EF+,3RI*U_!4;6S/DIZ'_'H8#.RT2T=V&!V_] M;KR:7KX9KZ?D;/W[Y72^'L`7:5O@1+T@I!Y6#`U78X^5-KIGDK7AT%);>B81 M'E@K&[;0'E3ME!?+4$L7@-JZO"/&RIOK![3):YC$XPSHPV*>^V]FPH]EPJ]D MEC^/]?==3/N#6/U+V'"^@,D_?:E^\^)_[!K(5R[A<4KA$4K+QR;[.RJI?3Q2 M]4CD8`X2RT]$JIZ"Y)]\'-1IQQL_B#_ZX;%R!(8[EU*2S=^"1-80XD+K/"#7]V[&LQ7X.+[],`7OIV.R@Y8>OG=+![4>1QTZIDX6H5J5.PKV^X:6 MM;1?R9,1JG#*3F0`%:KDD4-*Q>U#C)-&V\.8RQ1X%FUCMY$RRDUO!AE?\6-S-XWQKMV*_HXY=T]K^ M+59M;`A7\>/VZU\VN1!_^./)5+_YM65L?*1I6K5)&I$#Z8<9IIZ7G6@=PKQ4 MW&_-CR^BU\SX[-(4;WUQ8=MS!_0#)%7NHOM\CQMO;44J5P">+V<*>IYEJ\"7 M.!&"7ZCKE8\!S)\[IH&T1Y'FRV_0@:=2HX38[G!H(:.#C`;VX6]]7R;/@Q;F MJ[LUT=`1KX1T#80+D6UG>P;+JKU=&3SKVA`85>/=]`OO?=XV"^WN=SEM+.Y8 M7\*8?M_A+5-+Q(H%:ZZ8Z=(UQW`/2WH25$5;9&J=XN2!.#^!UOT^$BN0"8B MCE>U9=V*]+J@L=+-T:BM>0NM]H@::]%1YJ0K8'"LO%VLUV")YT>3Q?OWBSF@ MFU6&\TG$$G@X<=04/2ZCZH0RG)846_KQ(J:%7W=T[;!H:@.R&AKY:U+2,"20 M@@^;TRQU=R)2J5KQ)GD<)I(7X.#'X(FNA[$(K!#8>C'6;RF@?JE6[+IX`-U M[L`Z`Q64JV14]N5NF\AVBXY16CE7D.]OP>TE>UV;&T<4Q8NM)%)QT\TE$@<] M)$.*+H7[4%1,>*>G"=AA#A+4@SC?.W;()!WO6U%%`^K68XV]+1+-VFX7)2]G M`)^](X:*SDQQ1XXEYF+@)'=1;EI*U>K!$^> M%KL6]3A-X^#NF)(`0-X89K_S`U4FZ%"N*RV'A^,M(5EYM7RQ\0V,X#YH+NU) MI)HE^9I2MDKSU>TJ1\0?,P9$$X,.Z*8*/:D5+&/H5FIW`?NLM_!B_R[QLL! M'/:6]2ZKHA^_*SB5_>H*S`I_+)O]0R"G6M;VH5>.LGZ]'VK[?G56;O MM,)"R4I+,%0*XC@?[#H`2;@S5K%_9;MD!6;$.V:E_L^-:)O)F+YGJV#.$CJ3FI'&=3C;W3NN@@\\X)$_H)4%\+]#2.^KB';C M1Q2GP6_T]P94=52*6CQ**J9E0A2<]%%51]VML.J'JAFO*DG'-K\B0HI]'&*R MGS=]I@_)9X$!U`_6`@WJWJF-SH15>W5K-!S:@.FHCM,+4`I3 M5%;%OVY@\@K%](1,EUG6FV,21#!))NCQ+HBRIDJOO]13RE^BJI(A2]7<]#"F M:#D6T57#D/?FPWHVG^+T#:=N;V;S`=1^TYB@U=U@+;;O;6;W[YS')6K9!*TA>9T"KMF=?<\G1 MIPTBEU4N8_04[.#NS?.'!.YF47D@;KQ-@R=:<9A7QJ]'%\4.[EYVR68>$))#?/A7\N\MMD[6/ZAYEDYX^R77ASO(NZ3/NA\<&UL5N[!6VV#CN?D;NO%W<"SU@@QK7U0X#ED]H"LBU=>TG`FCB:8X$P( MNX#"::GH_,/QTG\F7XLYUST+A1KG_9I"E@Y:U+:/Z4CE9!5#\;39YY`] M',;1*4X_,@Y,\=\Z^Y1479YU-HIEL3>(6#^!QW;1#1W5TW;YTZ%<,6T!)Y+C M=%V`XCA.QD>XJ]P$Q`V58KE3M.3)F;.!;;F?F"GT)2&&0-?+'Y=%L2K;)0=S MVYF\LY%FO[3(PE9I\$5DMT\TV0RO8B^=@30Z(:EVT=E0XJPE_/"CK2&`!A!S MES':PR3!V;(?WD!)X)4(UZ,O5]@.:3CF^XO#8H<*'!(9.!5N)H?[BAC\/(!# M?8I=W^:20@K!UJL:WW%[^%_A38)=`ON;4M'P\C>9;T=IM+ M\DYA,HFMQB"2R'[?L+(=L,6>C!!5"==4")RDAA6M+0),'*LM(,QEI*97S>>+ M+O6R19/0QPW=!W#'CML=-(M/9SJ:IE].U'W9W`^@[U;XI473FD<5BM5G6DJ. M?L,_%9)S7+6H"W:0<:29':^L,ZS-3/Y#C52NSBCF7B1IN$!1_KQ=(Y"^% M*6%((X;-'J(SWXN(,SRM2KTR.)"/]*+.0\IONPY^AG`5\%Q;_2#"6C`5V.\` M!APTZ9.!14DS/'"B83=`N*_>2':8WN#7DFWV/P;1_6DKU1NX1S$LZZ7!9/HY MC7T4[X+(CY]G*7RD%\IA3?S*W91S1VV`H#)>.2^CTSM-6L45>\+4YE5PV0;!P?R1RSV<_@IWSJ*6[B,483_N87TK-(,Z-AV\]E*$J7L[Q.5NNMKU5M/)=+ZY_07,UNL/TVLP MGDP6'^A9:K!<+>;XWY,I/6;MNOZ-"?:012@T"^1T,%>OF-.Y/:Y(8;':DT$+ M>N$#K0=5ZI+36%@;G-1!79]\#P//,`5%QP[GP)9[PG!+2KEBS!`.CS&JCLYA M*CY+IJ33.%HFT;%TC$CHQ6JI``V'*D>,Y'8DQ:?I7EX2'_P(^&&(/OD8=@`G MAV"'CG?I_A@"OVK@M)<,^)4J`=C`[ZXN7O_IQW;]>:J&'X[^^`-Y.+!"]'K8 M9!R#4H8.^U"44)UU1DK!W[`*VI/M3]7%Y?;2J[J.J(!]6Z>/,M]-+S:#@XY# M[:+>3#L#_!:FAP=9B6Y1=RE4YFZJ2RMRL_TYO+(%;2'UB-LM`<80E-4_/>F_%ZMB:5<9:KZ7HZWYQ* MYDQ6L\UL,KZM+5D^I_C"ILVL(KL8Z91C-/`:JU$IW'K'%/*7NE9"PWI MDTVD3"TQ00;2JA$ZS:R8J2UVY88&M*PU-'KQBMT.A%]NMR%EG[Z*F7J#@>S>TB&?4(I'HPLF*^&KLLMG=( M]ZKP(IB**/\.%7OQ1F3<9AA1\*-Y&46#]*Q+40;#%E\UH>Y-J*H1"V&Y;4KK(0 M=['RY19M,XK77?#\.R/]6X1VGX(PQ`W%,QB,M>`NA.,D@:F<])UT\W>LJ6M( M>BUO-DG?Q;&(]/KVO+>+Q?7/L]M;ROC%YMUT!6;SS7C^=O;F=D"L[P8F9*&/ MZZS7,E-E?0?_SEA_XP?Q1S\\PE/+>,FRBFC^!L6BAA06&;?)6`4_(H)*U;V; M\6P%/HYO/TS!^^EX_6&5;7`>#!&5.ASI=TR=9B*M*JODUAVN,#_A(1[%S]*! M4D&R7&L62!HO.'-MVUUUEKD1+SV+M;W9_".FRV*%,]8+,)]N!L,;E4Y&VKW1 M7(;F*M77HB6VW1T$*ANTV.,TF50,IW/@O"S3!"5I0J]^O_,34J7I6;02;<=8 M<33(T)CI<0@C]S;Y:Z4EPN,1Y@Z\];OQ:GKY9KR>DEGL^^5TOA[6JI,E;*(^ M$-(X$6%DMW8TPD(+71^1J'S*YMWG*!6L'X9@"MHY`<$PW<.Q![X7A;,./.6. MNZL&PV\%%+2/'4CZBWG6@*'#.&#`M>SPR&]6A'X%<2Y23=]Y@[FJ?'F45RIO M?$)1XL'JJ*OH3'SN4,6&=SV]F:Y6>.!<37$JC:>A0^&4.@10QUYJG@64J-;/ M_2GY<5R:283*XJ%E_"L*.<0^M-T-TIY&>KW2J-+(T:B59Q1:=<:42@G@YTWLXR1U M*]HMH"J>OQ^YN" `YL,DG1EXA12B:\U?1VO)E>7R['J\TO`',)S^69FI+Q7WF.QX:5M;?+J4 MY^U,0+19L4W9H0T,9C74J`AX40B_!$$$,FP69^W'WP`V^67)>@&GX^*QK#:2 MJF;ZPP5/2SQBM+7ZX6K3S_G[G#K1E6LI'CP&/&EQ@R,DIZC4E>C8-*#"4 M[?-\J.Q[$.'YM`1(V5!RTAGR:&(9LWICBB70#GIDJ5RKJSN\,%15QYB::M^4 MKCCKMP*.U*\1M9OF\@$G1-']90KCQ^'<.]X).3J$YO2H)JDK5K28W?+NC-U3 M/XZ"Z#Y9PIA^828GE[?C:'<=A,=V*5E%Z?PM2J4-:2NQ;Y.I:JY$Y%2QX%V" M._(S/2*\RQZ`%WB\W:$P].,$'#!;$Z+]TBT]57&`.G56G802Q2KOE'PXO'XR MVOK)`]ECEM!5_6B7GPJ,[FD):LXZNK9>>?6DLI[QQ9.*GFQ24M>I^-))'5O> M^L-R>4MW'X]OP7KR;GK]X79*MF3,%_/+R7C]#I#-ENOR0]?-;#Z>3^C_FFQF M'V<;Y^5N]#&%#+N[>2&EHHGZ=91:?AV6H:]3M/WU.G@*=C#:)5EA@_+\ M[^SQT.9Z%]6R3)V.JG'9.G5G/:S/='`OKFZG:NXKG+7`3[( MO%N;5?#4K=2KXNEZ/S.*K:WG='%L$\"C*H*I#BB5+HH[54H]D"E^6]#FK/.< M"]LN5WPD:32=R\K/OQE:49M#\JWT.[?D^3WCG%/2!(.YJ-"R]S,,[A_(Q,M_ M@K%_#VF-=!1E\]($H&.:I'C^BNT/>HXJQ9_ZW%4%#%IS6IY!C;FNN$V&H26! MV^_OT=.K'0RRJ(+_T0PF^*=_C'%,VY&X=A/Z]PVB,9\5!P#JSSI2N=4"&^3D M&671C2WKE3\!\IOCW?C,7D"2E]?8;U\5(Q#EZ)X)=/EG^1N,?3_\!?KQ%)," MCZ\-=,C$BAHK7#$#5/*,V@*HQ#X/JT(UK]@XDCT&Y#G``H!(.*Y[(NM*I/[: M&Y5,.!H%RL46SP3X:[0]$J;AD2!`.S;:A3+%P1"VC`'.F19M@5QDG(=POHY7 M/`+9LX%`6]QO2/$U-TYOL,0+1`MLG0G.TP@W]_EG&(9_B]"G:`W]!$5P-TN2 M(XP;(%.2+6828ED#F`LMVX*[BA,>[.6Z7B8"B,SEKT0(%%(@$W.`=EZW(<6WS$)W0[R.:J:MLZ(YSZ?*@T]D8>S(!K58M(9MGJ@Q MQ-F&[2)=Z$,,>(%J@?LBJ2]E0"8T!/Q+>ACI]02+#6RM.BE$EL_*#4K*"<[& M[E'\S*0$4Z+&A(:$,0%J]NSBGF5:#/>V1H%R^@04CX:`;797(:5WRT)R3;@. M8(:=L^)V>;P+@^U-B/S6%P+>\QIF:\^-$5NQ9A>O;<-BM#;E"ZQFOP/Z8`A( M974/4GBC+)161.L8;=DX*T)7\#X@J^-1.O=;-YV(1&HX;8H80[5NT"Y:F;;% M@&6H%)@]/0+DV1!@R^DPI/:"6>"M2]?QR[)TWL09IRBQ'\ZB'?S\-\A.#S@R M]52Y*6.>(]`/@3XZ1"@S.LWI/B:F9EO7;R1\K)L MG1?.]),RW2I!/VXFB]-793:V%13J0!8-XR!>2>)'R0&2C)D7WGIY(7 M(),%B\%\[E?'`>K24TP6"70;E))Z.?/'HM,GJQO\2W.)12+5^DK+PR:AA MT_9'([9YV6?=0`>/;(`J:)(=LPKMB4(;<4/8&5_#0,=-;>/Q*_-S8&B503=B?- M#DA[\A-$T'3U^H<<2^27HD9J4ES-N8);&#SY=R%,YC`5E_E55$IK)7^E2AVA MJ?'76-GGW\$?"]+:9KR\\N^Z_/'OF9L)`52^Z(\W%#GEZT":@BF"/8OQ[H0H2&#\%6YA\[_X* M.2WX((.NK=-2U4))3#V7Y\*MG;%#UZ,5Q.+QH[K&DVW\RI!Z4@$GG6\`JIPA MI%>LMH>1WL!ZI0/6)QC?H03>VL#LE2W,7I68S<\?L<.K_RV!]LH!:*]LYC[$ MFX_?X6)?/S8YB]9XB$_V69G>Q1ZG9C%N5G&:LL$&0ROYR^MLQ83#'9U:SYO, MVL$EN(E9;QFC+82[!!!&4;H34R3-.C0.Y0UW><;IE"%-G# M2SU6=#18A@ZC!CEBCIW,S;`!?7"&U'$TH\DWSQ)>U4=W-+&ZV%#<>QC`A-;! MSYJR03C6'F"W>8"8*_E"2G`R#]*3?<*G0^Z!ULZ# MA8\+X%>\$#E4^`$A=43"7Y05E@+[HIH4-1(4=:8`H>$3K=;H.E_H@TRH9Q`W M0J9%+Z[B^LK)@Q_?PZ1Z95AKIJ.M M64YD-#3-HIBRHQZF(;J^!2%(SQ2=1`3E51:[\BJ+W3&F6W7QX[@\`7O(]K.1 MLMO%0LF6W,`-MOXA2/TP^(T4/TN`CW7(6CB9F,292W`@/K,8EM\E!SX]P!A/ M7B*8/]SZ$8"?8;P-$E([+4KQZP,H!DEP'P7[8$M.T031'L]XZ'K-$[D1)D*T M4#\U\&?REX1'NL?8W^^#,,"><;Q#GR)RHAM;0OC7+?DWB9E8,8A!\/@(=T00 M[/U'K$(4R#7C9+TGC8_XK[N@T@DB7T[2!^?S''TJ(3.,-^.>LI%*6--T?$8F MVYI":#NUQ>'J732%2GD/,"5-#Q@V3JJUO*GES/(JTEU] MV\+R%:D!2`:;W_QBP;TRTI3?K.%G$J$=;UH](XRY*6CO,+::0$YPKK#8DV_G M04+&UR2_^+RU44\L5F[,XXF9[1%A6^UAXYW0D6`+B$#/VR"LQ4_PM"T$?`K2!_!V"MY!/TP?MGX, MG>_$D^`#:?1E5`1`+O$5`(6[ MS\T`*<;[V/BF+>];$SOJA)BK'#'Y[M](:,Z=;,ELE>-KOSO`CW7+*5O/$]'B5),HU'SZQ/*\LF^6()W8O%&'_I[U_F M\"M""%+MT/8.S)9X;;LEQU@OH+.W4YUK7A]N^1[TQ@@+YJX7\PWQ(-A'W@$0 M%G:(,^U:WP[.]:(/C*L:,+YH,`CV9W<`@]7!LSA-2C[!T,(5LVB/XD^JH-(X;BU5,(*[BP5X,U/'&1;ZZD=.A9K)DGPF#BO1@3GAJ00-U[3KV&6F1 M>DDJ#5_V.%9;"/%1M=C0@X^C00S!,8'TT^76 M#[?',-L1T;Y3>+I<.\ZO#?&+K*&I'CVZV2OCB4ESW)#*S@!HYK\'.HTJ]Y3E MVB!3)VMXU$"U=!F@)L"8W/F1&?G&V<$97)W1PW#&T]VQUI0HA;%@0F36B!Y( M07\!J^ZJN>O4E_=A/^ZWJRGFQT;P"5])WM9BOE(JMF0U)(LR]YC.1##+8IW M>=Z(H@AFYP#IFBP1JFQG(X=B4/A4K/Z25=WL2&&^2Q=CO+99K=B"ENW*+;R6 MXJ3U1(?:@F&8W;-S!VF3[B.ZTXXT`S>,;*![)J454?8]-R+SM+"R[W?[O`WA M!0CV($31/8P=)[B=^8$L8+8>KW0ME9&J6Q/.350[*6Q7SU8IBM-6H@9*/5!1 M/&UW(ZJ`ZA87N'R#6.>DJ&<%NV%:VL6EU37ZK@VP"GJ:"[5R& M)0OPN'%W#$(Z5;L$V[SGZ(9M%'V#V.G/\[ID9J)9.\>5! M3;7X!D\5\ M_>%V,YN_!=/_7D[GZ^E7#4U.!MD3-,^5*[*7*M45Y%FBE>5(N?USYH>*2XZ* M%OZ5&>IFAI^","3I8);^[=KYWQ>Z`JI!.X7P)5WEE.NJQ"UK*YEJ/GK/[U17 M*U5-R#*[0:Q']H8\_82N&_3Z2^7Z6DE4=VD(P>IJ87W(:!^='=I:86^XU,_F MNN&RS..J[_$6_PO_6/R$_[\[/X'XE_\/4$L#!!0````(`).$KT"]?G,D$!T` M`*;)`0`5`!P`=F%S;RTR,#$R,#,S,5]P&UL550)``-5OK)/5;ZR3W5X M"P`!!"4.```$.0$``.U=W7/C-I)_OZK['WS.L\?CY&[W)I6Y+8T_IESKV"K; M26Z?4C`%R;RE"`6D;"M__0$@*?$#'PV0,@'MO&0_O2V3 MHQ=,LYBDGX_//GP\/L)I1&9QNOA\O,Y.4!;%\?'?_N??_^VG_S@Y^8I33%&. M9T=/FZ/'9[+,2'ITC]GKZ^OGYX_>$#H8O3[S]^/#O]WY]O'J)GO$0G<9KE*(WP\1&C_S$3 M/]Z0".6BAC7VMR>:5`)^.-V6I:3@_W=2D9WPGT[.OC_YX>S#6S8[+JO(/P,* MJ?/GTZ%5^WI$Q0K!&]59M9[^BHL!\E";['\R/^[R_WUTKN3Z>< MXC3%^0UZP@DK4K#GFQ7^?)S%RU6"J]^>*9[+Y224;L5PZWSBUCG["[?.=SO) MIWVJM^#0>20Y2H:IIY#7K6NGF/Z5OAW*M+HJWPYI9=8C\3M8N59,_TI/,8W) M[#*=[;_B[:*&JOQ#CN@[0*5;6'\%]E]KBZJ^H(PL\2R.4/(A(LM"^CV.<)HG MF^LL6^,9&V_(.LW92#6E)&5_1GC)/F=F%;AP5L6S[S_^4+C_[Z"2G:M^3I;+ M.!=2)NGLG`CI;*2-L5-]M>*<*_F0D^B?SR29L5Y]^<_R"TS5VJ55'A'-EOA(R>XV3A"'B M+G_&]#IE,XI%_)2X84PKSKF27]99G.(L8PA^BE,QJW.IG%2, MKPCEPT@QH/#QD")G7PL0ZNY"4!9G=_,IQ1F3)\1Q\33..5UM\"9)[#K`VI?A MK,X=7:`T_K,J8YJ@]&Y^M$]K&\4V6,>DV9,Y1D?2-G?,X8_S.>A>=%I[^;G M*'N^2LAK]DN*UK.8D;G-;QR*V9]2.],)'"]7%#\SHO@%Q7TW!90^K_A>4 M\'#$PS/&^:Z4*?,]*1M$1"\83%U06>^AWIXUZC/1)-&:`X)AX)(YGGQSGU&#>[R(><%I?HN6N*6BCJ1424[25*&.B`EMJH-H M5$ED?S;@T(UYEA2G*]'33Z+G.-DB:4[)TK)1"$C#>NU_/((4<)23([E@0MDB M]_/Q1QXV9W*+A=Q-86REUD+EI!X*>2=LG(O95W+-.NS;W_%&"@X%30,='9K` MX*'7L0\^.I)+@)SY#I#S->4VOHHSYJS_@1&]3&<7;$1K8<1$5II0318,4H": MNH%%+;S$R_>^XZ50[S><)']/R6OZP-;M),4S$3ZE4L=BH&TX&"5M,/"QT;F/ MPU&64`+IAS"`]"M)V'(:TM#F149`&AAJ0QKVF-8H"2@S]5Q@8$L@_9\/L@E#YY%=* MT4!,BR(PH.CTZX./EMP2%G$`Q;3]5,21U<)0>V(@/)[`Q*-[X$!0JU;'S@T MI)9@^&L88"@W>_@.MMAGR>[6.<_+XOEP\M$&P-`<<[0,@>''0OM>XX^VF!)A M_^T[PBJ==\N^*_9+>Q)CH&I%'CM4P0`(IJ<;:I2R2ZA\"@LJ1;*7&2P2.BE< M&G2!`D:MZQ"0:4BO8GC>1WDK'1Z96`50ZI]:V"@^!0<'B4;]$%`(K!K=^\CM MA-5Y)I";H/841?JM-%+K6S#MKM/)K>%;$JN6]SX&6^FW3666!.RU-"T'T*() M!A$0'?NYA);D"B%]@ZL_G79,>\-^V-_>NTVJ0C\,SU'V)%1?9R<+A%8%D'&2 M9]4O;427/_^^37VYFU_%*:M9S(9CDL6:G7L;EA(/,):>'=G="),L8XVA4%?^ ML7+KK8\CJU!&#K6:*&@:"G5H1M.+)Y[Q1"SV#T]N?T$)YKFU^3FB=,/6HR*/ MM;UM:L-3[:'">$;STOJV(VY*-]VTM`BQ?PH3/79V1@\G^$QH_HCIDJ>59WDC ML;IR>AJ2RLE)2?Q%#$`E($#DDL9.QNCA3+4I_*4!VL[5AJ=RMC`>?R'DHC00 M4T#18V=P]`?93K'RP-04T;R61M_"EXF\!2TUN?^H`JIJ"2BU5/(^6'/>$"T_`H,.!SF;!M/X`#2]OH\1%6Q-,@#*#CQS6 MEAE*-&EINHLTS]$"T<:$#H6,<.-]A2[2%9ET*>9ERTKK"UM"]`G+>;'.LDK% M(DHKRFP&$;VSY"&LPFYB]!0G,=\+9#.%[K6:BJPJ6[;2VG`V'PRB3RPS$W:5 M]B?%K-H8GJ(-GQ/JTSOD1*U-]S;1:/X!T#`$J%O3.Z@%U[?:VP+=?8,G\R:F M&%WCV0-*<";N!,[X1?Y*Q)AI=\#1T?J/'["FEC#2R76/XOB%IJX1Y$A2TS51 M)*,+`T%W0(Y/I'CGR!#FB2_"PYEL49_@1O6G'+B!UE<9JHO8<2W;:VB#* M*#GX!#*F$];/@S04I46E%)YCQJR5#4ZDTH*/&;4NSM?GB,B)6C''-I'G(`'I M9H,3E<`Q`DJ*,#1W>3<89?@)1?]\W#WB4%7]*XK3KY1DBIF+*WMM*+)C]QQ" M/>UA.UC9%35BBMJ@\^DI)7,LE@HHN<*&2;6!N#FS5A)[#CLK71WFV$K!P>>Q MB7W#![CF2;9VHZSOF\+Y?0<>>Y6L(&A52ECWU\T9#S6&(I34%;0M"BY)8^L"VBW0ZP>5-$3=OMES):7]9\ MQLP3)9U\Y>=%S@"LG;KK/V`:@5:\9!4HR2P(=[]$9$Q(+2!+-M$2UC-.%(3^ M0PBLIB6&='*#WR:!X`=BTV!1LP?`Z+'BL#%R"',AXS`]R'1(5DJX">F`AW:K M6WD`3_*6=_&87]L-!%QPG=VAI2TCW!QYSF#$*7$<(?*>YRC.,6S M2T13-O9GDRA:+]1;W%^-W]$;]V-5A?NW?[T4?MSW_Z'A6S^UD)+RP@=:H/C]P,!5M^(QS+N';:P>CGG?\ M]MJ!KZ\=3)*$O/+>A/;IRX=LE;JHHR05F56=>O\BW7R58M%8ZFRSY@\Y_BM^5-Y2IPR>#B.W& M57J*]1&?^[&9$=*#%3OPIH7',_)O-Y)\NY'D6U*`-BF`+9WNJ`#_3.QI3C$5 MSS)K\P1,3-+4`363Y[%0)]W=$PS4!83K:YH:%N]^3];Y,Z'QG[N8@!1K*F(I MQKK$06'+H*L[IKJ"P\UJ8U_L5$+#3620:76W MSK,H9I$X"R"ZK@)DQP+1U!I)PJ!7@%;T&2UAITV4&W?^550C7N- M:77O`59I9Z"J7ULJH_)"._YJD>0Q51V)1*\=R7@.S=`8!*14RU_)96ZO7.W( M"C?*7M?G`=.7.,(&6$BH),AH4(4"#K5J3OAHB!LC>*ZX0W-W=7E-"PP+O-6(D/Q53[J^8T&O2I.?;Z.`(?XM!=)[*;96]=R MH%6`0JS$@D,LM#SI2_S!];NYF"GP)4TY(CRP58UB<@EGV'IA,X,/ZO,:J76M M?^TJ5GP=K4-8M`DQ:=7L$V;)Q4#3DACN?+-0I5)4BH?VQP8<=A^#0H-")W

M.BZ3-K"9K-+B,+*BF-^KI#@*9Z.!GGVH#@$=*\`@9&)0`NO8< M7CK"#W\J:SWA`L]J(9+#S:D3;S7PB_8[M[E(OE3OO]>_^`P*M0K@UF^(V,<] MEN]Y;6ZQ*Y$N+M]6?,M"=5C32%==FJNF&R_J@1,F<_$5IZQN"3\:,UO&:$B,-678VEI_8:5C:(6:#*(#7<8[FAMZ&@$AINHO55J=S&9JF-U*=I=JTX1!#24*MF#HBYJ'Y?[O.O; M6REIJE4B7C$;!M-OW]DRTH^F^W6:8];VN1@_GQ23%#W1-NM'3C1:QX`W$P&J MV.PE1OF\OZCD.LQN/Q5=)L4+GF4V=J>I*29N?2PLH`:.A*@+G`91<,!1J]@/ M.`VYXS3#&-B7@M]!Y'9)%*CK7TD&!XZ%4K(0P@]C>.`TJ="@WW MW*C2)M`9`G1F$`KHH(HZ0$LC^O`W+VRGF.#Y.T!PN&?<=FN2*V;HXH6:-5-T MEWS_!<\)+2^E?D1O.+M\8UHSC>,4T4B.9 M?D\E^=P%WL_$X,ZSURJYGQCT8A&]U;GT)U]PBKM;B`:J!N8E5/[CU:2:)=8D MXAS.!?JU)L+J_0R%A.KSY#J800PXNS*<'C/W&-'-'E!<<(OU'TDM7/9Y3'5 M+RB+(YVK@G/+G!F$VV=L]C.%FT.$%%/%RAQR"+SPF9#G=(H0"_N=\C#,!2[^ M5>7Q#":P_DIV3X'>F?>*3>'C11G#BC:UL-8DG8G_2XJ.-_N_=28>1-6K"FR$ M?15K:*KABQTOSV`X>)/1VJF5Y]!;I>VS[>^B2KA96Q+S*!Z:`U#N3M*J*0^D MF\"ML0]D:TMWWRL+)4X\^(`.3P09H.2J?0+X*SN%51,N$QDI=759-XH M**;4/(LA3M9Y9V<62*U0MT,]6IQU;79H53R>8\RR@WW=BJ`)P/V%+!_ M4LNKO$ZX1^D,2!&N^2+.HH1D:ZH\U-%3"JPOJZ4,=SSU-S:'?69E35CSH`6^ M72^?,+V;B^K4KM33>[!^0DICN`KQQM_98H`,9#B]EP36BG=[U]JX^]8/;CNKW9SX[96JEOQ`*3=]R@E MI&/&^7EUII3P#8W9E\TOK&&NTVTJ^R3*XY?B=DI%PK>S@%VTWUJ`']LB`>[/ M]F@MJZU;^W+4N[H!QLMV,<'LD?#TSC2*$]Q0[Y'TZW?[+*)ZGG`O18S6*)#G M`%M&MF$IC09C&>^]QGW"ACA9K.DY]E%![EM@%0O^[K5O!PE\ZQ%#GSW85P?I M+-0M+/0^F-97*/AKPT2@H#Z` MW@6]UI7LLGI*?(IIO6NASX-R= MX8!S'BQ.W>WW/N"UJI_#P4"_)L)M;6OF.4>K.$>)^MT;2T9%+]`Q>F26:OY8 M73[`$(?C%YYMW9YM.?$JC:/E'7-SS;;U)5W?QC*=739@^;(N;2CW`"XB:>M[ ML<;\?&;->3&O5R[QC?"%,"OQJV<.'L`6MAD6P?J"@P_0=!6^3E^8:H3&`(S*6X"%HM,.P2)05YQ`' M\1V0^@@?F%X]3GL3WQML:+8(VO4>C161.)M0A^$+(XW%#.,29;ASDZ)#8MZ M,2AA"1Z*1CL,BT99<8<8J>!J\KMC[#&IXM+#LLMU&,@T6&,/X.R6Z'#7C^_X MK((,4[01I_(IFG5O`[5A,@:)FDS!@Q-@B_V$A9H%.EPOY$E"HJ+W72Y7"=E@ M7`8/:F_1P[RGF5_O1W7\P8/6SD)[\*VZLMUO3/(/RJRSTK4=>M4L.M?:80D> MHT8[#.Y6.\4Y7)7D+1*GE%\@FF^JW01QS6$YAA@Q"6%6HE//'#Q.+6PS+&+U M!?>X1,D_$:=TPJS&AZ3(STPA)HML1=7*L=C@)=&J$-I\@=UP?3&0.?X3^P. M'>B$O+D[5*"S_0BOR]4!_F&OR+&TGU<:^/2KH8.<8<(LLH?5CV:NZ7)^6GV4 M?>Q\#I[TYIC-86#5Y7(H68-'+-@N@^=Q*(NMXW@2UWM4$]E''#B,SAC=IR\9UWUW!]F&+N1^]V$\`ZG[X>X4&$_U0SW MF36X%5M#D3VC]>TFP?8%9]L,=&4(N/#`WSD&739DU1X@SZ,KUJX%.AXDP+"I M0EN>!9OUN2\)($#O4;0"QCM>CS;EZ#.)_EC'%%?Q]&F"4OY^YR7[53Q+WS*3 M/6-U]-Z"T3>'"P$!Z6$;D,/55$(HRLL-_H@,W#K.8Y'S&!0L:)UM,P1R;0K_UY[5PN=-@\QJ MM<4=W+JX.%'38U8+$*#W*%H!8UX:%6$\$R^=_H8H91.?RS=,HSCKN%@(Z>[2 M*`VI;VX4TK3$2G^0X]046U[XI"DNW&7G/5Z5DYF[^2W)50DZ)K+2TFJR0%$& MU'L(A*F+"GX>65>M?KO)!7YJ^WL(J01L7=(#`)Q!_Z%!URTN^%/7=:]]G65K M?HSW;CYMO+@Z26?%#YA]%+]H1EI[(9(QV$9(H#`>Q&9#C]LV%7&_YV[L$1UN M)^>IMO,4.U@\.]MF"`S;%.Y^`=XA+-KAR\)!%NW:XMS#)V-[D,OY'$?,%)=O MT3-*%_B>&>5J@5Z`=F&M7I2U8O4>FCTL80=-NX+V,72-#LT)&S@HW;`QXE>4=,Z:6/%H MP=CA"12%>MV'@%^G!(=[2TK:*9^[LN*J+UZ%<(YY-R#$#2CY%N"B)7;@W7$/ARHW-VDW5('+"/>N(GZ@B&FV2[5(9]L(SC4SCC('P9:OBHO" M^89\=F)[;>XC?VNK:)]'4KMO8IM(.^4UGU:[\9,FO<6MU$#U1 M]8ZG@B@LT()4[0$_E?PQ4N%4GE:QG7B=/C"-LSF*BC>TROL"*HW:3K6?E,I_ MNDH)"W7#&*N/5W2MP!B[00K'9%Z#E)LW4BU%]0C&7'#VS9 MJG`1F"TL*#J:HP?VX"7NYY$^#Q=&KC-SR]U?>"D#W7[YTVG'XC?LA^*;]%.C M-?!;SIS.[KG?1GMP'[#$LSA"R0>VDBY*OZ,+E):O/O)TF`0Q)U9.Y!C$CD=[ MB+16+XYUDL2S;25K)KB;ERV"DFUKJI9S@\JLGC,=1N9X2V.4KREN-'EK#:PD MJ!:[$H+1_,>P34P`ZC<]RB#E"]TS16G^A61>%0S(0E2'2$HW5]>7L\Q(LTGK,68:O[3JT?6:M_ M2;J9LD.(*DW53]1X-_R8H4`&M5/KYAYE\=R9]"LV<+?S@!?.V$]CSW$Z-5/LE1K(JLU1)=EX>\.M*EW$6920C`UL*D=BP:%06\HQWGK& MU';$1>?6*D91AMC<@<@.O8/S)\&?4/M)\/$"QI6)V:JR5J'RE,TYR?)L5^7J M1@%%WQ]&V#8`W4_8B#%X8,6_U"NN\C$#2;,UJDK::+YI(&R1H2W:]&[]:EGL M*/2L7>#^D=_)-\6TC")R14?SC9>(IFP4XM41%5%X/1-9=7!`23;>"8I6E50^ MR$BG4-$'OV%L'0+7K]G759+%:0>UQ(%2Q-Z]8UZAF(I$T)\QXNZI".*/!=UM M;7;^4C4K@9"6#:PG':V?RJJEZJL@6HVZ/O194(L1.UV;?5=7`N^_!LF!C['5 MZW[5HSZU)Z-Y&LQ@6[CZQ%-38[&RM<#("R ME?`II1PQ5[]3*Y7/@)"J=?7!`T`:BU@IVNS=&OGU!%.YW,![[I=U%J+N9W6J9^[(=D]H`?O5O4&,21^V;75U7E-AY M!!81>*__2LCL-4Z2:GIRS42GBYA/3T;K_;4Z[:HSR3*<9\;AW(FW!(@E[V@. M`U1/E>-P8[:QD`^.Q`T&I*=YFA[&J@[7;,>1A<#IJ_V MVV@XTE25V_`!E!-[MR\W+%;^S4QS3 M*PZ@C#?=J%\B6J^0HOM#R;=7OIK(1[SC5EXULQ=PX#28PR^_`&YCTL<63?]@ M*K.X^]:BK,#]A#@U]$P2ID3&C^WFF_$V_T7QJBU_Z<=J%[SU<;R$QHXU>6@: MD-9HRUZE130D"^2&N%R`^^]/&0XG3D<] M':&IDW'2[\1;.T]JP3O>A6R0>JHU`R*4I.S/:.1LI5O\JJH3;QUQ(6YVG=9I8M96JT3SX-!@ M$K?7HP\@<<2@1A;1>%6<5M2HPL;>?^!\,B.K?(>O;9RCAXQMZ,-)QHCWS0^' M(S*,"5MW#_2O8!%D<:K8>[G%\@O_#\\,9[_\/U!+`P04````"`"3A*]`!?9- M@K$(``#-/```$0`<`'9A'-D550)``-5OK)/5;ZR3W5X M"P`!!"4.```$.0$``.U;W7/B.!)_OZK['WR\W%[5$2"9F=VDAMURB).XCMBL M[61N[F5+V`)48R1&DI-P?_VU9!L,&)N/[%WVBB?\T=WJ[I^ZI9:;S[^\3F/C M&7-!&.TV.F?MAH%IR")"Q]U&(II(A(0T?OGYSW_Z_)=F\PY3S)'$D3&<&\&$ M306CAH<3"0(,,PQQ#"Q-1?PJKD0XP5-D2,3'6#IHBL4,A;C;F$@YNVJUGI%@ M4QR1$,5G(9NVSMN=\_;%10<4B/$44WG+^/0&CU`2RV[C>X)B,B(X:AB@,157 MKV(AZ>7EY>SEXHSQ,0AI=UK_?.C[>NR<5@VUP[@I,5@@YS.\%#]"8JB%YV\4 M2Z?9[C273#&AWU;T>1WR.-?HHJ5>#Y'`"^4WZ#/].Y>7ERW]=D$*@DB%:$*% M1#3$1?I(+AB*Q!];ZSB;$3IBV1-XIGQ[ ME>/AX9&AO7VEM.@V!)G.8N5*_6S"\:C;4/.EF4^2WV8S"P5#'N:!2QA$K]KJV(T MW-/3LK9E)*W3#PD1E0Y-&%I5$SFV8SGRJ_=XP2-1M M5%(LQLY'C_"(4**CI`W)LMTVFD8NH7B):&2DXHR"O,^M=2'K\A.!(Y?^K*_7 M9W[&G9%4<:Y-KMT9EYIMY\N>YC@XJ=PW2G>.1-GY8&?&$_$[(+UPN MW)$[4WM?T$=`INVQ*?AD`D3D&?>9V"G,#Y%6.3/.=\\!?@`/'BP'9H5[:[@# MRS,#&T@-TU%D#P//N@=*^\DR^JY_2A)'394>$I/;F+WL/2M*&"LGP,6A$Z!G M^O?&;=_]``!&,(. M/<5N;ZX:,,\WP;PV?5O''*18'^)OB6K/LP.[9_8-L]=S'YW`=NZ,`81NS[9. M^*[CZ^.Q2G`>GC&N$-'+)NRKJ%P)QGJR&@0O-A'TK3N5.`W/&KB>1BE=-&&G MY02G>-R"UP3VFZH"UKL;6.D*)>N6=S7(?"A!YM[TK"9$F)5N8F"ITW",:O>G2)0\KT'AXR8*>L,(*Y."X`%RFT;E!,$:!+>(\"<4)_@! M(^4XO>5+42A_50/$ITT@;DW;,Y[,_J-E/%BF_^BE&[X3%&M09.NZ*KUVN>_/%[O<+RL%7`XH\*"QZIT*OM-"3+/PV87&$N;"^)T3.LR)O\WD-#F6E=^#V_G'O]F\L MS_^K8?WZ:`=?3PALG$=/IT3JHB$][E`''Y@N3[FJ"&HP*2FZ595G!^E1DK8&LI$)7A883]+\:MN\_ MPOI2/'#T7`>N>__WI>+GUEH_4/I@M6M(]0R1J3H[-.A&RUJQ$VR,T&RE/2IM M=^NS4`M;;5TJ96SA6(K\27,IZNQ51'G72*4Z55U1E>JL\ZB+HQ4HZ1C;18<" M6W9]M"8Z:OA\;U6*?/G-\'*+#>=G:9+A(4CY'^2KQ%AQ6VF/,5KJ:2T^R< M-SN?CM=#[JV#/&3\5:?*&=\?B9Q)7[T%%L5FVEU\H%G473/G4YZX4)XX0HL/ M+:[:#G=40%.K83\TVS\U.^W]`-AH#-YQU)Q!#?SQ,$O+6W]W&;_(Z:2,1T?` M9O/R?IHE*;Z+^4""R6G^@:OV>7ARSXV&U"?]M%^*TBUCWUU]-&>0QQ.>V MQ%.U902SDJ&01";*J#O.DEE.2H"D85`2Q^I;0+BO MB6YC)/`0A=\* M9SJYE7>(*`6%V)P#^[.^%Y^$H%V54[Y@,IX`J.8SYFB,(0D.,7='^O.MFT@E M5/V!1_6VA%#OWY`X6;2@:=<<*J#H(*&(Q>_IGBCAV;>'K;%1T?IN9@,40V,G M\A4C)0<_O(&1Z?TA-NJS&Z'^GR6R@^7%ES!MU);W_^VYO#1DS\G<8T*ZHTTK M5DS<1O)NK*Q)8S8%-T`JNL'Y[]8D7;![+ZYWXXHZP`O?;W563FT*V"#]\\Q< M1>?WA,QTI$H(P&$BE6X!RWHJZ5BG=;$:!V\K]H_C32$21:E[&%.;]<&[37T0 M*$;IFN>.S#`$72"5/Y,(T^)B<+"$=^.CFN#+FINT3?I@]99QU8F=Q+I!<,QQ M\0QVD51W8WDW3JB;*-7]+"6KY:X,_\/U4I_@I@4(W/T'4$L!`AX#%`````@` MDX2O0`X6_H2S8```M7P$`!$`&````````0```*2!`````'9A&UL550%``-5OK)/=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`DX2O M0,MC;MZL#@``I,X``!4`&````````0```*2!_F```'9A`Q0````(`).$ MKT#:ZB1;+4$``$1<`P`5`!@```````$```"D@?EO``!V87-O+3(P,3(P,S,Q M7VQA8BYX;6Q55`4``U6^LD]U>`L``00E#@``!#D!``!02P$"'@,4````"`"3 MA*]`O7YS)!`=``"FR0$`%0`8```````!````I(%UL0``=F%S;RTR,#$R,#,S M,5]P&UL550%``-5OK)/=7@+``$$)0X```0Y`0``4$L!`AX#%`````@` MDX2O0`7V38*Q"```S3P``!$`&````````0```*2!U,X``'9A'-D550%``-5OK)/=7@+``$$)0X```0Y`0``4$L%!@`````%``4`OP$` '`-#7```````` ` end XML 33 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.6 Html 7 139 1 false 0 0 false 3 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://vasomedical.com/role/DocumentAndEntityInformation Document and Entity Information true false R2.htm 010000 - Statement - CONSOLIDATED CONDENSED BALANCE SHEETS (unaudited) Sheet http://vasomedical.com/role/ConsolidatedCondensedBalanceSheetsUnaudited CONSOLIDATED CONDENSED BALANCE SHEETS (unaudited) false false R3.htm 010100 - Statement - CONSOLIDATED CONDENSED BALANCE SHEETS (unaudited) (Parenthetical) Sheet http://vasomedical.com/role/ConsolidatedCondensedBalanceSheetsUnauditedParenthetical CONSOLIDATED CONDENSED BALANCE SHEETS (unaudited) (Parenthetical) false false R4.htm 020000 - Statement - CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (unaudited) Sheet http://vasomedical.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossUnaudited CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (unaudited) false false R5.htm 030000 - Statement - CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS (unaudited) Sheet http://vasomedical.com/role/ConsolidatedCondensedStatementsOfCashFlowsUnaudited CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS (unaudited) false false R6.htm 060100 - Disclosure - ORGANIZATION AND PLAN OF OPERATIONS Sheet http://vasomedical.com/role/OrganizationAndPlanOfOperations ORGANIZATION AND PLAN OF OPERATIONS false false R7.htm 060200 - Disclosure - BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES Sheet http://vasomedical.com/role/BasisOfPresentationAndCriticalAccountingPolicies BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES false false R8.htm 060300 - Disclosure - SEGMENT REPORTING AND CONCENTRATIONS Sheet http://vasomedical.com/role/SegmentReportingAndConcentrations SEGMENT REPORTING AND CONCENTRATIONS false false R9.htm 060400 - Disclosure - SHARE-BASED COMPENSATION Sheet http://vasomedical.com/role/SharebasedCompensation SHARE-BASED COMPENSATION false false R10.htm 060500 - Disclosure - LOSS PER COMMON SHARE Sheet http://vasomedical.com/role/LossPerCommonShare LOSS PER COMMON SHARE false false R11.htm 060600 - Disclosure - FAIR VALUE MEASUREMENTS Sheet http://vasomedical.com/role/FairValueMeasurements FAIR VALUE MEASUREMENTS false false R12.htm 060700 - Disclosure - ACCOUNTS AND OTHER RECEIVABLES, NET Sheet http://vasomedical.com/role/AccountsAndOtherReceivablesNet ACCOUNTS AND OTHER RECEIVABLES, NET false false R13.htm 060800 - Disclosure - INVENTORIES, NET Sheet http://vasomedical.com/role/InventoriesNet INVENTORIES, NET false false R14.htm 060900 - Disclosure - BUSINESS COMBINATION Sheet http://vasomedical.com/role/BusinessCombination BUSINESS COMBINATION false false R15.htm 061000 - Disclosure - GOODWILL AND OTHER INTANGIBLES Sheet http://vasomedical.com/role/GoodwillAndOtherIntangibles GOODWILL AND OTHER INTANGIBLES false false R16.htm 061100 - Disclosure - DEFERRED REVENUE Sheet http://vasomedical.com/role/DeferredRevenue DEFERRED REVENUE false false R17.htm 061200 - Disclosure - RELATED-PARTY TRANSACTIONS Sheet http://vasomedical.com/role/RelatedpartyTransactions RELATED-PARTY TRANSACTIONS false false R18.htm 061300 - Disclosure - STOCKHOLDERS' EQUITY Sheet http://vasomedical.com/role/StockholdersEquity STOCKHOLDERS' EQUITY false false R19.htm 061400 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://vasomedical.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES false false R20.htm 061500 - Disclosure - RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS Sheet http://vasomedical.com/role/RecentlyIssuedAccountingPronouncements RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS false false All Reports Book All Reports Process Flow-Through: 010000 - Statement - CONSOLIDATED CONDENSED BALANCE SHEETS (unaudited) Process Flow-Through: Removing column 'Mar. 31, 2011' Process Flow-Through: Removing column 'Dec. 31, 2010' Process Flow-Through: 010100 - Statement - CONSOLIDATED CONDENSED BALANCE SHEETS (unaudited) (Parenthetical) Process Flow-Through: 020000 - Statement - CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (unaudited) Process Flow-Through: 030000 - Statement - CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS (unaudited) vaso-20120331.xml vaso-20120331.xsd vaso-20120331_cal.xml vaso-20120331_lab.xml vaso-20120331_pre.xml true true XML 34 R20.htm IDEA: XBRL DOCUMENT v2.4.0.6

RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS
3 Months Ended

Mar. 31, 2012

RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS [Abstract]

RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS
NOTE O - RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

Other Comprehensive Income: Presentation of Comprehensive Income

In June 2011, new guidance was issued that amends the current comprehensive income guidance. The new guidance allows the option to present the total of comprehensive income, the components of net income, and the components of other comprehensive income either in a single or continuous statement of comprehensive income or in two separate but consecutive statements. The amendments in this update do not change the items that must be reported in other comprehensive income or when an item of other comprehensive income must be reclassified to net income. The new guidance is to be applied retrospectively and is effective for fiscal years, and interim periods, beginning after December 15, 2011, with early adoption permitted. The Company does not expect that it will have a material impact on its consolidated condensed financial statements.

In December 2011, the FASB issued authoritative guidance to defer the effective date for those aspects of the guidance relating to the presentation of reclassification adjustments out of accumulated other comprehensive income. The adoption of this new guidance will not have an impact on the Company's consolidated financial position, results of operations or cash flows as it only requires a change in the format of the current presentation of other comprehensive income.

RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS	3 Months Ended
RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS	Mar. 31, 2012
RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS [Abstract]
RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS	NOTE O - RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS Other Comprehensive Income: Presentation of Comprehensive Income In June 2011, new guidance was issued that amends the current comprehensive income guidance. The new guidance allows the option to present the total of comprehensive income, the components of net income, and the components of other comprehensive income either in a single or continuous statement of comprehensive income or in two separate but consecutive statements. The amendments in this update do not change the items that must be reported in other comprehensive income or when an item of other comprehensive income must be reclassified to net income. The new guidance is to be applied retrospectively and is effective for fiscal years, and interim periods, beginning after December 15, 2011, with early adoption permitted. The Company does not expect that it will have a material impact on its consolidated condensed financial statements. In December 2011, the FASB issued authoritative guidance to defer the effective date for those aspects of the guidance relating to the presentation of reclassification adjustments out of accumulated other comprehensive income. The adoption of this new guidance will not have an impact on the Company's consolidated financial position, results of operations or cash flows as it only requires a change in the format of the current presentation of other comprehensive income.